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ABSTRACT 
CD8+ T-cells recognise pathogens and cancer through a specific interaction between 
the T-cell receptor (TCR) and a 8-14 amino-acid residue peptide presented by class I 
major histocompatibility complex (pMHCI) molecules expressed on the target cell 
surface. The first structures of murine and human TCR/pMHC complexes, published 
in 1996, revealed a number of important features of the TCR/pMHC interface. 
Currently, <25 unique human TCR/pMHC complexes are reported in the literature. 
This is a relatively low number compared with the number of antibody or unligated 
pMHC structures. The lack of structural information regarding human TCR/pMHC 
complexes has compromised the determination of a comprehensive and accepted set 
of rules that govern T-cell antigen recognition. Difficulties in generating 
TCR/pMHC complex crystals partly explain the low number of these structures. The 
first part of this thesis reports the development of a new crystallization screen 
(TOPS) designed specifically for the generation of such protein crystals. I also had 
access to MART-1-specific TCRs, the MART-1 protein being expressed by virtually 
all fresh melanoma tumour specimens. Different human leukocyte antigen (HLA)-
A*0201-restricted peptides from this protein are presented at the melanoma cell 
surface. As TCRs are known to bind to cancer-derived “self” peptides with weak 
affinity, there is considerable interest in designing enhanced affinity TCRs for the 
recognition of HLA-A*0201-MART-1. My work concentrated on the MART-1-
specific TCR MEL5 and its affinity-enhanced variant selected by phage display, 
α24β17. I analysed the biophysical properties of α24β17 and determined that it 
bound HLA-A*0201-MART-1 with >30,000-fold enhanced affinity and distinct 
thermodynamics. Comparison of TCR/HLA-A*0201-MART-1 complex structures 
solved with TOPS and binding biophysics showed that: (i) TCR affinity can be 
enhanced by increasing interactions between the TCR and the MHC surface; (ii) 
soluble α24β17 retains the peptide specificity by a novel mechanism involving 
interactions with solvent molecules; and, (iii) MEL5 interaction with the 
physiologically relevant MART-127-35 nonameric antigen led to a peptide anchor 
residue switch, a TCR-induced modification that has never been observed before. I 
also initiated a preliminary study on the generation of genetically modified Jurkat 
cells and CD8+ T-cells expressing a range of affinity-enhanced TCRs directed 
against melanoma for adoptive cell therapy. These results suggested that melanoma 
specificity is retained after MEL5 transduction and that there is no need to optimize 
beyond a TCR affinity threshold to obtain optimal T-cell activation. Collectively, 
these data shed light on the complex and unpredictable nature of T-cell antigen 
recognition.  
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1.1 GENERAL CONCEPTS OF ADAPTIVE IMMUNITY 
The human immune system provides defence against pathogens by triggering two 
broadly defined types of immunity: innate immunity and adaptive immunity. Both 
types of immunity usually work together for effective pathogen clearance 
(Medzhitov and Janeway, 2000). Innate immunity relies on phagocytes (monocytes, 
macrophages and neutrophils), cells that release inflammatory mediators (basophils, 
mast cells and eosinophils), natural killer (NK) cells as well as components of the 
complement system and lies behind most inflammatory responses (Delves and Roitt, 
2000a). My work focussed on adaptive immunity which general concepts are 
discussed herein. 
 
Adaptive immunity is controlled by immune cells called lymphocytes. There are two 
types of lymphocyte, B and T lymphocytes. Lymphocytes express antigen-binding 
receptors that are manufactured by gene rearrangement of germline gene segments. 
This process, described in detail below, has the capacity to produce huge numbers of 
individual receptors that each exhibit a different binding specificity (Davis and 
Bjorkman, 1988). The principal roles of B-cells are to secrete immunoglobulins 
(Igs), the antigen-specific antibodies responsible for the suppression of extracellular 
micro-organisms, and to perform antigen exposure to T-cells when specialized into 
antigen-presenting cells (APCs) (Delves and Roitt, 2000a; Delves and Roitt, 2000b). 
The principal roles of T-cells are to: (i) promote immunity against intracellular and 
extracellular pathogens by activating innate immunity cells and B-cells (helper T-
cells, THs) (Cavani et al., 2012; King et al., 2008; Ma et al., 2010; Zelante et al., 
2009); (ii) promote immunosuppression to avoid autoimmunity and to prevent 
immune response from becoming uncontrolled (regulatory T-cells, TRegs) (Boehm, 
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2011; Dong and Martinez, 2010); and, (iii) eliminate pathogens by killing virally 
infected cells and cancer cells (cytotoxic T-cells, CTLs) (Boehm, 2011; Laugel et al., 
2011). One of the most important aspects of adaptive immunity is its ability to 
generate immunological memory, the capacity to “recall” previous infections and to 
react more rapidly upon subsequent antigen exposure (Delves and Roitt, 2000a). The 
process of vaccination where a deliberate exposure to a harmless version of a 
pathogen, or a specific antigen from a pathogen, is used to generate memory cells 
that can provide immediate protection to future infections is dependent on this 
important recall function (Medzhitov and Janeway, 2000).  
 
1.2 T-CELLS 
As my work has focussed on a particular aspect of adaptive immunity mediated by 
T-cells, the rest of my thesis will focus on these important cells. T-cells develop in 
the thymus from common lymphoid progenitors arising from the bone marrow or 
foetal liver. Broadly speaking, T-cells can be divided into “conventional” T-cells and 
“unconventional” T-cells.  
 
1.2.1 Conventional T-cells  
Most T-cells bearing an αβ TCR, made from the Vα and Vβ genes, and expressing a 
co-receptor (CD4 or CD8) are conventional T-cells that recognise protein antigens in 
the form of short peptides (Lefranc, 1990) (Table 1.1). The vast majority of T-cells 
in human or mouse peripheral blood or lymphoid organs are conventional T-cells 
and it is this subset that has received most attention to date. Conventional T-cells 
recognise protein antigens that have been processed and presented in a binding 
groove of molecules called Major Histocompatibility Complex (MHC) molecules. 
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Table 1.1. Conventional T-cell classes adapted from (Dong and Martinez, 2010; 
Murphy, 2012) 
Class Subset 
Co-receptor expressed on 
T-cell membrane 
Helper T-cell (TH) 
TH1, TH2, TH3, TH9, TH17, 
TH22 and T follicular 
helper cell (TFH) 
CD4 
Regulatory T-cell (TReg) 
TR1, natural TReg, 
inducible TReg (iTReg) and 
CD8αα T-cell 
CD4 or CD8αα 
Cytotoxic T-cell (CTL) CD8αβ T-cell CD8αβ 
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Thus, T-cells are said to exhibit “MHC restriction” (Zinkernagel and Doherty, 1974; 
Zinkernagel and Doherty, 1997). These peptide-MHC (pMHC) complexes are 
recognised by the TCR which engages both the peptide and MHC components of the 
bipartite antigen (Garboczi et al., 1996; Garcia et al., 1996; Townsend and Bodmer, 
1989; Townsend et al., 1985). 
 
The conventional αβ T-cells lineage is divided into two subsets: CD4+ T-cells 
restricted by class II MHC (MHCII) and CD8+ T-cells restricted by MHCI 
(Bluestone et al., 2009; Laugel et al., 2011). The CD4+ subset includes the THs and 
TRegs whereas the CD8
+ subset usually represents the CTLs (Murphy et al., 2008). 
However, cytotoxic CD4+ T-cells have also been identified (Fleischer, 1984; 
Marshall and Swain, 2011) and some CD8+ T-cells have regulatory functions 
(Laugel et al., 2011; Terry et al., 1990). CD8+ T-cells can be divided into two subsets 
depending on which form of the co-receptor they are expressing (CD8αα homodimer 
or CD8αβ heterodimer). CD8αα intraepithelial T-cells have been found in the gut 
and can have regulatory functions through the production of IL-10 and TGFβ 
(Leishman et al., 2001; Terry et al., 1990) but their role is less well-understood than 
CD8αβ T-cells (Laugel et al., 2011). CD8αβ T-cells (known as TC or CD8
+ CTL) 
can kill infected and transformed cells via production of cytolytic molecules such as 
perforin and granzymes A and B (Delves and Roitt, 2000a). CD8αβ T-cells can 
protect the host from cancer and viral infections (Laugel et al., 2011). CD8αβ T-cells 
also secrete “type-1” (IL-2, TNF-α and IFN-γ) or “type-2” cytokines (IL-4, IL-5, IL-
6, IL-10 and IL-13) (Croft et al., 1994; Inui et al., 2001; Seder et al., 1992), however 
these cytokine profiles were first described for CD4+ T-cells (Mosmann et al., 1986). 
Although CD8+ T-cells play an important role in suppressing viral infection, the 
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CD8+ T-cell mediated response to cancer is usually less effective (Miles et al., 2010). 
Moreover, CD8+ T-cells are also implicated in other health-related problems such as 
organ transplant rejection (Mannon et al., 1998) and autoimmunity (Agostini et al., 
1993; Bulek et al., 2012a). Although my work has been focussed on conventional T-
cells, I provide a description of unconventional T-cell types below for the sake of 
completeness. 
 
1.2.2 Unconventional T-cells 
There are various types of unconventional T-cells (Gapin, 2009). All γδ T-cells are 
thought to recognise unconventional ligands and to fall in this category. The γδ T-
cell lineage represents a small percentage of the T-cell population in peripheral blood 
(~1-10%) but these cells are abundant in tissues, especially in epithelial layers (Pang 
et al., 2012; Plattner and Hostetter, 2011). γδ T-cells express a heterodimeric TCR 
made from the Vγ and Vδ genes. γδ T-cells have been conserved throughout 
vertebrate evolution and are therefore likely to perform a very important function. γδ 
T-cells can recognize antigens such as phospho-antigens, lipids and glycolipids 
presented by MHC complex-related proteins (“non-classic MHC”) (Hayday, 2009) 
but can also recognize antigens directly just as antibody molecules do (Bukowski et 
al., 1994; Johnson et al., 1992). Another unconventional T-cell subset, described as 
mucosal-associated invariant T-cells (MAIT) (Porcelli et al., 1993; Treiner et al., 
2005), recognize microbial vitamin B metabolites presented by the MHCIb molecule 
MR1 (MHC-related molecule 1) (Kjer-Nielsen et al., 2012; Treiner et al., 2003). 
MAITs bear an αβ TCR made from the Vα7.2 and Jα33 variable genes in humans 
and Vα19 and Jα33 variable genes in mice (Gapin, 2009). The invariant TCR α chain 
has also been found to preferentially associate with a limited number of TCR β 
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chains (Vβ2 and Vβ13 in humans and Vβ6 and Vβ8 in mice) (Treiner et al., 2005). It 
has been suggested that MAIT cells could have a positive role in regulating Ig A 
secretion in the intestine (Treiner et al., 2003; Treiner and Lantz, 2006) or could 
have immunoregulatory functions in autoimmunity (Croxford et al., 2006). Other 
unconventional T-cells are recognizing antigens presented by an MHCI-related 
protein, the CD1 molecule. CD1 molecules present diverse lipid antigens and are 
classified into group 1 (comprising CD1a, CD1b and CD1c) and group 2 (containing 
only CD1d); CD1e molecule being considered intermediate (Murphy, 2012). T-cells 
that recognize lipids presented by CD1 express neither CD4 nor CD8. Among these 
T-cells, another known important unconventional T-cell subset is called natural killer 
T (NKT) cells (Kronenberg, 2005). The most commonly described group of NKT 
cells is the Type 1 or invariant NKT (iNKT) subset that is involved in immunity to 
infectious disease, autoimmunity and in tumour surveillance (Gapin, 2010; Juno et 
al., 2012). Human iNKT cells use an invariant TCR Vα24-Jα18 chain associated 
with variant TCR Vβ11 chains to recognize lipid antigens presented by the non-
polymorphic MHCIb molecule CD1d (Brennan et al., 2012; Davodeau et al., 1997; 
Porcelli and Modlin, 1999). Bacterial (Kinjo et al., 2006) and self (Brennan et al., 
2012) iNKT ligands have been described but no viral-associated ligands have been 
reported so far despite iNKT activation during viral infection (Juno et al., 2012). 
Finally, a glycolipid not produced by mammals that strongly activate iNKT cells, 
namely α-galactosylceramide (α-GalCer), is one the best characterized iNKT TCR 
ligand due to its potential as a vaccine adjuvant and is widely used in the study of 
iNKT TCRs/CD1d interactions (Borg et al., 2007; Gadola et al., 2002; Gadola et al., 
2006; Juno et al., 2012).  
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1.3 THE SHAPING OF THE T-CELL REPERTOIRE 
1.3.1 TCR gene assembly 
The recombination mechanism leading to the assembly of antigen receptors is 
common for both B-cells and T-cells and was first described for antibodies 
(Tonegawa, 1983). The initial observation, that the sequences of Ig genes in mature 
B-cells were different of that from embryonic tissues (Tonegawa, 1983), was crucial 
for the understanding of antigen receptor diversity generation. The process of 
functional B-cell receptor (BCR) and TCR gene assembly is called somatic 
recombination (or somatic rearrangement) and involves congregation of sequentially 
ordered random segmental germline DNA rearrangements of the variable (V), 
diversity (D) and joining (J) gene segments under the control of recombinase-
activating genes 1 and 2 (RAG-1 and RAG-2) (Bonilla and Oettgen, 2010). The 
human germline TCR α locus (on chromosome 14) is constituted of 70-80 V, 61 J 
and 1 constant (C) segments whereas the TCR β locus (on chromosome 7) is 
constituted of 52 V, 2 D, 13 J and 2 C segments (Murphy et al., 2008). The overall 
variety of rearranged DNA fragments during somatic recombination is the result of 
both combinatorial and junctional diversity (Schatz, 2004). The combinatorial 
diversity relies on both the number of germline gene segments that can combine at 
either the TCR α or β locus and the pairing of the randomly generated α and β 
chains. However, the combination of germline gene segments is restricted by the 
facts that not all segmental gene rearrangements are equally likely to occur and that 
random pairing of the TCR chains does not always produce a functional TCR 
(Boehm, 2011). Junctional diversity can produce a “random” nucleotide region in 
each TCR chain using P-nucleotides (generating palindromic sequences) and N-
nucleotides (non-templated nucleotides) absent in the germline DNA. This 
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randomisation process is active during the joining of VJ segments (α chain) or the 
joining of DJ segments followed by the joining of VDJ segments (β chain) (Schatz, 
2004). Up to 20 N-nucleotides can be added by the TdT (terminal deoxynucleotidyl 
transferase) enzyme at the blunt ends before ligation of the DNA while the 
Artemis:DNA-PK (DNA-dependent protein kinase) complex mediates the insertion 
of P-nucleotides at the ends of asymmetrical DNA fragments generated during 
excision of the non-coding segments (Murphy et al., 2008; Schatz, 2004). The 
junctional diversity is considered to introduce most of the TCR genetic variability 
and it is believed that T-cells have the ability to generate 1015-1020 unique TCRs 
from a limited number of genes (Arstila et al., 1999; Davis and Bjorkman, 1988; 
Nikolich-Zugich et al., 2004).  
 
The clonal selection theory (Jerne, 1955; Jerne, 1971) suggested that individual 
lymphocytes are specific for a single antigen only, an idea that was widely accepted. 
The ability of V(D)J rearrangements to produce a theoretical 1015-1020 unique TCRs 
meant that the TCR repertoire could be extensive enough to recognise the >1015 
potential foreign peptides (Sewell, 2012). Consequently, the clonal selection theory 
of T-cell recognition remained largely unchallenged prior to seminal work by Mason 
(Mason, 1998; Sewell, 2012). Mounting evidence now excludes theories based 
around a single TCR for each peptide antigen (Mason, 1998; Sewell, 2012). It has 
been estimated that the human naive T-cell pool is constituted by less than 108 
distinct αβ TCRs (Arstila et al., 1999) and it has been shown that the T-cell clone 
expressing the 1E6 TCR was able to respond to over 106 decameric peptides 
(Wooldridge et al., 2012). Hence, extensive T-cell cross-reactivity provides a 
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potential mechanism for how a limited TCR repertoire can provide broad antigenic 
cover (Sewell, 2012). 
 
1.3.2 T-cell selection 
T-cell progenitors originate from foetal liver and bone marrow stem cells and 
migrate to the thymus where they mature into T-cells before populating peripheral 
lymphoid organs (Delves and Roitt, 2000a). Thymic education is a spatially and 
temporally regulated process in which thymocytes undergo several morphological 
and genetic differentiation steps based on MHC restriction. The process is 
characterised by the differential expression of various phenotypic cell-surface 
markers and leads to the selection of T-cells expressing a functional TCR. 
Developing αβ T-cells undergo an extensive selection that shapes the mature 
repertoire of T-cells to ensure self-MHC restriction as well as self tolerance in 
processes called positive and negative selection (Starr et al., 2003). The different 
stages of thymocyte development can be discriminated with the differential 
expression of the co-receptors CD4 and CD8.  
 
First, progenitor cells differentiate into double negative (DN, CD4- CD8-) 
thymocytes in the thymic stroma with the rearrangement of the germline DNA 
described in the previous section. Thymocyte precursors first rearrange their TCR β 
gene and the product of the rearranged allele is then expressed on the thymocyte 
surface as part of a pre-TCR complex consisting of the CD3 components and the pre-
T α invariant chain that comprises only the constant region (Bosselut, 2004). The 
cells then migrate to the thymic cortex where the rearrangement of the TCR α chain 
occurs, and the product of the rearranged allele associates with the TCR β and the 
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CD3 complex potentially forming a functional αβ TCR (Bosselut, 2004; Chaplin, 
2010). DN thymocytes differentiate first into immature CD8 single positive (ISP) 
cells and then into double positive (DP) cells that express low levels of a clonotypic 
TCR and both the CD4 and CD8 co-receptors before positive selection (Bosselut, 
2004; Murphy et al., 2008) (Figure 1.1). Cells are positively selected by receiving 
survival signals if they express a TCR with an intermediate affinity for self pMHCs 
expressed on epithelial cells in the thymic cortex and they mature into CD4 or CD8 
single positive (SP) cells (Delves and Roitt, 2000a). Thymocytes expressing a TCR 
that has a very low or no affinity for pMHC complexes are thought to “die by 
neglect” as they are unlikely to be useful and do not receive a survival signal. It is 
believed that about 90% of T-cell precursors are not selected at this stage and 
therefore die by neglect in the thymus (Palmer and Naeher, 2009). At both the DP 
and SP stages, cells expressing a TCR with a high affinity for self pMHC molecules 
are deleted in the process called negative selection (Kappler et al., 1987). These 
potentially harmful self-reactive T-cells are eliminated by induction of apoptosis 
when they interact with dendritic cells and macrophages in the thymic medulla 
(Delves and Roitt, 2000a). Moreover, the expression of some, but not all, tissue-
specific proteins in the thymic medulla is controlled by a gene called AIRE 
(autoimmune regulator) (Metzger and Anderson, 2011). Hence, intrathymic negative 
selection could apply even to proteins that are otherwise restricted to tissues outside 
the thymus. The autoimmune regulator protein AIRE, expressed in medullary 
stromal cells, interacts with several proteins involved in transcription and seems to 
lengthen transcripts from promoters that would otherwise terminate (Murphy, 2012).  
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Figure 1.1. Simplified schematic representation of thymocyte development from 
the double negative (D	) to the single positive (SP) stages. 
Thymocyte precursors enter the thymus and rearrange their TCR β gene. The product 
of the rearranged allele is then express on the thymocyte surface as part of a pre-
TCR complex which also includes the pre-T α invariant chain and CD3 components. 
Cells differentiate into double positive (DP) thymocytes that arrange their TCR α 
gene and express a clonotypic αβ TCR. Cells with intermediate avidity for self 
pMHC complexes survive and differentiate into mature CD8+ T-cells and CD4+ T-
cells while those with low or no avidity die by neglect (positive selection). Figure 
from (Bosselut, 2004). 
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These two processes of selection ensure that only T-cells with a relatively weak 
affinity for self-peptide/MHC populate the periphery (Alam et al., 1996; Liu et al., 
1998).  
 
1.3.3 T-cell activation and differentiation 
Differentiation of CD4+ and CD8+ naïve T-cells into effector T-cells in the 
peripheral immune organs is initiated through signals from APCs. These signals may 
be contact-dependent through surface molecules or soluble factors like cytokines 
(Delves and Roitt, 2000a; Delves and Roitt, 2000b). The required signalling can be 
grouped into three types of signals: 1, 2 and 3 (Murphy, 2012). Signal 1, the antigen 
specific signal, is the interaction between the TCR and its cognate pMHC on the 
APC. Signal 1 alone leads to T-cell inactivation by anergy or apoptosis, often 
resulting in antigen tolerance (Murphy, 2012). APCs that can activate naïve T-cells 
bear cell-surface proteins known as co-stimulatory molecules or co-stimulatory 
ligands. These interact with naïve T-cell-surface receptors, known as co-stimulatory 
receptors, to transmit a signal that is required along with signal 1 for T-cell 
activation; this signal is called signal 2 (Delves and Roitt, 2000a). The best 
understood of these co-stimulatory receptors is the cell-surface protein CD28. CD28 
is present on the surface of all naive T-cells and binds the co-stimulatory ligands 
B7.1 (CD80) and B7.2 (CD86) which are expressed mainly on specialized APCs 
such as dendritic cells (Murphy et al., 2008). Signal 2 drives the T-cell towards an 
activation state referred to as TH0 (Delves and Roitt, 2000a). This state is 
characterized by sustained proliferation, surface-marker up-regulation and a mixed 
cytokine expression profile. Signal 3, also transmitted by the APC, drives CD4+ and 
CD8+ T-cell differentiation into effector cells (Thomas, 2004). This signal conveys 
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crucial information on the pathogen and infected tissue. The different T-cell subtypes 
(Table 1.1) are associated with distinct signals that induce their formation, different 
transcription factors that drive their differentiation and unique cytokines and surface 
markers that define their identity (Murphy et al., 2008; Thomas, 2004). 
 
1.3.4 Immunological synapse 
In addition to the co-receptor CD4 or CD8, the αβ TCR is associated on the T-cell 
surface with the CD3 complex. The main role of the CD3 machinery is to transduce 
signals to the interior of the cell when the TCR contacts its cognate pMHC (Delves 
and Roitt, 2000a; Delves and Roitt, 2000b). T-cell activation also involves antigen-
independent cell-cell interactions including CD2 (LFA-2), CD40L, LFA-1 and CD28 
located on the T-cell surface which contact CD58 (LFA-3), CD40, ICAM-1 and 
CD80 (B7.1)/CD86 (B7.2) on the surface of APCs, respectively (Murphy, 2012). On 
encounter of an APC, a T-cell initiates a process of cell surface molecular 
rearrangement culminating in the formation of organised cell-cell interfaces called 
“immunological synapse” or supramolecular activation clusters (SMAC) (Alarcon et 
al., 2011; Grakoui et al., 1999). The SMAC is organised into (i) a central area 
(cSMAC) in which the TCR/CD3 complex, its co-receptors CD4 or CD8 and the co-
stimulatory protein CD28 are positioned for optimal interaction with pMHC, CD80 
and CD86 on the APC; and (ii) a peripheral area (pSMAC) where LFA-1, CD43, 
CD45 and ICAM-1 are sequestered. These latter molecules located in the pSMAC 
regulate the activity initiated by the cSMAC members (Alarcon et al., 2011; Davis 
and Dustin, 2004). 
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1.4 PEPTIDE PROCESSING AND PRESENTATION BY MHCI MOLECULES 
Human MHC molecules are called human leukocyte antigens (HLAs). These MHC 
glycoproteins bind peptide fragments of proteins that have been synthesized within 
the cell or that have been phagocytosed by the cell. Peptides derived from exogenous 
proteins are assembled with MHCII proteins on the surface of specialized antigen 
presenting cells (APCs) such as macrophages and dendritic cells (DC). Peptides from 
endogenous proteins are presented by MHCI that are found at the surface of almost 
all nucleated cells. This elegant system allows T-cells to inspect the internal 
proteome for anomalies. MHCI molecules are composed of a 44 kDa polymorphic 
transmembrane α heavy chain associated with the 12 kDa non-polymorphic β2-
microglobulin (β2m) protein (Bjorkman, 1997). In humans, the heavy chain of the 3 
major class I HLA molecules (HLA-A, HLA-B and HLA-C) and β2m are encoded 
by distinct genes on chromosome 6 and chromosome 15, respectively. Protein 
fragments are generated from cellular proteins through the action of the proteasome, 
a proteolytic machinery composed of more than 25 subunits, and are presented in the 
context of MHCI molecules in a process referred as the MHCI antigen processing 
pathway (Figure 1.2) (Niedermann, 2002). The main role of the proteasome is the 
degradation of proteins as part of normal cellular homeostasis and it is therefore 
constitutively expressed in almost all cells (Tanaka et al., 2012; Zoeger et al., 2006). 
The proteasome contains multiple active protease sites spaced in such a way that 
they digest proteins into peptide fragments of different length (Mazza and Malissen, 
2007; Probst-Kepper et al., 2004). If a pathogenic threat is detected, release of IFNγ 
by cells such as macrophages signals a transformation of the proteasome into an 
immunoproteasome (Kloetzel and Ossendorp, 2004). 
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Figure 1.2. Class I MHC antigen processing pathway. 
Antigenic proteins found within the cell (endogenous antigens) are degraded into 
peptides by the immunoproteasome and transported into the endoplasmic reticulum 
(ER) via the transporter associated antigen processing proteins (TAP 1 and TAP 2). 
Some of these peptides bind to class I MHC with the help of chaperone proteins 
calreticulin, Erp57 and calnexin and are transported to the cell surface for immune 
surveillance by CD8+ T-cells. Figure from (Chaplin, 2010). 
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The immunoproteasome differs from the proteasome in three catalytic subunits 
(LMP2, MECL1 and LMP) and it produces peptides of the appropriate length for 
transport into the endoplasmic reticulum (ER) and with carboxy-terminal residues 
that are preferred anchor residues for binding to most MHCI (Kloetzel and 
Ossendorp, 2004; Murphy, 2012). Proteasomal cleavage fragments are transported to 
the ER via a transporter system consisting of two ATP-binding cassette subunits, the 
transporter associated with antigen processing 1 and 2 (TAP 1 and TAP 2). Peptides 
in the ER might require further processing before loading onto MHCI and an ER-
resident aminopeptidase ERAAP (Endoplasmic reticulum aminopeptidase associated 
with antigen processing, known as ERAP1 in humans) is implicated in this process 
(Kloetzel and Ossendorp, 2004). Studies have shown that ERAAP is required for the 
generation of the normal repertoire of MHCI peptides (Hammer et al., 2006) and that 
ERAP1 trims precursor peptides by a “molecular ruler” mechanism (Chang et al., 
2005). 8-14 residue-long peptides are eventually generated and the loading of 
peptide into the peptide-binding groove of the class I HLA heavy chain inside the ER 
occurs under the direction of the protein tapasin with the help of chaperone proteins 
calreticulin and Erp57 (Garbi et al., 2006; Momburg and Tan, 2002). The peptide-
MHCI (pMHCI) heavy chain complex is stabilized by the chaperone protein 
calnexin which dissociates when β2m binds (Chaplin, 2010). The pMHCI complex is 
then transported through the Golgi apparatus to the cell surface in exocytic vesicles. 
Interestingly, despite “exogenous” antigens being presented by class II MHC, studies 
have shown that under certain circumstances these antigens can also be presented by 
class I MHC (Chaplin, 2010). This phenomenon, designated as “cross-presentation”, 
plays an important role in antiviral immunity as some viruses have the ability to 
suppress the class II MHC endogenous pathway of antigen presentation (Sigal et al., 
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1999). Cell surface expressed pMHCI can then be sampled by CD8+ T-cells. Since 
my work was funded to focus on the recognition of MHCI-restricted peptides by 
tumour-specific TCRs, I will not go into further detail about MHC class II. 
 
1.5 STRUCTURAL BASIS OF TCR/pMHC RECOGNITION 
1.5.1 Introduction to X-ray crystallography 
The resolution of light microscopy is limited by the wavelength of visible light. This 
makes mitochondria, at about 500 nm in diameter, the smallest cellular structures 
visible by light microscopy (Henze and Martin, 2003; McCoy, 2009). Proteins are 
even smaller, the majority ranging from 4 to 6 nm in diameter; over 100 times 
smaller than the wavelength of red visible light (approximately 1000 nm) 
(Polikarpov et al., 1997). Resolving structure at the atomic level requires the use of 
radiation with a wavelength in the X-ray range, about 1 Å (0.1 nm) (McCoy, 2009; 
Polikarpov et al., 1997). However, as X-rays cannot be focused by a lens in the same 
way as visible light to create an image of the object, obtaining a protein structure at 
atomic resolution using X-rays requires very different methodology. The first step 
involves generating crystals of the molecule of interest in order to obtain a well 
ordered arrangement of molecules that will provide a diffraction pattern when 
exposed to X-rays. Crystallization occurs when the concentration of protein in 
solution is greater than its limit of solubility. The limit of solubility can be reached 
by slowly increasing the concentration of precipitant (such as polyethylene glycol 
(PEG) or a salt) in a protein solution. Under most conditions the protein will 
precipitate when it reaches its limit of solubility. However, under some conditions, it 
can enter a supersaturated meta-stable phase and it is from this phase that crystals 
form (Asherie, 2004) (Figure 1.3A).   
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Figure 1.3. Schematic representation of the phase and energy diagrams for 
crystallization of proteins. 
(A) Representation of a phase diagram showing the solubility of a protein in solution 
depending on the concentration of precipitant. Figure adapted from (Asherie, 2004). 
(B) Representation of an energy diagram showing that an activation barrier must be 
overcome for the crystallization of proteins to occur (nucleation). Figure adapted 
from (McCoy, 2009). 
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For a protein to crystallize, it must overcome an energy barrier analogous to that of 
conventional chemical reactions. The high-energy intermediate is the "critical 
nucleus" that seeds crystal growth (McCoy, 2009) (Figure 1.3B). Protein crystals are 
arranged as lattices containing several repeating units (“unit cells”) organized and 
oriented in a regular fashion. After being grown, protein crystals are soaked in 
cryoprotectant (such as glycerol or ethylene glycol), cryo-cooled in liquid nitrogen 
(100K) and then brought to an X-ray beam facility such as a synchrotron (Garman, 
1999; Zhao, 2011). When the X-ray beam hits the protein crystal, the molecular 
electron clouds scatter the X-rays to form a diffraction pattern (or reflections) that 
can be recorded on photographic film (Blundell and Johnson, 1976) or measured on 
a charge-coupled device (CCD) detector (Smyth and Martin, 2000). In order to 
collect a full set of diffraction patterns from every angle required to build a 3D 
picture, the protein crystal is rotated through 180 degrees. One obstacle that comes 
up from the use of X-ray crystallography is the “phase problem”. Each reflection has 
an intensity and a phase angle, but only the intensities can be measured by the 
detector. In order to solve the three-dimensional protein structure, the phase 
information can be recovered by 2 methods: “experimental phasing” using heavy-
atoms incorporated in the protein crystal (Garman and Murray, 2003; McCoy and 
Read, 2010) and “molecular replacement” using a known molecular model to solve 
the unknown crystal structure of a related molecule (Evans and McCoy, 2008). 
Electron density maps can be generated using both amplitude and phase information 
and are used to solve the three-dimensional structure of the protein. Once the initial 
structure of the protein has been modelled, the model undergoes rounds of 
refinement to ensure that the experimental data fit the observed data obtained from 
the new structure (Smyth and Martin, 2000). An indicator of model quality is the R 
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factor (or Reliability factor), which calculates the discrepancy (%) between the 
observed and calculated amplitudes (Smyth and Martin, 2000). An R factor near 
20% is considered acceptable (Brunger, 1992). The final refined protein structure 
will allow the understanding of the physical mechanisms by which proteins perform 
their functions.  
 
1.5.2 Structure of pMHCI 
Human pMHCI is composed of the HLA α heavy chain non-covalently associated to 
β2m and a peptide (Figure 1.4). The heavy chain comprises 3 extracellular domains 
(α1, α2 and α3) (Figure 1.4A), a transmembrane domain and a short intracellular 
domain that anchors in the cell membrane. Structurally, α1 and α2 domains are 
formed of a long α helix and several anti-parallel β-sheets. The MHC α1-helix and 
α2-helix form the sides of the peptide-binding groove and the β-sheets form the base 
of the groove (Figure 1.4A&B). The α3 domain forms an immunoglobulin-type fold 
that consists of 5 antiparallel β-sheets (Figure 1.4A). The β2m molecule is mainly 
made of 6 anti-parallel β-sheets (Figure 1.4A) (Madden, 1995; Rudolph et al., 
2006).  
 
The peptide binding groove has been described in terms of “pockets” or “sub-sites” 
(A to F), with each pocket composed of diverse amino acid sequences that alter the 
shape and chemical composition of the groove (Saper et al., 1991) (Figure 1.4B). In 
HLA-A*0201 (the most common Caucasian allele), the MHC B pocket generally 
accommodates peptide positions 1 or 2, while the C-terminus of the peptide binds to 
the MHC F pocket.  
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Figure 1.4. Crystal structure of HLA-A2 in complex with an heteroclitic 
melanoma peptide (FLTGIGIITV) to represent the overall structure of 
pMHCI. 
(A) pMHCI is composed of an α heavy chain (α1, α2 and α3 domains in blue 
cartoon) non-covalently associated to β2m (red cartoon). The peptide (rainbow stick) 
binds in the MHC binding groove formed by the α1 and the α2 domains. (B) 
Schematic representation from above the peptide binding groove showing the MHCI 
binding pockets (A-F) as described in (Saper et al., 1991). (C) The peptide 
conformation in MHCI is generally characterised by a prominent central bulge 
allowing TCR/peptide interaction. Figure adapted from the A2-FLT structure 
published in (Ekeruche-Makinde et al., 2012). 
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This anchoring is essential to stabilise pMHC at the cell surface during presentation, 
and allows other peptide residues to form the classical ‘peptide-bulge’ that generally 
contact the TCR during T-cell recognition of MHCI-restricted peptides 
(Borbulevych et al., 2007; Rudolph et al., 2006) (Figure 1.4C).  
 
1.5.3 Structure of αβ TCR 
The αβ TCR, an heterodimeric glycoprotein formed by a disulfide-linked α and β 
chain, is stabilized by an extracellular, membrane-proximal, inter-chain disulfide 
bond at the T-cell surface. The αβ TCR is structurally similar to an antibody Fab 
fragment (Figure 1.5A) (Garcia et al., 1999; Rudolph et al., 2006). The α and β 
chains contain a constant (C) domain that anchors into the T-cell membrane (via a 
linker) and a variable (V) Ig-like domain that contacts the pMHCI. Each domain is 
constituted by several anti-parallel β-sheets linked together by short α-helices and 
intra-domain disulfide bonds allow the immunoglobulin fold (Figure 1.5A) (Garcia 
et al., 1999; Rudolph et al., 2006). The C domains are relatively conserved for all αβ 
TCRs, with Cα being more acidic and Cβ being more basic, hence a highly polar 
Cα/Cβ interface involved in TCR pairing (Garcia et al., 1999; Turner et al., 2006). 
The V domains are composed of 3 hypervariable complementarity determining 
regions (CDR1-3) loops and another loop on the V domains called the hypervariable 
region 4 (HV4) (Garcia et al., 1996) or framework region (FW) (Miles et al., 2010) 
that contact both the MHC and the peptide (Figure 1.5B). CDRs 1 and 2 are encoded 
within the V gene segments (as described in section 1.3.1), but CDR3 loops are also 
made from junctional diversity (Turner et al., 2006).  
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Figure 1.5. Crystal structure of melanoma specific TCR DMF5 to represent the 
overall structure of αβ TCR. 
(A) The αβ TCR consists of a disulfide linked α (green cartoon) and β (pink cartoon) 
chain, with the CDR loops at the bottom of the V domains. The C domains (top) are 
relatively conserved for all αβ TCRs with the Cβ domain presenting an extended 
loop. (B) View from below of the CDR and FW loops of the TCR variable region. 
Figure adapted from the DMF5 TCR structure published in (Borbulevych et al., 
2011). 
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1.5.4 General features of TCR binding revealed from TCR/pMHC structures 
The crystal structures of several TCR/pMHC complexes (Figure 1.6A) have been 
solved and reviewed (Rudolph et al., 2006; Turner et al., 2006). TCRs bind to 
pMHCs in a diagonal docking mode with a “crossing angle” ranging from 22° to 70° 
and a mean around 35° (Figure 1.6B). The Vα domain mainly lies over the N-
terminus of the peptide and the MHC α2-helix whereas the Vβ domain lies mainly 
over the C-terminus of the peptide and the MHC α1-helix (Figure 1.6C), this fixed 
polarity being common to all TCR/pMHC complexes reported to date (Garcia et al., 
2009; Rudolph et al., 2006). The CDR loops have different roles during antigen 
recognition because of their position on the pMHC surface with the CDR2 loops 
contacting mainly the MHC helices, the more variable somatically rearranged CDR3 
loops contacting mainly the peptide and the peptide-proximal regions of the MHC 
helices and the CDR1 loops in-between (Cole et al., 2009). HV4s have also been 
found to contact the MHC and/or the peptide (Borbulevych et al., 2011; Miles et al., 
2010). Due to the fixed polarity, a number of TCR docking mode theories have been 
proposed (Colf et al., 2007; Mazza and Malissen, 2007) including the peptide-centric 
model where the TCR/peptide contacts determine the CDR1 and CDR2 footprint on 
the MHC helices and permits optimal contacts to be formed with the MHC surface 
(Sherman and Chattopadhyay, 1993) and the MHC-centric model where the shared 
structural determinants on MHC recognized by CDR1 and CDR2 determine the 
docking mode with disregard for the peptide or prior to peptide scanning by the 
hypervariable CDR3 loops (Daniel et al., 1998). 
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Figure 1.6. Crystal structure of the type 1 diabetes autoreactive 1E6 TCR 
complexed to HLA-A2 presenting the preproinsulin (PPI) self peptide PPI15-24 
to represent the overall structure of αβ TCR/pMHCI complex. 
(A) 1E6 (blue and orange cartoon) binds to PPI15-24 (yellow sticks) presented by 
HLA-A2 (grey and red cartoon) in a diagonal docking mode. (B) The black diagonal 
line indicates the mean crossing angle of TCRs onto pMHCs (~35°) (Rudolph et al., 
2006). (C) View down the center of the MHC binding groove showing the positions 
of the 1E6 TCR CDR loops (CDRα loops and CDRβ loops in blue and orange 
ribbon, respectively) when binding to HLA-A2 (grey cartoon) presenting PPI15-24 
(yellow sticks). The Vα domain mainly lies over the N-terminus of the peptide and 
the MHC α2-helix whereas the Vβ domain lies mainly over the C-terminus of the 
peptide and the MHC α1-helix. Figure adapted from the 1E6/A2-PPI15-24 structure 
(Bulek et al., 2012a).  
51 
 
Some evidence supports the peptide-centric theory, notably the analysis of TCRs 
with long CDR3β loops and pMHCs displaying bulged peptides (Borg et al., 2005; 
Housset and Malissen, 2003; Mazza and Malissen, 2007). Structure of a TCR bound 
to a MHCI displaying a 13-mer “super-bulged” peptide showed that the CDR2 loops 
made limited interactions with the MHC surface (Rudolph et al., 2006; Tynan et al., 
2005). The structure of a TCR bound to MHCI displaying an 11-mer peptide showed 
that the peptide is “bulldozed”, or flattened, by the TCR CDR3 loops during binding, 
allowing the TCR CDR2 loops to contact the MHC surface (Tynan et al., 2007). A 
further study showed that the TCR CDR1 and CDR2 loops played a minimal 
energetic role, compared to the CDR3 loops, during the binding of the LC13 TCR to 
HLA-B*0801-FLRGRAYGL (Borg et al., 2005). Finally, re-investigation of the 
interaction between the A6 TCR and the B7 TCR with HLA-A*0201-LLFGYPVYV 
(A2-Tax) (Ding et al., 1999; Ding et al., 1998; Garboczi et al., 1996), that share the 
same Vβ-gene (Vβ6-5) encoding their CDR1 and CDR2 loops, revealed that the A6 
and B7 TCRs bound to the same N-terminal region of the A2-Tax complex. This 
comparison showed that the A6 and B7 TCR CDR3 loops shared a number of 
identical contacts with the Tax peptide, whilst their CDR2 loops bound to distinct 
regions of HLA-A*0201-LLFGYPVYV. However, a second MHC-centric model of 
TCR engagement, known as the “two-step model”, has also been proposed (Wu et 
al., 2002). In a biophysical study, Wu et al. evaluated the contribution of IEk-MCC 
individual residues on the 2B4 TCR binding by mutating residues to alanine (alanine 
scan) and measuring the effects by surface plasmon resonance (Wu et al., 2002). The 
results suggested that MHC contacts dictated the initial association, guiding TCR 
docking in a way that was mainly independent of the peptide, whereas peptide 
contacts determined the stability of the binding. These authors concluded that this 
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two-step process facilitated the efficient scanning of diverse pMHC complexes on 
the surface of cells and also made TCRs inherently cross-reactive towards different 
peptides bound to the same MHC. Additionally, the murine 2C TCR was solved in 
complex with both self (Ld-QL9) and non-self (Kb-dEV8) antigens (Colf et al., 
2007). These data showed that the 2C TCR binding to the two antigens with different 
conformational modalities was not simply a result of the peptide/CDR3 interactions, 
hence supporting the MHC-centric model. Moreover, another recent study involving 
four murine TCRs expressing the same TRBV gene (Vβ8.2) suggested the existence 
of germline-encoded TCR/pMHC interaction “codons” allowing the TCRs to dock 
with an invariant modality by using “ancient” MHC anchor points (Feng et al., 
2007). In support of this notion, some conserved residue interactions between a TCR 
and a MHCI have been observed elsewhere (Rudolph et al., 2006). Among them, 
three residues within MHCI (positions 65 and 69 on the α1-helix and position 155 on 
the α2-helix), described as the “restriction triad” (Burrows et al., 2009; Tynan et al., 
2005), have shown the highest average number of contacts between the TCR and the 
MHCI in previously reported TCR/pMHCI structures (Rudolph et al., 2006). These 
fixed interactions support the idea that common TCR/MHC contacts could have an 
important role in conserving the diagonal docking mode (Bridgeman et al., 2012).  
 
Another important feature of the TCR/pMHC interaction is the conformational 
flexibility of both the TCR and the pMHC upon binding. Currently, three main types 
of conformational changes have been observed and are described in more detail 
elsewhere (Chapter 5). First, TCR flexibility has been shown upon pMHC 
engagement (CDR loops and constant domain) (Armstrong et al., 2008b; Beddoe et 
al., 2009). Second, movements of the MHC α-helices have been described (Auphan-
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Anezin et al., 2006). Finally, there have been reports that TCR binding can induce 
peptide conformational changes (Rudolph et al., 2006; Ruppert et al., 1993). This 
structural plasticity could be important for immune surveillance by allowing T-cells 
to cross-react with a large number of antigens (Housset and Malissen, 2003). The 
ability of TCRs to cross-react has been highlighted structurally with examples such 
as the BM3.3 TCR complexed to 3 pMHC ligands (Mazza et al., 2007; Reiser et al., 
2003; Reiser et al., 2000), the 2C TCR complexed to 4 pMHC ligands (Colf et al., 
2007; Degano et al., 2000; Garcia et al., 1998; Luz et al., 2002), the A6 TCR 
complexed to 5 pMHC ligands (Ding et al., 1999; Gagnon et al., 2006; Garboczi et 
al., 1996) and more recently the melanoma-specific TCRs DMF4 and DMF5 
complexed to 2 different melanoma pMHC ligands (Borbulevych et al., 2011). 
 
1.6 BIOPHYSICAL BASIS OF TCR/pMHC RECOGNITION 
1.6.1 Introduction to Surface Plasmon Resonance and biophysics 
It is possible to monitor the formation and the dissociation of complexes between 
biomolecules in real time using Surface Plasmon Resonance (SPR) biosensors. SPR 
biosensors have been used to characterise a diverse set of interaction partners (e.g. 
receptors, antibodies, enzymes, nucleic acids or viruses) and the information 
obtained from SPR analyses is both qualitative (e.g. epitope mapping or site 
specificity analyses) and quantitative (e.g. affinity, kinetic or thermodynamic 
analyses) (Karlsson, 2004). This section will briefly describe the physical basis of 
SPR and the different parameters obtained with this technique. 
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1.6.1.1 Basis of SPR 
SPR physical principles are complex and beyond the scope of this introduction but a 
basic understanding is useful to understand the data. Essentially, SPR detects 
changes in refractive index in the aqueous layer close to a sensor chip surface which 
correlates to the changes in mass or buffer composition (Figure 1.7A). When a light 
beam passes from material with a high refractive index into material with a low 
refractive index (e.g. glass and water, respectively) some light is reflected from the 
interface. At an angle of incidence (θ) above a critical angle of incidence (θc), the 
polarized light is completely reflected (total internal reflection) and by coating the 
glass surface with a layer of metal (e.g. gold) some of the light is “lost” into the 
metallic film (van der Merwe, 2001). This “lost” light generates an electromagnetic 
component called an evanescent wave which excites electrons in the gold film 
resulting in the formation of surface plasmons (electron charge density waves) 
within the gold film (Jason-Moller et al., 2006). At θ, the energy transfer is 
concomitant with a drop in the intensity of the reflected light, the reflected light 
angle being called the surface plasmon resonance angle (θspr or SPR angle). The 
local refractive index can be influenced by both biomolecules adsorbed onto the thin 
metal layer (ligands) and analytes in a mobile phase running along a flow-cell and 
binding to the ligands. Thus, if binding occurs, the local refractive index changes and 
it leads to modification in energy transfer and shift of θspr (Pattnaik, 2005). A 
sensorgram depicts the changes (∆θspr) which are monitored in real-time and 
measured in response or resonance units (RUs), 1 RU being the equivalent of a 10-4° 
θspr shift (Pattnaik, 2005; van der Merwe, 2001). SPR allows the determination of 
several ligand-receptor interaction parameters. The interaction between a TCR and a 
pMHC will be used to describe these parameters in the sections below.  
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Figure 1.7. Schematic representation of Surface Plasmon Resonance. 
(A) As the analyte (yellow) binds to the surface bound protein (red), the local 
refractive index shift and the SPR angle (θspr) moves from I to II. Figure adapted 
from (Homola, 2003). (B) Sensorgram representing the shift in θspr from I to II which 
is recorded as an increase in Response Units (RU) allowing the determination of the 
association (kon) and dissociation (koff) rate constants. Figure adapted from (Murphy 
et al., 2008). 
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1.6.1.2 Kinetic and affinity parameters 
The interaction between a TCR and a pMHC can be described by:  
 
Here, the kinetic parameters kon (or ka) and koff (or kd) are the association rate 
constant (or on-rate constant) and the dissociation rate constant (or off-rate constant) 
for the formation and the dissociation of the TCR/pMHC complex, respectively, and 
can be measured by SPR (Stone et al., 2009) (Figure 1.7B). kon is a measure of the 
time that a TCR at a given concentration takes to reach an equilibrated state of 
binding to the pMHC. Therefore, kon is measured in terms of complex formation per 
second in a 1 M solution of TCR and pMHC with its units being M-1s-1. koff is a 
measure of the stability of the TCR/pMHC interaction and does not depend on the 
TCR and pMHC concentrations. Therefore, koff is measured in terms of complex 
decay per second with its units being s-1. A related parameter, the half-life of the 
TCR/pMHC interaction (t1/2), can be derived from the koff. It represents the time 
needed for half of the TCR molecules to dissociate from the pMHC and can be 
calculated as t1/2=ln2/koff (Irving et al., 2012). When the reaction has reached 
equilibrium, the affinity of the TCR/pMHC interaction can be represented by the 
equilibrium association constant (KA) which is directly related to kon and koff. It is 
defined by the equation KA= kon/koff (Karlsson et al., 2006; van der Merwe, 2001) 
and thus has units M-1. However, the affinity is more commonly expressed in terms 
of equilibrium dissociation constant (KD), which is the inverse of KA (KD=1/KA) 
with KD=koff/kon having units in M. Therefore, an interaction with a fast kon and a 
slow koff will be of higher affinity than the opposite (slow kon and fast koff) and a 
lower KD equals a higher affinity. If the kinetic parameters are too fast to be 
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measured, these constants can be obtained using standard Scatchard approaches 
where at equilibrium 
 =
 × 



 
with the brackets (e.g. [TCR]) indicating the concentration of the molecules (De Mol 
and Fischer, 2008; Stone et al., 2009). Thus, in a typical SPR experiment with 
immobilized pMHC (ligands), when the concentrations of ligated and unligated 
pMHC are equal (i.e. half maximal RU in an SPR titration with increasing TCR 
concentrations) the KD is equal to the concentration of TCR required to reach this 
half saturation (Stone et al., 2009). Finally, the affinity can also be expressed in 
terms of “binding free energy” or standard Gibbs free energy (∆G° in cal.mol-1) from 
the affinity constants (van der Merwe, 2001) with units as follows: 
° =  

°
=  
1
 × °
= − 
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where R is the universal gas constant (1.9872 cal.K-1.mol-1), T is the absolute 
temperature in Kelvin (298.15 K = 25°C), C° is the standard concentration (1 M), KA 
or KD are the equilibrium affinity constants in M
-1 or M, respectively. 
 
1.6.1.3 Thermodynamic parameters 
Thermodynamic analysis of TCR/pMHC interactions has increased the 
understanding of the molecular determinants of TCR binding and specificity 
(Armstrong et al., 2008a). The binding free energy ∆G° of TCR/pMHC (or any 
protein-protein) interactions described in the previous section consists of a heat 
component taken up (endothermic reaction) or released (exothermic reaction) during 
the binding process, namely enthalpy (∆H°) (Murphy and Freire, 1995). The other 
component is entropy (∆S°), related to the variation in the degree of “order” during 
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binding (De Mol and Fischer, 2008). To obtain these thermodynamic parameters 
using SPR, KDs first have to be measured over a range of temperatures. If it is 
assumed that ∆H° is independent of the temperature, the linear form of the van’t 
Hoff equation can be applied: 
° =  

°
= ° − ° 
By plotting ln(KD/C°) (or ln(KD) only as C°=1 M) against 1/T for each temperature, 
∆H° and ∆S° will be deduced as the slope of the linear plot equals ∆H°/R and the y-
intercept equals -∆S°/R. However, for most protein/ligand interactions ∆H° varies 
with the temperature (van der Merwe, 2001). In this case, the non-linear (integrated) 
form of the van’t Hoff equation is fitted: 
° =    = ° − ° + ° −  − ° 


 
where T is the temperature in Kelvin (K) at which the KD is measured, T0 is the 
reference temperature (298.15 K = 25°C), ∆H° is the enthalpy change upon binding 
at T0 (cal.mol
-1), ∆S° is the standard entropy change upon binding at T0 (cal.mol
-1.K-
1) and ∆Cp° is the specific heat capacity (cal.mol
-1.K-1) which is assumed to be 
temperature-independent and is a measure of the variation of ∆H° with temperature. 
The variation of each parameter (∆H°, ∆S° and ∆Cp°) reflects the structural 
modifications occurring during binding (Armstrong et al., 2008a; Armstrong et al., 
2008b). ∆H° variation is caused by the formation and the disruption of non-covalent 
bonds (van der Waals (vdW), hydrogen and ionic bonds). A reaction with a negative 
∆H° is enthalpically favourable. This can be due to conformational rearrangements 
during the binding process and involves bonds between the TCR and the pMHC, but 
also bonds of solvent and intramolecular bonds (van der Merwe, 2001). For example, 
it has been estimated that trapping of water in a protein-protein complex could 
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increase the enthalpy binding from -1.5 to -3 kcal.mol-1 per water molecule (Cooper, 
2005) and that the average energy for the formation of a salt bridge is ~ -3.7 
kcal.mol-1 (Kumar and Nussinov, 1999). ∆S° is generally interpreted in terms of the 
change in the order/disorder balance during complex formation. It comprises the 
restriction of conformational freedom and alternation of bonds involved during 
binding. A reaction with a positive ∆S° indicates that disorder increases during 
binding, which is entropically favourable. Hydration can be an important factor for 
∆S° (e.g. in hydrophobic binding) as the burial of water-accessible surfaces can 
result in the expulsion of ordered water molecules and can contribute to the binding 
due to increases in entropy (De Mol and Fischer, 2008). ∆Cp° variation is almost 
entirely attributed to solvent effects and can be interpreted in terms of solvent-
accessible polar (hydrophilic) and apolar (hydrophobic) surface areas buried during 
binding (Murphy and Freire, 1995). An increase in accessible apolar surface 
increases ∆Cp° whereas the burial of apolar surface decreases ∆Cp°. However it is 
important to note that if the standard errors of the measured KDs are above 1%, ∆Cp° 
cannot be interpreted with statistical significance (Tellinghuisen, 2006; Zhukov and 
Karlsson, 2007). Indeed, as ∆Cp° is determined from the second derivative of ∆G° 
(directly related to KD) with respect to temperature, van’t Hoff ∆Cp° changes can 
vary with the exclusion of only a single data point or even a change in the error 
associated with a data point (Armstrong et al., 2008a; Zhukov and Karlsson, 2007). 
In a recent study, Zhukov and Karlsson assessed how uncertainty in KD 
measurement propagates to the thermodynamic parameters and concluded that 
comparison of protein-protein interactions with regard to the magnitudes of ∆Cp° 
should generally be avoided (Zhukov and Karlsson, 2007). 
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1.6.2 TCRs bind to pMHCs with weak affinity and relatively slow kinetics 
The biophysical data accumulated by techniques such as SPR or isothermal titration 
calorimetry (ITC) show that TCRs bind their cognate pMHCs with relatively weak 
affinity (KD = 0.1-270 µM) (Bridgeman et al., 2012; Cole et al., 2007) compared to 
other Ig-like proteins such as antibodies (KD = nM-pM) (van der Merwe and Davis, 
2003). MHCII-restricted TCRs seem to bind with a weaker affinity compared to 
MHCI-restricted TCRs with average KDs around 92 µM and 32 µM, respectively 
(Bridgeman et al., 2012; Cole et al., 2007). Likewise, anti-pathogen specific TCRs 
bind with a higher affinity compared to self-reactive TCRs (autoimmune or cancer-
specific TCRs) with average KDs around 8 µM and 90 µM, respectively (Bridgeman 
et al., 2012; Cole et al., 2007). As it has been recently shown that weak TCR binding 
affinity is generally associated with a less sensitive/effective T-cell response (Irving 
et al., 2012; Schmid et al., 2010; Thomas et al., 2011), these differences in affinity 
correlate with the idea that CD8+ T-cells recognizing the self-derived tumour-
associated antigens (TAAs) have been subjected to immune tolerance mechanisms in 
order to prevent autoimmunity (Boon et al., 2006).  
 
Kinetically, TCRs bind pMHCs with slow-to-moderate kons (generally between 10
3 
M-1.s-1 and 105 M-1.s-1) (Bridgeman et al., 2012; Davis et al., 1998), slower than the 
106 M-1.s-1 expected for this kind of geometrically constrained protein-protein 
interaction (Janin, 1997; Vijayakumar et al., 1998). Slow kons support the idea of 
TCR, MHC and peptide conformational flexibility in the unligated state, with only a 
particular conformation among the several conformations being able to bind the 
pMHC (Rudolph et al., 2002; Rudolph et al., 2006). However, in some cases kons are 
only slightly below 106 M-1.s-1, indicating that the conformational changes are most 
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likely small disorder-to-order transitions (Davis-Harrison et al., 2005). The range of 
the experimental koffs measured for the interaction between TCRs and agonist 
pMHCs is narrow (0.01 s-1 to 0.73 s-1), with an average koff of 0.24 s
-1, which is 
consistent with TCR/pMHC structural data showing a similar number of bonds 
between the different complexes (Bridgeman et al., 2012; Rudolph et al., 2006). 
Interestingly, several studies suggest that the koff most likely governs T-cell 
sensitivity. This tight kinetic window might allow T-cells to be really sensitive to a 
very low number of pMHCs because of T-cell activation by serial triggering or 
kinetic proofreading (see section 1.7 below) (Manz et al., 2011; Sewell, 2002) 
contrary to engineered T-cells expressing enhanced affinity TCRs displaying longer 
koffs (below the kinetic window) that fail to recognise low density pMHC ligands 
(Thomas et al., 2011). This notion is further supported by studies showing that faster 
koffs (above the kinetic window) can result in T-cell anergy and extremely fast koffs 
can lead to T-cell antagonism (Boulter et al., 2007). 
 
1.6.3 Thermodynamic features of TCR/pMHC interaction 
While the kinetic parameters and the affinities of TCR/pMHC interactions 
determined to date fall into a narrow window, the enthalpies and entropies associated 
with each complex can vary dramatically. TCRs were presumed to bind pMHCs with 
a “thermodynamic signature” consisting of an unfavourable entropy variation (∆S° < 
0) and a favourable enthalpy variation (∆H° < 0) (Willcox et al., 1999a; Willcox et 
al., 1999b). Together with the kinetic and structural data, the unfavourable entropy 
changes suggested that instead of only adjusting conformation upon binding, TCR 
CDR loops presented flexibility in the unbound state (Armstrong et al., 2008a). 
However, due to several observations of entropically favourable TCR/pMHC 
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interactions (Colf et al., 2007; Davis-Harrison et al., 2005; Ely et al., 2006), it is now 
clear that there is no enthalpic/entropic “signature” but rather different binding 
thermodynamic features depending on each particular TCR/pMHC complex. 
Currently, ∆H° varies from -30 to 18 kcal.mol-1 and ∆S° varies from -80 to 80 
cal.mol-1.K-1 (Armstrong et al., 2008a; Holland et al., 2012). Thermodynamic 
analysis, coupled to structural analysis, gives insight into how structural features 
contribute to binding energetics. Most of the thermodynamic data obtained so far 
correlates with the conformational changes and dynamics observed for TCR binding 
to pMHC, but unfortunately thermodynamic analyses are not available for all of the 
TCR/pMHC interactions for which both ligated and unligated TCR and/or pMHC 
structures are available (Armstrong et al., 2008b). Generally, data suggests that 
favourable enthalpy and unfavourable entropy can be linked to conformational 
changes (Willcox et al., 1999a) whereas unfavourable enthalpy and favourable 
entropy can be linked to the expulsion of solvent molecules upon binding (Cole et 
al., 2009).  
 
1.7 TCR TRIGGERING MODELS 
On the T-cell surface, the αβ TCR associates non-covalently with a signalling 
complex which contains a number of invariant CD3 transmembrane proteins 
including γ, δ, ε and ζ chains. These subunits associate with each other, forming the 
CD3ζζ homodimer and CD3εδ or CD3εγ heterodimers (Koning et al., 1990; 
Manolios et al., 1994). Immunoreceptor tyrosine-based activation motifs (ITAMs) 
are present in all CD3 subunits cytoplasmic domains and are phosphorylated by an 
intracellular tyrosine kinase called Lck upon T-cell antigen recognition (Barber et 
al., 1989). The phosphorylation of these tyrosine residues is known to be crucial in 
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TCR signalling leading to T-cell activation (Kersh et al., 1998a). The process by 
which TCR/pMHC interactions result in these biochemical changes is referred to as 
“TCR triggering” and there is currently no consensus on the mechanisms involved in 
this process (van der Merwe and Dushek, 2011). Several models of TCR triggering 
have been described including: (i) conformational change models (Alam et al., 1999; 
Reich et al., 1997), (ii) segregation/redistribution models (Davis and van der Merwe, 
1996; Viola et al., 1999), (iii) aggregation models (Boniface et al., 1998; Irvine et al., 
2002; Trautmann and Randriamampita, 2003), (iv) kinetic proofreading model 
(McKeithan, 1995; Rabinowitz et al., 1996) and (v) serial triggering model (Valitutti 
et al., 1995). The kinetic proofreading (KP) and serial triggering (ST) models are not 
mutually exclusive and are detailed below as they are relevant to the work presented 
in this thesis. 
 
First, the KP model proposed to explain how small differences in the half-life of the 
TCR/pMHC interactions are translated into differences in TCR signalling 
(McKeithan, 1995; Rabinowitz et al., 1996). It suggested that TCR signalling 
requires a series of sequential steps that are fully reversed upon dissociation of the 
TCR/pMHC complex (McKeithan, 1995; Rabinowitz et al., 1996). This model was 
notably supported by the partial phosphorylation of CD3 subunits occurring when a 
suboptimal ligand is presented to the TCR (Kersh et al., 1998b). The initial KP 
model proposed that a TCR must bind to a pMHC long enough to initiate the 
phosphorylation events that lead to T-cell activation, hence only the half-life/off-rate 
dictates the T-cell response (or absence of response) (McKeithan, 1995). However, 
the KP model was initially confronted by the ST model (or equilibrium affinity 
model (Jansson, 2011)) where T-cell activation is related to the KD of the 
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TCR/pMHC interaction (hence related to kon and koff) (Stone et al., 2009; Tian et al., 
2007). The ST model is based on the fact that small numbers of agonist pMHCs can 
trigger a large number of TCRs (Valitutti et al., 1995) and it has been shown that a 
single specific pMHC is sufficient for TCR triggering (Irvine et al., 2002). Contrary 
to the KP model, it stated that the on-rate was also involved in T-cell activation as 
the fast kons and relatively short half-lives of TCR/pMHC interactions would 
increase the number of engaged TCRs (Valitutti, 2012; Valitutti et al., 1995). 
Moreover, it was supported by the fact that T-cells expressing TCRs with an half-
life/affinity beyond a certain threshold (or “affinity ceiling”) might become less 
effective (Sewell, 2002). Indeed, by transducing CD8+ T-cells with different TCRs 
presenting a range of affinity for NY-ESO-1, Schmid et al. showed in a recent study 
that above a certain affinity threshold T-cell avidity and function were not further 
enhanced (Schmid et al., 2010). Finally, a theoretical study has recently shown 
support for both models (Dushek et al., 2009). Dushek et al. refined the initial KP 
model and suggested a new model in which fast kon allowed a single TCR to rebind 
to the same pMHC before diffusing apart and the rebinding was assumed to be fast 
enough to allow the activation steps. Thus, a fast on-rate can compensate a short 
half-life. Also, in a mathematical model based on TCR down-regulation for an array 
of TCR mutants, Coombs et al. suggested an optimal half-life of TCR/pMHC 
interaction by combining the KP and the ST models (Coombs et al., 2002). A short 
half-life led to TCRs failure to achieve the active proofreading step whereas a long 
half-life prevented serial engagement of the TCRs. 
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1.8 IMPROVING TCR AFFINITY 
As described earlier in this Chapter, TCRs bind their cognate pMHCs with relatively 
weak affinity (KD = 0.1-270 µM) and TCRs bind with a weaker affinity to tumour-
associated antigens compared to pathogenic antigens. As it has been shown that T-
cell sensitivity can be related to TCR affinity (Holler et al., 2001; Schmid et al., 
2010), extended research has been undertaken in order to enhance the affinity of the 
TCR/pMHC interaction. TCRs with improved affinity could be used for soluble 
therapy (described in Chapter 4) or for adoptive cell therapy (ACT) (described in 
Chapter 6). A number of different methods have been described to modulate TCR 
affinity such as direct isolation of high-affinity T-cell clones or genetic engineering 
of the TCR antigen-binding region (using in silico modelling or display 
technologies).  
 
1.8.1 Selection of high-affinity TCRs using allo-restriction 
High-affinity TCRs can be obtained by using alloreactive T-cells as such cells have 
undergone thymic selection in the absence of the restricting HLA molecule (Kronig 
et al., 2009; Sadovnikova and Stauss, 1996). Sadovnikova et al. published in 1996 a 
study where they isolated mouse CTLs specific for the Mdm2 (murine double-
minute 2) protein, an ubiquitously expressed self protein which is frequently over-
expressed in tumours and presented by allogenic H-2Kb class I molecules, using the 
allo-restricted T-cell repertoire of H-2d mice (Sadovnikova and Stauss, 1996). Thus, 
allo-restricted CTLs were generated by stimulating naive H-2d splenocytes with H-
2Kb APCs pulsed with mdm100 (an Mdm2-derived peptide). Approximately 50% of 
the CTL clones were of “high avidity” (meaning that they recognised low densities 
of antigenic peptide at the cell surface) and efficiently recognized Mdm2-expressing 
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tumour cells. Using similar allo-restricted approaches, several groups have isolated 
T-cell clones and TCRs (Kronig et al., 2009; Schuster et al., 2007; Wilde et al., 
2009) against different cancer-associated antigens. Using this method, Xue et al. 
isolated a TCR and CTL clones specific for an HLA-A2 restricted peptide epitope of 
the Wilms tumour antigen-1 (WT1) which could selectively kill immature human 
leukemia progenitor and stem cells in vitro (Xue et al., 2005). They isolated high-
avidity CTLs specific for WT1 peptide presented by HLA-A2 from HLA-A2 
negative (HLA-A2-) donors and CTLs from HLA-A2 positive (HLA-A2+) donors 
which were then transduced with the WT1-specific TCR using a retroviral vector. 
The gene-transduced T-cells acquired WT1 peptide specificity and showed stable 
long-term TCR expression. They also demonstrated that TCR-transduced human 
CTLs are functionally active in vivo, highlighted by the elimination of leukemia cells 
in the nonobese diabetic–severe combined immunodeficiency (NOD/SCID) mice 
(Xue et al., 2005). 
 
Instead of generating T-cells using an allo-restricted approach from HLA-
mismatched donors, a second option to avoid tolerance to self inducing low-affinity 
T-cells is to use TCRs from xenogenic T-cells that have matured in a non-tolerant 
host (Kieback and Uckert, 2010). HLA-A2 transgenic mice have been generated and 
can be immunized with a human antigenic peptide which is homologous to the 
mouse amino acid sequence (eg MDM233-41) or that differs from the mouse in critical 
positions (eg MDM280-88) (Stanislawski et al., 2001). Thus, it is possible to expand 
T-cells restricted to human MHC from a xenogenic repertoire. Using this method, 
several murine TCRs specific for human tumour associated antigens (eg MDM2, 
p53, gp100) have been isolated (Cohen et al., 2005; Morgan et al., 2006; 
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Stanislawski et al., 2001). However, the immunogenicity of fully murine or partially 
humanized mouse TCRs cannot be excluded if such proteins were used in human 
patients. 
 
1.8.2 Rational design of high-affinity TCRs 
Zoete et al. used a rational in silico design approach for the generation of high-
affinity TCRs (Zoete et al., 2010) that optimized the interaction between the TCR 
and the pMHC based on Molecular Mechanics-Generalized Born Surface Area 
(MM-GBSA) free energy calculations and crystal structures of TCR/pMHC 
complexes (Zoete and Michielin, 2007). For example, the MM-GBSA approach was 
applied to the BC1 TCR, this TCR being closely related to the 1G4 TCR (four amino 
acid differences between 1G4 and BC1) specific for NY-ESO-1, to estimate the 
contribution of individual amino acids to the binding energy with NY-ESO-1 (using 
1G4/A2-NY-ESO-1 crystal structure) and identify amino acid replacements in the 
BC1 TCR that would enhance or reduce the TCR/pMHC interaction (Irving et al., 
2012). By combining optimized BC1 TCR α and β chains they developed a panel of 
A2-NY-ESO-1 specific TCRs with up to 150-fold increase in affinity compared to 
the wild type BC1. 
 
Another rational design recently performed by Alli et al. involved the mutation of a 
glycine to serine at position 107 within the CDR3β stalk of TCRs. This group used 
structural analyses to identify a glycine-serine variation in the TCR that modulated 
antigen sensitivity (Alli et al., 2011). Glycine at position 107 (G107) is unique to 
TRBV13-2 in mice (among 23 TRBV) and to TRBV12-5 in humans (among more 
than 54 TRBV). The alignment of the TRVB revealed that most CDR3β displayed a 
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serine at position 107 (S107) both in mice (18/23 TRBV sequences) and humans 
(45/54) (Alli et al., 2012; Turner et al., 2006). Structural analyses revealed that the 
hydroxymethyl side chain of the S107 was positioned to intercalate into the core of 
the CDR3β loop and created a network of van der Waals bonds. On the contrary, 
G107 did not have any side chain and left a gap. They hypothesized that the gap 
present in TRBV13-2 CDR3β was energetically unfavourable and that a mutation 
into S107 would increase the stability and hence enhance the affinity. 
Experimentally, the mutation with a serine led to a ~10-1000 fold enhanced antigen 
sensitivity in 3 of 4 TRBV13-2 TCR tested but biophysical analyses was not 
performed to measure the affinity of the TCRs for their ligands and to evaluate the 
mechanism of their enhanced reactivity (Alli et al., 2011). 
 
1.8.3 Display technologies 
Despite being applied successfully for the development of monoclonal antibodies, 
initial efforts using a method to display and to select high affinity TCRs showed 
limited success (Weidanz et al., 1998). This was probably because of the difficulty in 
expressing TCRs in a soluble form, notably due to the reduced abilities of the TCR α 
and β chains to associate compared to the heavy and light chains of the antibodies 
(Rudolph et al., 2006). However, this problem was overcome with recent strategies 
using yeast, T-cell, or phage display (Figure 1.8) coupled to some of the methods 
described in Chapter 3 to improve TCR stability. Typically, in all three different 
display technologies, a T-cell clone that is specific for the desired pMHC antigen 
was used as a source for cloning the genes that encode the TCR α and β chains. After 
random or site-directed mutagenesis, these genes were cloned into the display system 
and selected for pMHC binding (Richman and Kranz, 2007).  
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Figure 1.8. Schematic representation of the different display technologies to 
increase TCR affinity. 
(A) Cartoon showing yeast display of a scTCR construct, including N- (HA) and C-
terminal (c-myc) expression tags, by fusion to the yeast mating protein Aga-2 which 
is, in turn, linked by disulfide bonds to the integral yeast cell wall protein Aga-1. The 
scTCR expression can be monitored by antibodies against the expression tag and the 
variable domains or with the specific pMHC (Figure adapted from (Stone et al., 
2012)). (B) T-cell display of a full-length TCR expressed on the surface of a TCR 
deficient T-cell hybridoma after transduction with a retrovirus (Figure adapted from 
(Richman and Kranz, 2007)). (C) Representation of the phage display process to 
engineer TCR affinity, the method used for the generation of the high-affinity TCRs 
used during my PhD. Individual CDR loops were mutated and inserted into three 
cistronic vector pEX746 with the TCR β chain fused to phage coat protein pIII and 
the TCR α chain targeted to the periplasm to allow its association with the β chain 
after transformation into E. coli. The produced phages, expressing a single TCR, 
were screened with the pMHC of interest and the best sequences for each loop were 
then combined. 
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The yeast display technology targets the TCR to the yeast cell surface by fusing the 
coding sequence to that of a native yeast mating protein Aga-2 (Stone et al., 2012) 
(Figure 1.8A). While this system has been successful in the isolation and affinity 
maturation of antibodies (Bowley et al., 2007; Siegel, 2009), TCRs have posed a 
more formidable challenge. In this display system, the TCR has been displayed as a 
stabilized single-chain TCR (scTCR), in the Vβ-linker-Vα form described in 
Chapter 3. Two mouse TCRs were engineered for higher affinity using this system: 
3.L2 TCR (MHC class-II restricted) which binds the foreign antigen I-Ek-Hb 
(Persaud et al., 2010) and 2C TCR (MHC class-I restricted) which binds an 
alloantigen H2-Ld-QL9, a foreign antigen H2-Kb-SIYR and a self-antigen H2-Kb-
dEV8 (Richman and Kranz, 2007). The major limitation in using this display 
technology for the generation of high-affinity TCRs is the need to mutate the TCR 
variable domains in order to allow the scTCR to be expressed on the yeast surface 
before affinity maturation. To date, the only TCRs that have been obtained with this 
yeast surface display are those with clonotypic antibodies that allowed for the 
stabilization and display of the single-chain format (Chervin et al., 2008). 
 
TCRs have also been engineered by T-cell display using a retroviral vector to 
introduce the TCR α and β chains into a TCR deficient T-cell hybridoma (Kessels et 
al., 2000) (Figure 1.8B). The introduced TCR was expressed on the surface in its 
native conformation, complexed with the CD3 subunits, allowing for a fully 
functional T-cell. Although TCRs have not been engineered for higher affinity using 
this method, Kessels et al. reported an alteration of the F5 TCRs specificity, the 
parental F5 TCR being specific of the influenza A epitope (ASNENMDAM) 
whereas one of the mutants had acquired a specificity for a different influenza A 
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strain epitope (ASNENMETM). A drawback of T-cell display is the more limited 
potential for combinatorial library diversity. This is related to low retroviral 
transduction efficiency. Even though Kessels et al. estimated that after optimization 
of transduction and sorting strategies it could be possible to achieve a retroviral TCR 
display libraries 106-107 in size (Kessels et al., 2000), mammalian cell libraries are 
more likely in the range of ~104 (Richman and Kranz, 2007) while yeast and phage 
display technologies reliably produce libraries of ~107 and ~1010 transformants, 
respectively (Li et al., 2005b; Stone et al., 2012). 
 
A third system, phage display, preceded the development of the yeast display system 
by almost a decade and has been used extensively to identify and affinity mature 
antibodies (Richman and Kranz, 2007). It targets the protein of interest on the 
surface of the phage by fusion to the N-terminus of a viral coat protein (Figure 
1.8C). As with yeast display and for the reasons described above (TCR stability), 
TCR engineering by phage display initially yielded limited success (Stone et al., 
2012). However, the stabilisation of the TCR α and β chain pairing described in 
Chapter 3 (‘Boulter-disulphide’ method for “dsTCRs”, section 3.2.1) has helped to 
solve these issues and allowed affinity maturation of TCRs by phage display 
(Boulter et al., 2003; Li et al., 2005b). Individual CDR loops were mutated and 
“dsTCRs” were cloned into a three cistronic vector (pEX746) for phage display, with 
the TCR β chain fused to phage coat protein pIII and the TCR α chain targeted to the 
periplasm to allow its association with the β chain (Li et al., 2005b). Vectors were 
then transformed into E. coli and the produced phage, expressing a single dsTCR, 
were screened with the pMHC of interest. The best CDR sequences for each loop 
(from TCRs displaying enhanced affinities) were then combined to create high-
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affinity TCRs. Li et al. generated more than ten different high-affinity TCRs using 
phage display and this affinity maturation method has generated the highest 
TCR/pMHC binding affinity to date (KD = 26 pM) (Li et al., 2005b). For example, a 
variant of the A6 TCR specific for the HTLV-1 Tax peptide displayed a binding 
affinity (KD = 2.5 nM) 720 times stronger than the wild type TCR (KD = 1.8 µM) (Li 
et al., 2005b) and high-affinity variants of the SL9 TCR specific for the HIV Gag 
peptide were recently used to design artificial HIV specific T-cells with an enhanced 
ability to kill HIV infected cells (Varela-Rohena et al., 2008). Finally, the high-
affinity variants of MEL5 TCR used during my PhD were generated with this 
method. 
 
1.9 AIMS OF THE THESIS 
The work reported within this thesis aims to further improve our knowledge of the 
interaction between the T-cell receptor (TCR) and the peptide-major 
histocompatibility complex (pMHCI). Specifically, I aimed to: 
1. Develop an optimized screen for the crystallization of TCR/pMHC 
complexes 
2. Analyse the specificity of a high-affinity TCR directed against a melanoma 
antigen 
3. Investigate the structural and biophysical differences between TCRs with 
different affinities in the recognition of melanoma antigens 
4. Determine the optimal TCR affinity for adoptive cell therapy directed against 
melanoma 
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2.1 BACTERIAL CELL CULTURE 
2.1.1 Culture medium and bacterial strains 
Luria-Bertani (LB) medium: 10 g/L tryptone (Fisher Scientific), 5 g/L yeast extract 
(Fisher Scientific) and 5 g/L NaCl (Fisher Scientific). 
 
LB agar medium: 15 g/L agar bacteriological (Oxoid), 10 g/L tryptone (Fisher 
Scientific), 5 g/L yeast extract (Fisher Scientific), 5 g/L NaCl (Fisher Scientific) and 
supplemented with 30 mg/L kanamycin (Sigma-Aldrich®) or 50 mg/L carbenicillin 
(Sigma-Aldrich®) for the selection of transformants. 
 
TYP medium: 16 g/L tryptone (Fisher Scientific), 16 g/L yeast extract (Fisher 
Scientific), 5 g/L NaCl (Fisher Scientific) and 2.5 g/L potassium phosphate dibasic 
(Acros organics). 
 
Freezing medium: LB medium mixed with 25% glycerol (Sigma-Aldrich®). 
E. coli One Shot® TOP10 (Invitrogen™) competent cells were used as host for all 
DNA manipulations except with lenti vectors pELNSxv and grown in LB medium. 
E.coli XL10-Gold® (Stratagene) competent cells were used as host for lenti vectors 
and grown in LB medium. E. coli Rosetta 2(DE3)pLysS (Novagen®) competent 
cells were used for protein expression and grown in TYP medium. All cells were 
grown at 37°C. 
 
2.1.2 Transforming competent cells 
Transformation was performed as described by the vendors (Invitrogen™, 
Stratagene and Novagen®). Briefly, 25 µL of competent cells were thawed on ice for 
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5 min and 1 µL (approximately 50 ng to 100 ng) of plasmid DNA was added to the 
aliquot. After 10 min incubation on ice, cells were incubated in a water bath at 42°C 
for 30 sec. After a 2 min recovery period on ice, 125 µL of room temperature (RT) 
S.O.C. media (Invitrogen™) was added and the mix was incubated at 37°C and 220 
revolutions per minute (rpm) for 1 hour in an Orbi-Safe New Orbit incubator 
(Sanyo). Bacterial cells were then streaked out on LB agar medium plates 
supplemented with antibiotics and grown overnight at 37°C. Several of the colonies 
that grew were then picked, cultured overnight into LB medium supplemented with 
30 mg/L kanamycin or 50 mg/L carbenicillin and cells were centrifuged and re-
suspended in freezing medium for storage. 
 
2.2 MOLECULAR BIOLOGY 
2.2.1 Plasmids 
All the plasmids were purified using a QIAprep spin Miniprep Kit (Qiagen), 
Zippy™ Plasmid Miniprep Kit (Zymo Research) or PureLink HiPure Plasmid Filter 
Purification Kit (Invitrogen™) following the manufacturer’s recommendations and 
DNA concentration was measured using a NanoDrop ND1000 (Thermo Scientific). 
 
2.2.1.1 Vectors for protein expression 
The pGMT7-plasmid (Banham and Smith, 1993) was used as the vector for protein 
expression, conferring a resistance to ampicillin/carbenicillin. It contains a sequence 
encoding the protein of interest inducible with IPTG (Isopropyl β-D-1-
thiogalactopyranoside) under the control of the T7 promoter, the sequence being 
cloned between BamHI and EcoRI restriction sites. These vectors, initially generated 
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by PCR mutagenesis and PCR cloning, were used to produce the α-chain and the β-
chain soluble domains of MEL5 and α24β17 TCRs, HLA-A2 heavy chain, biotin 
tagged HLA-A2 heavy chain and β2m (Appendix 1). 
 
2.2.1.2 Vectors for the production of lentivirus 
Eight sequences encoding different proteins for the lentiviral expression of TCRs 
with different affinities toward a melanoma antigen were designed. After being 
chemically synthesized by GeneArt, plasmids rCD2-pMA, MEL5-pMA, Mel αwtβ5-
pMA, Mel αwtβ9-pMA, Mel αwtβ12-pMA, Mel αwtβ13-pMA, Mel αwtβ15-pMA 
and Mel αwtβ17-pMA were generated. All plasmids conferred a resistance to 
kanamycin (Table 2.1). These plasmids were used as starting vectors in the cloning 
strategy (section 2.2.2) and sequences were inserted into the lenti vector pELNSxv 
(Dull et al., 1998) to obtain 7 different lenti vector listed in Table 2.1. Packaging 
plasmids for the production of lentiviruses were pRSV.REV, pMDLg/p.RRE and 
pVSV-G (Dull et al., 1998) and, as well as pELNSxv, conferred a resistance to 
ampicillin/carbenicillin. 
 
2.2.2 Cloning of a range of different affinity TCRs toward melanoma into a 
lentiviral vector 
All the different cassettes cloned into pELNSxv were based on the same model. The 
2A-like sequences (T2A and P2A) were utilized to construct a tricistronic vector 
bearing the TCR α chain along with the TCR β chain and the rCD2 reporter gene. 
Restriction sites XbaI and BspEI, SmaI and XhoI, and NsiI and SalI, flanked the 
TCR α chain, TCR β chain and rCD2, respectively (Chapter 6 Figure 6.4).  
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Table 2.1. List of the different lenti vectors generated during my PhD. 
Starting 
vector 
MEL5-
pMA 
Mel 
αwtβ5-
pMA 
Mel 
αwtβ9-
pMA 
Mel 
αwtβ12-
pMA 
Mel 
αwtβ13-
pMA 
Mel 
αwtβ15-
pMA 
Mel 
αwtβ17-
pMA 
Destination 
vector 
rCD2-pMA 
Cloning 
sites 
XbaI/XhoI 
Intermediat
e cloning 
vector 
MEL5 
rCD2-
pMA 
Mel 
αwtβ5 
rCD2-
pMA 
Mel 
αwtβ9 
rCD2-
pMA 
Mel 
αwtβ12 
rCD2-
pMA 
Mel 
αwtβ13 
rCD2-
pMA 
Mel 
αwtβ15 
rCD2-
pMA 
Mel 
αwtβ17 
rCD2-
pMA 
Destination 
vector 
pELNSxv 
Cloning 
sites 
XbaI/SalI 
Final lenti 
vector 
pELNSx
v MEL5 
rCD2 
pELNSx
v Mel 
αwtβ5 
rCD2 
pELNSx
v Mel 
αwtβ9 
rCD2 
pELNSx
v Mel 
αwtβ12 
rCD2 
pELNSx
v Mel 
αwtβ13 
rCD2 
pELNSx
v Mel 
αwtβ15 
rCD2 
pELNSx
v Mel 
αwtβ17 
rCD2 
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First, the cassettes TCR α chain-T2A-TCR β chain were excised from the GeneArt 
starting vectors using XbaI and XhoI restriction enzymes and cloned into the 
linearized rCD2-pMA destination vector (Table 2.1). E. coli One Shot® TOP10 
(Invitrogen™) competent cells were transformed with the new pMA intermediate 
plasmids (Table 2.1). Plasmids were then purified and sequences were confirmed by 
automated DNA sequencing (Lark Technologies). The TCR-rCD2 cassettes were 
then excised from positive intermediate plasmids using XbaI and SalI restriction 
enzymes and cloned into linearized pELNSxv to obtain 7 different lenti vectors 
(Table 2.1). 
 
2.2.3 Enzymatic digestion 
All restriction endonucleases and enzymatic digestion buffers were purchased from 
New England Biolabs. Enzymatic digestion of plasmid DNA was performed in a 
final volume of 20 µL with 2 µg of plasmid and a restriction enzyme volume 
maintained at less than 10% of the total volume. After a 2h00 incubation at 37°C, 
restriction fragments were separated by electrophoresis. 
 
2.2.4 Agarose gel purification and ligation 
The enzymatic digestion sample was mixed with 5 µL of DNA Loading Buffer 
(Bioline) and restriction fragments were separated by electrophoresis for 1h00 at 100 
V in a 1% agarose (Invitrogen™) gel containing 1X SYBR safe DNA gel stain 
(Invitrogen™) in 100 mL of Tris-acetate-EDTA buffer. A molecular weight marker 
(HyperLadder™ I, Bioline) was loaded at the same time as the samples to estimate 
the size of the restriction fragments and they were visualised with a Transilluminator 
(Modern Biology Inc). Inserts and vector backbones of interest were then extracted 
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and purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s recommendations and DNA concentration measured 
using NanoDrop ND1000 (Thermo Scientific). The ligation of inserts into vector 
backbones was performed using 1 µL of T4 DNA ligase (New England Biolabs) and 
50 ng of vector backbone with a molecular ratio of vector to insert of 1:1 and 1:3 in a 
final volume of 10 µL of DNA ligase buffer (New England Biolabs) at RT for 30 
min. Ligation product was then used to transform competent E. coli as described in 
section 2.1.2. 
 
2.3 PROTEIN CHEMISTRY 
2.3.1 Protein expression as inclusion bodies 
E. coli Rosetta 2(DE3)pLysS transformed with a pGMT7-derived plasmid vector 
containing the sequence encoding the protein of interest were grown overnight at 
37°C on LB agar plate supplemented with 50 mg/L carbenicillin. A starter culture of 
the clone producing the most protein of interest was first prepared. In order to do so, 
individual colonies were picked and grown at 37°C and 220 rpm in 30 mL of TYP 
supplemented with carbenicillin until the suspension reached an optical density at 
600 nm (OD600) between 0.4 and 0.6. The protein production was induced in a 5 mL 
aliquot using 0.5 mM IPTG (Fisher Scientific) for 3h00. 20 µL of suspension with 
and without induction were subjected to SDS-PAGE analysis and the gel was stained 
with SimplyBlue™ SafeStain (Invitrogen™) as described in section 2.3.5. Starter 
cultures were then added to 1 L of TYP, supplemented with 100 µM carbenicillin, 
and cells were grown as described above until the suspension reached an OD600 
between 0.4 and 0.6. Protein expression was induced for 3h00 with 0.5 mM IPTG 
and cells were then centrifuged for 20 min at 4000 rpm in a Legend RT centrifuge 
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(Sorvall®) with a Heraeus 6445 rotor. The pellet was dissolved in 40 mL of lysis 
buffer (10 mM Tris pH 8.1 (Fisher Scientific), 10 mM magnesium chloride (MgCl2) 
(Acros organics), 150 mM NaCl (Fisher Scientific), 10% glycerol (Sigma-
Aldrich®)), sonicated on ice for 30 min at 60% power using a 2 sec interval with a 
Sonopuls HD 2070 coupled to a MS73 probe (Bandelin) and incubated at RT for 30 
min with 0.1 g/L DNAse (Fisher Scientific). The suspension containing proteins in 
the form of inclusion bodies (IB) was treated twice with 100 mL of wash buffer 
(0.5% Triton® X100 (Sigma-Aldrich®), 50 mM Tris pH 8.1 (Fisher Scientific), 100 
mM NaCl (Fisher Scientific), 10 mM EDTA pH 8.1 (Fisher Scientific)) and 20 min 
of centrifugation at 4°C and 10 000 rpm with an Evolution RC centrifuge and a 
SLA-1500 rotor (Sorvall®). The pellet was re-suspended in 100 mL of re-suspension 
buffer (50 mM Tris pH 8.1 (Fisher Scientific), 100 mM NaCl (Fisher Scientific), 10 
mM EDTA pH 8.1 (Fisher Scientific)) and centrifuged as before at 10 000 rpm. 
Finally, the pellet was dissolved in 10 mL of guanidine buffer (6 M guanidine 
(Fisher Scientific), 50 mM Tris pH 8.1 (Fisher Scientific), 2 mM EDTA pH 8.1 
(Fisher Scientific), 100 mM NaCl (Fisher Scientific)) and the protein concentration 
was determined by measuring the optical density at 280 nm (OD280) using NanoDrop 
ND1000 (Thermo Scientific). A 20 µL fraction of the suspension in lysis buffer, 
washing buffer and re-suspension buffer was subjected to SDS-PAGE and stained 
with SimplyBlue™ SafeStain (Invitrogen™) (described in section 2.3.5) during this 
process in order to check the quality of the IB production. 
 
2.3.2 Refolding of pMHCI 
Approximately 30 mg of HLA-A2 (or HLA-A2 with a biotin tag) heavy-chains IB 
preparation, 30 mg of β2m IB preparation and 4 mg of peptide (ProImmune) were 
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mixed and denatured for 30 min at 37°C in a final volume of 6 mL of guanidine 
buffer supplemented with 10 mM dithiothreitol (DTT) (Sigma-Aldrich®). Protein 
refolding was initiated by diluting the previous mix in 1 L of a pre-chilled MHC 
redox buffer (50 mM Tris pH 8.1 (Fisher Scientific), 400 mM L-arginine (SAFC®), 
2 mM EDTA pH 8.1 (Fisher Scientific), 6 mM cysteamine (Sigma-Aldrich®) and 4 
mM cystamine (Sigma-Aldrich®)). Protein refolds were then left stirring at 4°C for 
3h00, transferred into 12.4 kDa MWCO (molecular weight cut-off) dialysis tubing 
(Sigma-Aldrich®), dialysed twice for 24h00 against 20 L of 10 mM Tris pH 8.1 
(Fisher Scientific) and finally filtered on Metricel® 0.45 µm membrane filter (Pall) 
and purified by anion exchange and gel filtration (described in section 2.3.4). 
 
2.3.3 Refolding of soluble TCR 
Approximately 30 mg of TCR α chain IB preparation and 30 mg of TCR β chain IB 
preparation were denatured separately for 30 min at 37°C in 3 mL of guanidine 
buffer supplemented with 10 mM DTT (Sigma-Aldrich®). Protein refolding was 
initiated by diluting the denatured TCR α chain in 1 L of a pre-chilled TCR redox 
buffer (50 mM Tris pH 8.1 (Fisher Scientific), 2.5 M urea (Sigma-Aldrich®), 2 mM 
EDTA pH 8.1 (Fisher Scientific), 6 mM cysteamine (Sigma-Aldrich®) and 4 mM 
cystamine (Sigma-Aldrich®)) for 30 mins. The denatured TCR β chain was then 
added to the TCR redox buffer and TCR refolds were then left stirring at 4°C for 
3h00. Refolds were transferred into 12.4 kDa MWCO dialysis tubing (Sigma-
Aldrich®), dialysed twice 24h00 against 20 L of 10 mM Tris pH 8.1 (Fisher 
Scientific), filtered on Metricel® 0.45 µm membrane filter (Pall) and purified by 
anion exchange and gel filtration methods described below. 
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2.3.4 Fast Protein Liquid Chromatography (FPLC) purification 
Refolded proteins were purified first by anion exchanged and then by gel filtration 
using Fast Protein Liquid Chromatography (FPLC). The filtered refold preparation 
was loaded onto a 7.9 mL POROS® 10/100 HQ 50 µm column (Applied 
Biosystems™) pre-equilibrated with 20 mL of 10 mM Tris pH 8.1 (Fisher 
Scientific). Proteins were then eluted at 5 mL/min with a salt gradient (0-500 mM 
NaCl in 10 mM Tris pH 8.1) and 1 mL fractions were collected. Fractions 
corresponding to the protein of interest were analysed by SDS-PAGE (described in 
section 2.3.5) and fractions containing the protein of interest were pooled together 
and concentrated down to 500 µL with 10 kDa MWCO Vivaspin 20 (Sartorius) or 10 
kDa MWCO Vivaspin 4 (Sartorius) by centrifugation for 20 min at 4000 rpm and 
4°C in a Legend RT centrifuge (Sorvall®) with a Heraeus 6445 rotor. Proteins were 
stored at 4°C before gel filtration. Concentrated protein preparations were then 
loaded with a 2 mL injection loop onto a 24mL Superdex 200 10/300 GL column 
(GE Healthcare) pre-equilibrated with the appropriate elution buffer (Phosphate 
Buffer Saline (PBS, Oxoid), BIAcore buffer HBS (10 mM HEPES pH 7.4, 150 mM 
NaCl, 3.4 mM EDTA and 0.005% surfactant, GE Healthcare) or crystal buffer (10 
mM Tris pH 8.1 (Fisher Scientific) and 10 mM NaCl (Fisher Scientific))). Elution 
was performed at a flow-rate of 0.5 mL/min and 1 mL fractions containing the 
protein of interest were analysed by SDS-PAGE and concentrated down, as 
described above, to 100 µL. Protein concentration was measured by UV 
spectrophotometry on spectrophotometer Biomate 3 (Thermo Spectronic). 
Absorbance value at 280 nm was used to calculate the protein concentration 
(!"#$%&) using the Beer-Lambert law !"#$%& =
'()*
+,-./012×34560//0
 where the distance 
the light travels through the cuvette (789$##$ ) is 1 cm and the molar extinction 
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coefficient (:!"#$%&) obtained with ProtParam software (Wilkins et al., 1999) equals 
95800 M-1.cm-1 for pMHCI complexes, 77350 M-1.cm-1 for the MEL5 TCR and 
86860 M-1.cm-1 for the α24β17 Mel TCR. Pure protein sample was then kept at 4°C 
if used within two days or frozen at -20°C for short-term storage and -80°C for long-
term storage. 
 
2.3.5 Sodium dodecyl sulphate – Polyacrylamide gel electrophoresis and 
SimplyBlue™ staining 
Proteins were separated by Sodium dodecyl sulphate - Polyacrylamide gel 
electrophoresis (SDS-PAGE) using the NuPAGE® system (Invitrogen™). A 20 µL 
aliquot of protein sample was mixed with 5 µL of 5X Laemmli buffer (Laemmli, 
1970) (315 mM Tris pH 6.4 (Fisher Scientific), 10% glycerol (Sigma-Aldrich®), 2% 
SDS (Sigma) and 0.0125% Bromophenol Blue (Sigma)) and denatured at 95°C for 
5min (non-reducing conditions). For reducing conditions, 50 mM DTT (Sigma-
Aldrich®) was added prior to denaturation. Samples were analysed on NuPAGE® 
Novex® 4-12% Bis-Tris gels in 1X NuPAGE® MES running buffer at 200 V for 45 
min and 10 µL of SeeBlue Plus 2 Pre-stained Standards (Invitrogen™) or 5 µL of 
BLUeye Prestained Protein Ladder (GeneDirex®) was used as molecular weight 
marker. The gels were stained with SimplyBlue™ SafeStain (Invitrogen™) and 
destained with Milli-Q water (Millipore™) following the manufacturer’s 
instructions. 
 
2.3.6 Biotinylation of pMHCI and manufacture of pMHCI tetramer 
For the multimerization of pMHCI molecules, biotin-tagged pMHCI complexes 
were first biotinylated. An aliquot of biotin-tagged pMHCI complexe, previously gel 
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filtrated in PBS, was adjusted to 700 µL with PBS and mixed with 100 µL of Biomix 
A (0.5 M Biocine buffer pH 8.3) (Avidity), 100 µL of Biomix B (100 mM ATP, 100 
mM MgOAc, 500 µM d-Biotin), 100 µL of d-Biotin (500 µM) (Avidity) and 1 µL of 
BirA enzyme (Biotin Protein Ligase) (Avidity) at 3 mg/mL. The mix was incubated 
for 2h00 at 37°C and gel filtrated in BIAcore buffer as described above in order to 
remove the excess of biotin. Biotinylated monomers were used for BIAcore 
experiments and, after multimerization, as tetramers in cell assays. 
 
Multimerization of the pMHCI molecules was performed by adding R-phycoerythrin 
(PE) conjugated streptavidin (Invitrogen™) or allophycocyanin (APC) conjugated 
streptavidin (Invitrogen™) in aliquots to saturate the biotin binding sites to a molar 
ratio pMHCI:conjugate of 4:1. Tetramer names are formed with the first 3 letters of 
the peptide followed by the chromophore name (eg for a tetramer presenting the 
peptide ELAGIGILTV and coupled to the R-phycoerythrin the name will be ELA-
PE). 
 
2.4 SURFACE PLASMON RESONANCE 
For both Surface Plasmon Resonance (SPR) methods, equilibrium-binding analysis 
and kinetic analysis, experiments were performed with a BIAcore 3000, or T100® 
(GE Healthcare) equipped with a CM5 sensor chip (GE Healthcare). Briefly, CM5 
chip coupling solutions (GE Healthcare) containing 100 µL of 100 mM NHS (N-
hydroxysuccinimide) and 100 µL of 400 mM EDC (1-ethyl-3-(3-dimethylpropyl)-
carboiimide) were used to activate the chip prior to streptavidin binding. 
Approximately 5000 response units (RU) of streptavidin (110 µL of 200 µg/mL in 10 
mM acetate pH 4.5 (Sigma-Aldrich®)) was covalently linked to the chip surface in 
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all four flow-cells and 100 µL of 1 M ethanolamine hydrochloride was use to 
deactivate any remaining reactive groups. 
 
2.4.1 Equilibrium-binding analyses 
For the equilibrium-binding analyses, biotinylated pMHCI at ~1 µM in BIAcore 
buffer was coupled to the streptavidin-coated chip. Approximately 500-2000 RU of 
pMHCI was attached to the CM5 sensor chip at a slow flow-rate of 10 µL/min to 
ensure uniform distribution on the chip surface. The surface was then saturated with 
1 mM biotin (Avidity) in BIAcore buffer. Ten serial dilutions (1 2<  dilutions) of 
soluble TCRs (MEL5 or Mel α24β17) in BIAcore buffer were injected over the 
relevant flow-cells at a high flow-rate of 45 µL/min at the concentrations indicated 
and at 25°C. For the thermodynamics experiments, this method was repeated at the 
following temperatures: 5°C, 10°C (MEL5 only), 13°C (α24β17 only), 15°C, 20°C, 
25°C, 30°C. Results were analysed using BIAevaluation 3.1 (GE Healthcare), Excel 
(Microsoft) and Origin 6.0 (Microsoft) software. The equilibrium binding constant 
(KD) values were calculated assuming a 1:1 interaction (= + > ↔ =>) by plotting 
specific equilibrium-binding responses against protein concentrations followed by 
non-linear least squares fitting of the Langmuir binding equation => =
@×@ABC
DEF@
. 
The thermodynamic parameters were calculated using the non-linear van’t Hoff 
equation (RT ln KD = ∆H° –T∆S° + ∆Cp°(T-T0) – T∆Cp° ln (T/T0)) with T0=298 K. 
 
2.4.2 Kinetic analyses 
Two different methods were used to obtain the kinetics (kon and koff): “single 
injection kinetics” and “single cycle kinetic” (Karlsson et al., 2006). Approximately 
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200 RU of biotinylated pMHCI at ~1 µM in BIAcore buffer was coupled to the 
streptavidin-coated chip at a slow flow-rate of 10 µL/min and the chip was then 
saturated with biotin (Avidity). α24β17 soluble TCR was injected at a high flow-rate 
of 45 µL/min in order to limit the effects of mass-transport on binding association 
measurements and re-binding effects on the measurement of TCR dissociation. 
 
For the “single injection kinetics” method, the α24β17 soluble TCR at approximately 
430 nM was injected for 240 sec (association time) over the four flow-cells and then 
the BIAcore buffer was injected for 1200 sec at the same flow-rate (dissociation 
time) at 25°C. Responses were measured in real-time and association rate constant 
(kon), dissociation rate constant (koff) and equilibrium binding constant ( =
G.HH
G.2
) 
were estimated by fitting of the data using BIAevaluation 3.1 (GE Healthcare) 
software. 
 
For the “single cycle kinetic” method, five serial dilutions (1 3<  dilutions) of the 
α24β17 soluble TCR from approximately 460 nM to approximately 6 nM was 
injected for 200 sec at 25°C. The dissociation time between each injection was 120 
sec and the dissociation time after the last injection was 3600 sec. Constants (kon, koff 
and KD) were estimated by global fitting of the data using BIAevaluation 3.1 (GE 
Healthcare) software. For the thermodynamics experiments, this method was 
repeated at the following temperatures: 5°C, 7°C, 12°C, 15°C, 19°C, 22°C, 25°C, 
30°C, 32°C, 35°C, 37°C and 40°C. The thermodynamic parameters were calculated 
using the non-linear van’t Hoff equation with Origin 6.0 software. 
89 
 
2.5 CRYSTALLOGRAPHY 
2.5.1 Crystallisation conditions for α24β17, A2-ELA-4A and α24β17/pMHCI 
complexes 
All protein crystallisation trials were set up in-house on a Phoenix (Art Robbins 
Instruments) crystallisation robot. Crystals were grown by vapour diffusion at 18°C 
via the sitting drop technique in 96-well Intelli-plate (Art Robbins Instruments) with 
a reservoir containing 60 µL of crystallisation buffer (mother liquor). 
 
For α24β17 TCR and A2-ELA-4A pMHCI crystallisation, the soluble TCR and 
pMHCI were concentrated down to approximately 10 mg/mL (0.2 mM) in crystal 
buffer. For the α24β17/pMHCI complexes crystallisation, TCR and pMHCI were 
mixed with a 1:1 molar ratio to obtain a protein solution at approximately 10 mg/mL 
(0.1 mM). Proteins were mixed with crystallisation buffers at a volume ratio of 1:1 
(0.2 µL protein and 0.2 µL mother liquor) from screens presented in Chapter 3. 
Crystallised proteins and optimal crystallisation buffers are detailed in Table 2.2. 
 
2.5.2 Crystallisation conditions for MEL5/A2-AAG and MEL5/A2-EAA 
complexes 
2.5.2.1 MEL5/A2-AAG: different TCR/pMHCI complexes mixing 
The crystallisation method presented above was slightly modified in order to obtain 
crystals for MEL5/A2-AAG complex. The protein solution of MEL5/A2-AAG 
complex at 0.1 mM in crystal buffer was supplemented with 1 µM of α24β17/A2-
AAG complex in crystal buffer. Crystallisation trial was then performed as described 
above.  
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Table 2.2. Crystallised proteins and optimal crystallisation buffer. 
Crystal 
Buffer (Molecular 
Dimensions) 
Polyethylene glycol 
(PEG) (Molecular 
Dimensions) 
Ammonium 
sulphate 
(Sigma-
Aldrich®) 
Glycerol 
(Sigma-
Aldrich®) 
α24β17 
0.1 M sodium 
cacodylate pH 6.5 
20% PEG 8000 0.2 M  
A2-ELA-4A 
0.1 M sodium 
cacodylate pH 6.0 
20% PEG 8000 0.2 M  
α24β17/A2-ELA 
0.1 M HEPES pH 
7.0 
20% PEG 4000 0.2 M  
α24β17/A2-EAA 
0.1 M HEPES pH 
7.5 
15% PEG 4000 0.2 M 8.7% 
α24β17/A2-AAG 
0.1 M HEPES pH 
7.0 
20% PEG 4000  15% 
α24β17/A2-ELA-4A 0.1 M Tris pH 7.5 15% PEG 4000  17.4% 
α24β17/A2-ELA-7A 
0.1 M Bis Tris 
propane pH 7.0 
20% PEG 4000 0.2 M 17.4% 
MEL5/A2-AAG 
0.1 M HEPES pH 
7.5 
25% PEG 4000  15% 
MEL5/A2-EAA 0.1 M Tris pH 7.5 15% PEG 4000  15% 
 
Table 2.3. Beamlines, wavelengths of detection and detectors used for each 
crystal at DLS. 
 
  
Crystal 
DLS 
beamline 
Wavelength of 
detection (Å) 
Detector 
α24β17 I24 0.978 Rayonix MX300 
A2-ELA-4A I03 0.976 ADSC Q315 CCD 
α24β17/A2-ELA I03 0.976 ADSC Q315 CCD 
α24β17/A2-EAA I02 0.979 ADSC Q315r 
α24β17/A2-AAG I03 0.976 ADSC Q315 CCD 
α24β17/A2-ELA-4A I03 0.976 ADSC Q315 CCD 
α24β17/A2-ELA-7A I03 0.976 ADSC Q315 CCD 
MEL5/A2-AAG I04-1 0.916 Marmosaic 300mm CCD 
MEL5/A2-EAA I04-1 0.916 Marmosaic 300mm CCD 
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Optimal crystals were obtained in 0.1 M HEPES pH 7.5 (Molecular Dimensions), 
15% glycerol (Sigma-Aldrich®) and 25% PEG 4000 (Molecular Dimensions) 
(Table 2.2). 
 
2.5.2.2 MEL5/A2-EAA: seeding from MEL5/A2-AAG 
The seeding kit Seed Bead™ (Hampton Research) was used to obtain crystals of 
MEL5/A2-EAA complex as no crystals were obtained with the methods described 
above. Crystals of MEL5/A2-AAG complex obtained in section 2.5.2.1 were used as 
seeds for MEL5/A2-EAA complex. In order to do so, the 0.4 µL drop containing the 
MEL5/A2-AAG crystals and 50 µL of mother liquor (0.1 M Tris pH 8.0, 15% 
glycerol, 25% PEG 4000) from the reservoir was added to the Seed Bead™ 
eppendorf and it was vortexed for 90 sec. This seeding mix was then serially diluted 
(1 10<  and 
1
100<  dilutions) into the same buffer and 35 µL of MEL5/A2-EAA 
complex solution around 1 mM was supplemented with 1 µL of  seeding mix or 1 µL 
of seeding mix dilution. Crystallisation trials were then performed as described 
above. Optimal crystals were obtained in 0.1 M Tris pH 8.5 (Molecular 
Dimensions), 15% glycerol (Sigma-Aldrich®) and 15% PEG 4000 (Molecular 
Dimensions) (Table 2.2). 
 
2.5.3 X-ray diffraction data collection, molecular replacement and model 
refinement 
Crystals were harvested in-house and cryo-cooled in liquid nitrogen (100 K). Data 
were collected in a stream of nitrogen gas at 100 K on different beamline at the 
Diamond Light Source (DLS), Oxfordshire, UK. The Table 2.3 compiles the 
beamlines, wavelength of detection and detectors used for each crystal. Reflection 
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intensities were estimated with the MOSFLM package (Leslie, 1992) and the data 
were scaled, reduced and analysed with SCALA and the CCP4 package (Ccp, 1994). 
Structures were solved with Molecular Replacement using PHASER (McCoy et al., 
2007). The model sequence was adjusted with COOT (Emsley and Cowtan, 2004) 
and the model refined with REFMAC5 (Murshudov et al., 1997). Graphical 
representations were prepared with PYMOL (Delano, 2002).  
 
2.6 MAMMALIAN CELL CULTURE 
2.6.1 Mammalian cell culture medium 
RPMI-PSG: RPMI-1640 medium (Invitrogen™) supplemented with 100 IU/mL 
penicillin (Invitrogen™), 100 IU/mL streptomycin (Invitrogen™) and 2 mM L-
glutamine (Invitrogen™). 
 
R2: RPMI-PSG medium containing 2% of heat-inactivated foetal calf serum (FCS, 
Invitrogen™). 
 
R10: RPMI-PSG medium containing 10% FCS (Invitrogen™). 
 
D10: DMEM medium (Invitrogen™) supplemented with 100 IU/mL penicillin 
(Invitrogen™), 100 IU/mL streptomycin (Invitrogen™), 2 mM L-glutamine 
(Invitrogen™), 2 mM Na pyruvate (Invitrogen™) and containing 10% FCS 
(Invitrogen™). 
 
CK medium: R10 supplemented with 2.5% Cellkines (Helvetica Healthcare), 200 
IU/mL IL-2 (Pharmacy) and 25 ng/mL IL-15 (Peprotech). 
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Freezing medium: 40% R10, 10% DMSO (Sigma-Aldrich®) and 50% FCS 
(Invitrogen™).  
 
2.6.2 Cell lines 
293T: 293T cells are a highly transfectable derivative of the HEK293 cells 
(Demaison et al., 2002) which constitutively express the simian virus 40 (SV40) 
large T antigen. These cells were grown in D10 at 37°C / 5% CO2 and used to 
produce the lentiviruses. 
 
HLA-A2 C1R: C1R is a human B-cell lymphoblastoid line lacking surface HLA-A 
and HLA-B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation 
followed by selection for class I monoclonal antibodies and complement (Storkus et 
al., 1989). Hmy.2 CIR B-cells expressing wild type HLA-A*0201 were generated 
previously (Purbhoo et al., 2001; Wooldridge et al., 2005). Briefly, cells were 
transfected with pcDNA3.1 mammalian expression vector (Invitrogen™) containing 
an insert encoding wild type full length HLA-A*0201 and cells were then cloned by 
limiting dilution. These cell lines, maintained in R10 medium at 37°C / 5% CO2, 
show 100% HLA-A2 expression and were used for the Jurkat activation assays, the 
peptide titration assays, the peptide library assay and the chromium release assays. 
 
Mel526 and Mel624: Mel526 and Mel624 cells lines are HLA-A2 positive 
melanoma cell lines established from cryopreserved single cell suspensions of 
metastatic deposits from patients and were identified as pure tumour cell populations 
by cytologic and immunocytochemical analysis (Topalian et al., 1990; Topalian et 
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al., 1989). These cell lines were maintained as monolayer cultures in D10 medium at 
37°C / 5% CO2 and were used as target cells for the chromium release assay. 
 
Jurkat TCR negative GLuc: Jurkat TCR negative J.RT3-T3.5 cells (ATCC® number 
TIB-153™) derived from Jurkat E6.1 cells (Weiss and Stobo, 1984) were grown in 
R10 at 37°C / 5% CO2. These cells lack the β chain of the TCR and do not express 
either CD3 or the αβ TCR on the surface (Liu et al., 2000). These cells have been 
transfected in-house by Dr John Bridgeman with a NFAT-luc construct (Stratagene, 
via Dr Reno Debets) containing NFAT (Nuclear Factor of Activated T-cells) 
responsive elements from the IL2 promoter driving the expression of Gaussia 
Luciferase. 
 
MEL5/MEL13: These CD8+ T-cell clones are expressing a TCR specific for the 
heteroclitic version of the melanoma antigen Melan-A/MART-126-35 
(ELAGIGILTV) in complex with HLA-A*0201 (Cole et al., 2009). Cells were 
grown in CK medium at 37°C / 5% CO2. These two clones were generated at the 
same time from the same CD8+ T-cell line by Professor Andrew Sewell and have a 
TCR that is identical at the nucleotide level. MEL5 and MEL13 are therefore 
considered to be an identical clone. 
 
Jurkat transduced and CTL transduced: these cells are respectively Jurkat TCR 
negative cells GLuc or CD8+ T-cells transduced with the different lentiviruses. They 
are expressing MEL5 TCR or a modified version of MEL5 and rCD2 on the surface 
and were grown in R10 or CK medium at 37°C / 5% CO2, respectively. Table 2.4 
lists the different transduced cell lines.  
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Table 2.4. List of the different transduced cell lines generated during my PhD. 
Cell 
type 
Transduced 
Jurkat 
TCR 
negativ
e GLuc 
Jurkat 
MEL5 
rCD2 
Jurkat 
MEL5 
β5 
rCD2 
Jurkat 
MEL5 
β9 
rCD2 
Jurkat 
MEL5 
β12 
rCD2 
Jurkat 
MEL5 
β13 
rCD2 
Jurkat 
MEL5 
β15 
rCD2 
Jurkat 
MEL5 
β17 
rCD2 
HLA-
A2 
positive 
CD8+ 
T-cells 
A2+ 
CD8+ 
MEL5 
rCD2 
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2.6.3 Cryopreservation and storage of cell lines 
Cells for cryopreservation were generally stored in 1ml of freezing medium in 
cryovials (Nunc) at cell concentrations of 5 x 106 or 10 x 106 cells/ml. Cryovials 
were stored in cryo-freezing containers (Nalgene) at -80°C for 48 hours and then 
transferred to liquid nitrogen containers. Cryopreserved cells were thawed at 37°C in 
a water bath and transferred gently using a Pasteur pipette (Fisher Scientific) into 
cool (4°C) RPMI-PSG. Cells were centrifuged for five minutes at 500 g then 
resuspended in the appropriate media. 
 
2.6.4 Cell counting by Trypan exclusion 
Cell counting was carried out by mixing 10 µl of cell suspension with an equal 
volume of Trypan blue (STEMCELL™ Technologies). 10 µl of this mixture was 
then transferred onto a clean Neubauer haemocytometer (Weber Scientific 
International Ltd). Viable cells were identified by the absence of Trypan staining at a 
100 times magnification on a light microscope (Olympus CK40 model). 
 
2.7 GENERATION OF TRANSDUCED JURKAT AND CTL LINES 
2.7.1 Lentivirus production 
For the production of a lentivirus batch, 15-30 x 106 293T cells were seeded one day 
prior to transfection into a 75 cm2 flask (Greiner Bio-One) in 25 mL of D10. Cells 
were transfected with a plasmid mix (15 µg pELNSxv containing the insert of 
interest, 18 µg pRSV.REV, 7 µg pVSV-G and 18 µg pMDLg/p.RRE) using 174 µL 
of Express-in™ (Open Biosystems) reagent in 3 mL of D10 supplemented with 10 
mM HEPES pH 7.4 (Invitrogen™). After 1 min incubation at RT with the 
97 
 
transfection mix, 22 mL of D10 supplemented with 10 mM HEPES was added and 
transfected cells were incubated. One day post-transfection, the supernatant was 
collected, kept at 4°C and 25 mL of fresh D10 medium was added in order to collect 
a 48h00 post-transfection supernatant. Both supernatant batches (24h00 and 48h00) 
were filtered separately with 0.22 µm filters (Miller®-GP, Millipore) into a 38.5 mL 
thin-wall ultracentrifuge tube (Ultra-Clear™, Beckman), ultracentrifuged for 2h00 at 
26000 g and 4°C (Optima™ L-100 XP with SW28 rotor, Beckman Coulter). Each 
pellet was dissolved in 2mL of D10 supplemented with 10 mM HEPES and 200 µL 
aliquots of the lentivirus suspensions were stored at -80°C. 
 
2.7.2 Jurkat TCR negative GLuc transduction and sorting 
For the transduction of the Jurkat TCR negative GLuc with a lentivirus, cells were 
seeded one day prior to transduction into 6-well plate (Greiner Bio-One) at 4 x 105 
cells/well in 4 mL of R10. Cells were transduced with 5 µL of the lentivirus 
suspension and were analysed two days post-transduction by fluorescence activated 
cell sorting (FACS) (section 2.8). In order to obtain a pure population expressing the 
TCR of interest, Jurkat transduced cells were magnetically sorted using MS Columns 
(Miltenyi Biotec) and MiniMACS™ (Miltenyi Biotec), following the manufacturer’s 
instructions. Briefly, up to 1 x 107 cells were resuspended in 400 µL of cold MACS 
buffer (PBS supplemented with 0.5% heat-inactivated FCS and 2 mM EDTA) and 
incubated on ice in the dark for 20 min with 10 µL of anti-CD3 FITC (fluorescein 
isothiocyanate) conjugated antibody (AbD Serotec). Cells were then washed twice 
with 2 mL of cold MACS buffer, resuspended in 400 µL of cold MACS buffer and 
incubated on ice for 20 min with 20 µL of anti-FITC microbeads (Miltenyi Biotec). 
Cells were magnetically sorted in cold MACS buffer, centrifuged for 5 min at 1500 
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rpm (PK 131 centrifuge with T516 rotor, ALC®), resuspended in R10 and incubated 
at 37°C / 5% CO2 in a 24-well plate (Greiner Bio-One). 
 
2.7.3 CTL transduction 
2.7.3.1 CTL sorting from peripheral blood mononuclear cells (PBMCs) 
CTLs were isolated from peripheral blood mononuclear cells (PBMCs). Buffycoats 
from 500 mL blood from healthy donors were purchased from the Welsh Blood 
Service or 50 mL samples were collected by venepuncture into a sterile container 
with preservative free heparin (LEO Laboratories Ltd) at a final concentration of 100 
IU/ml of blood. PBMCs were isolated on a Ficoll-Hypaque (Lymphoprep™, Axis-
Shield) density gradient centrifugation of blood diluted 1 to 1 with sterile PBS in 
sterile 50 mL Falcon™ centrifuge tubes (BD Biosciences) for 20 min at 2000 rpm 
(Sorvall RT 6000D centrifuge) without breaks. Buffy coat was aspirated from the 
gradient interface with a Pasteur pipette and placed in sterile 50 mL Falcon™ 
centrifuge tubes (BD Biosciences). Cells were then washed twice with RPMI-PSG 
and resuspended in RPMI-PSG. CTLs were magnetically sorted from PBMCs 
mainly as described in previous section. Briefly, PBMCs were centrifuged at 1300 
rpm for 10 min (PK 131 centrifuge with T516 rotor, ALC®) and the pellet was 
resuspended in 80 µL of cold MACS buffer per 1 x 107 cells. The cell suspension 
was mixed with 20 µL of anti-CD8 microbeads (Miltenyi Biotec) per 1 x 107 cells, 
incubated on ice for 20 min, and cells were magnetically sorted in cold MACS 
buffer. CTLs were washed twice with R10 and resuspended in CK medium at 5 x 
105 cells/mL. For the activation of these CTLs, 1 x 106 cells per well were seeded in 
a 24-well plate with 75 µL of Dynabeads® Human T-Expander CD3⁄CD28 
(Invitrogen™) and cells were incubated overnight at 37°C / 5% CO2. Non-sorted 
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PBMCs were also used as feeders (PBMCs irradiated with Cesium-137) for 
transduced CTLs expansion. 
 
2.7.3.2 CTL transduction, sorting and expansion 
Activated CTLs were transduced with 1 mL of the lentivirus suspension and 
analysed two days post-transduction by FACS for rCD2 and/or MEL5 TCR 
expression (section 2.8). In order to obtain a pure population expressing MEL5, 
transduced CTLs were magnetically sorted twice; first using an anti-rCD2-PE 
conjugated antibody (rCD2-PE) (AbD Serotec) and then using an ELA-PE tetramer 
as described above in section 2.3.6. Briefly, transduced CTLs were first incubated 
for 20 min on ice in the dark with 10 µL of rCD2-PE followed by a sorting using 20 
µL of anti-PE microbeads (Miltenyi Biotec). rCD2 positive transduced cells were 
then grown and maintained for 2 weeks in a 25 cm2 flask (Greiner Bio-One) with 1 x 
107 feeders in CK medium supplemented with 1 µg/mL phytohaemagglutinin (PHA, 
Alere Ltd) in order to expand them. This single positive population was then 
incubated for 20 min on ice in the dark with 12 µL of ELA-PE in MACS buffer 
supplemented with 50 nM dasatinib (Axon) in order to avoid induced cell death. 
Double positive cells (cells expressing rCD2 and the TCR of interest) were sorted 
using 20 µL of anti-PE microbeads (Miltenyi Biotec). Cells were grown first for a 
week with feeders in CK medium supplemented with 1 µg/mL PHA and they were 
then maintained in CK medium. 
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2.8 FLOW CYTOMETRY ANALYSIS 
The expressions on the cell surface of the TCR of interest, rCD2, CD3 or CD8 were 
detected by FACS. Cells were washed once in PBS and resuspended in 50 µL of 
PBS staining mix containing 5 µL of antibody conjugated to FITC, APC or PE. 
Staining mix was supplemented with 1 µL of pMHCI tetramer for the detection of 
expression of a specific TCR. Cells were incubated on ice in the dark for 20 min, 
washed twice with cold PBS and resuspended in 300 µL of cold PBS. Analysis were 
performed on a BD FACSCanto™ II (BD Biosciences) flow cytometer using BD 
FACSDiva 6.0 software (BD Biosciences). Results were analysed with FlowJo 7.6 
software (Tree Star, Inc). 
 
2.9 JURKAT ACTIVATION ASSAY  
In the wells of a 96-well round bottomed plate (Greiner Bio-One), 1 x 105 CIR cells 
(in 45 µl volume) expressing wild type HLA-A*0201 were pulsed in duplicate with 
5 µL peptide at 1 mM or 5µL of PHA at 1mg/mL at 37°C / 5% CO2 for 2 hours. 
Jurkat TCR negative GLuc were then washed once in PSG and resuspended in R10. 
1 x 105 Jurkat TCR negative GLuc (in 50 µl) were then added per well of pulsed 
targets and plates were incubated for 5h00 at 37°C / 5% CO2. Cell supernatant was 
collected and 50 µL of GLuc substrate (BioLux® Gaussia Luciferase Assay Kit, 
New England Biolabs) was added to 20 µL of supernatant in a 96-well Microfluor® 
2 plate (Thermo Scientific). Luminescence at 485 nm was measured with a 
FLUOstar OPTIMA (BGM LABTECH) and results were analysed with Excel 
(Microsoft) and GraphPad Prism 5 (GraphPad) softwares. 
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2.10 CTL EFFECTOR FUNCTION ASSAYS 
2.10.1 Peptide titration assay 
CTLs were washed twice in RPMI-PSG and rested in R2 overnight. In the wells of a 
96-well round bottomed plate (Greiner Bio-One), 6 x 104 CIR cells (in 45 µl volume) 
expressing wild type HLA-A*0201 were pulsed in duplicate with 5 µL peptide at the 
stated concentrations (from 10-12 to 10-3 M) at 37°C / 5% CO2 for 2 hours. Rested 
CD8+ T-cells were then washed once in PSG and resuspended in R2. 3 x 104 CD8+ 
T-cells (in 50 µl) were then added per well of pulsed targets and plates were 
incubated overnight at 37°C / 5% CO2. Cell supernatant was collected and assayed 
for MIP-1β by ELISA using a CCL4 Duoset ELISA kit (R&D Systems) as described 
in section 2.10.3. 
 
2.10.2 Peptide library screen 
2.10.2.1 A description of positional scanning combinatorial peptide libraries (PS-
CPLs) 
In PS-CPLs (Pepscan Presto), equimolar peptide mixtures are arranged into sub-
libraries that allow for systematic scans on each position of a ligand. Mixtures within 
each sub-library contain a fixed amino acid drawn from the natural 20 proteogenic 
L-amino acids in a single position whilst the other positions have all the 19 amino 
acids (excluding cysteine) residues combined in every possible way. This positional 
scan is serially repeated across all the positions of the library (Hemmer et al., 1998). 
Each collection of sub-libraries contains all possible peptide sequences of a given 
length representing trillions of peptides (Nino-Vasquez et al., 2004). Sequences 
containing multiple cysteine residues were barred by the exclusion of cysteine from 
the variable positions in order to reduce the chance of disulphide bond formation 
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between cysteine residues. The PS-CPLs are extremely diverse in their peptide 
composition. The decamer combinatorial peptide library screen used in this study 
contained 9.36 x 1012 ((10+19) x 199) different decamer peptides (Ekeruche-
Makinde et al., 2012). Cell activation with PS-CPL mixtures is described in section 
2.10.2.2. 
 
2.10.2.2 Peptide library screen assay 
CD8+ T-cells were washed twice in RPMI-PSG and rested in R2 overnight. In the 
wells of a 96-well round bottomed plate (Greiner Bio-One), 6 x 104 HLA-A2 CIR 
cells (in 45 µl volume) were pulsed in duplicate with 5 µl of peptide mixture from 
the decapeptide PS-CPL at a final concentration of 100 µM at 37°C for 2 hours. 
Rested CD8+ T-cells were washed once in RPMI-PSG and resuspended in R2. 3 x 
104 CD8+ cells (in 50 µl) were then added per well of pulsed targets. Plates were 
incubated overnight at 37°C / 5 % CO2. Cell supernatant was then collected and 
assayed for MIP-1β by ELISA using a CCL4 Duoset ELISA kit (R&D Systems) as 
described in section 2.10.3. 
 
2.10.3 ELISA (Enzyme-linked immunosorbent assay) for MIP1β 
ELISAs for the detection of MIP1β production were performed with a CCL4 Duoset 
ELISA kit (R&D Systems) and the recommended accessory reagents (Wash buffer, 
Reagent diluent, Strepavidin-HRP, Chromogen, Peroxide, and Stop solution). All 
wash steps were performed on an AquaMax 2000 microplate washer (MDS 
analytical technologies). Briefly, 96-well ELISA microplates (R&D Systems) were 
coated with 100 µl of capture antibody diluted according to the manufacturer’s 
recommendation. Plates were incubated overnight at RT after which they were 
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washed three times with wash buffer and blocked with reagent diluent. After another 
wash step, 100 µl of cell supernatant collected from an activation assay or 100 µl of 
standard solution was then placed in each well. Plates were incubated according to 
the manufacturers’ recommendation and washed again. 100 µl of detection antibody 
diluted in reagent diluent was then added per well. Plates were then incubated as 
recommended and washed before adding strepavidin-horseradish peroxidase diluted 
in reagent diluent. After a further incubation, plates were washed and carefully 
blotted. 100 µl of a 1:1 solution of stabilised chromogen and peroxide was then 
added per well. Plates were incubated in the dark for up to twenty minutes after 
which 50 µl of stop solution (2N sulphuric acid) was added per well. OD readings of 
plates were taken at 450 nm (Bio-rad iMark microplate reader) with correction set to 
570 nm. Results were analysed with Excel (Microsoft) and GraphPad Prism 5 
(GraphPad) softwares. 
 
2.10.4 Chromium release assay 
Target cells (CIR cells expressing wild type HLA-A*0201, Mel526 and Mel624) 
were resuspended in R10 and labelled with 51Cr (30 µCi per 106 cells) (Perkin Elmer) 
for 1 hour at 37°C then washed once and left for a further hour in fresh media to 
allow leaching. Labelled HLA-A2 C1R cells were then washed again and pulsed at 2 
x 103 cells/well in a 96-well round bottom plate (Greiner Bio-One) with 
ELAGIGILTV peptide at a final concentration of 100 µM. CD8+ T-cells were then 
added at the indicated E:T ratios (from 25:1 to 0.20:1) and plates were incubated for 
4 hours at 37°C / 5% CO2. Following incubation, 15 µl of cell supernatant was 
collected and mixed with 150 µl of scintillation cocktail (Optiphase supermix, Perkin 
Elmer) then analysed for radioactivity using a MicroBeta2 plate counter (Perkin 
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Elmer). Percentage cytotoxicity (or percentage specific lysis) was then calculated 
using the following equation: Specific lysis = [(Experimental lysis - Spontaneous 
Lysis) / (Maximum Lysis - Spontaneous Lysis)] x 100%. Values used for 
calculations were obtained as the average of three replicates. Results were analysed 
with Excel (Microsoft) and GraphPad Prism 5 (GraphPad) softwares. 
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Chapter background 
A key aim of my PhD was to analyse and further characterize the TCR/pMHCI 
interaction by SPR and by crystallography. My laboratory possessed the equipment 
required for efficient protein production and purification as well as a crystallography 
facility. Due to the wide array of commercial screens available in my laboratory for 
crystallography, the development of a specific TCR/pMHC screen was not initially 
planned. However, as my attempts at crystallizing my TCR/pMHCI complexes were 
unsuccessful with these screens, I decided to develop my own screen (TOPS) based 
on the crystallization conditions of previously published TCR/pMHC complexes. 
My colleagues and I crystallized and solved several structures using TOPS. Due to 
the efficiency of TOPS, we decided to write a scientific paper about TOPS (Bulek et 
al., 2012b) in order for other scientists to benefit from this screen. The development 
of TOPS is described herein. 
 
3.1 INTRODUCTION 
T-cells play an important role in the protection against pathogens and cancer and 
have been shown to cause/contribute towards many autoimmune diseases (Bulek et 
al., 2012a; Rudolph et al., 2006; Wong and Pamer, 2003). The T-cell receptor (TCR) 
recognizes foreign and self protein fragments bound to the self-major 
histocompatibility complex (pMHC) (Garboczi et al., 1996). The first structure of a 
murine TCR (2C) with MHC class I H2-Kb in association with dEV8 peptide was 
published in 1996 (Garcia et al., 1996). This was shortly followed by the structure of 
a human TCR (A6) in complex with HLA-A*0201-Tax (peptide derived from 
human T-cell lymphotropic virus type 111-19) (Garboczi et al., 1996). These structures 
provided the first insight into T-cell antigen recognition and revealed a number of 
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important features of the interface between the TCR and pMHC. Ten years later, 
only 10 unique human TCR/pMHC complexes had been solved, reviewed by 
Rudolph and co-workers (Rudolph et al., 2006). In recent years, this number has 
increased to <25 unique human TCR/pMHC complexes, but progress has still been 
relatively slow compared with the number of antibody structures, or unligated 
pMHC structures that have been reported. This lack of structural information 
regarding human TCR/pMHC complexes has compromised the determination of a 
comprehensive and accepted set of rules that govern T-cell antigen recognition and a 
number of conflicting theories still dominate the field (Bridgeman et al., 2012). In 
this Chapter I present the methods for producing recombinant TCRs and improving 
soluble TCR stability. I also briefly describe the requirements for the production of 
high-quality protein crystals and I then present the development of a crystallization 
screen optimized for TCR/pMHC complexes. 
 
3.1.1 Methods for producing recombinant TCRs 
Difficulties in generating sufficient quantities of soluble TCR and pMHC protein, 
and in producing high quality TCR/pMHC complex crystals, may explain the low 
number of these structures. Additionally, TCRs bind to pMHCs with relatively weak 
affinity (KD = 0.1-270 µM (Bridgeman et al., 2012; Cole et al., 2007)), which may 
further impede their ability to form stable complexes for crystallization. A number of 
approaches have been proposed for the production of stable, soluble recombinant 
TCRs, including modification of the expression vectors and optimization of culture 
conditions. To date, soluble TCRs have been generated using various eukaryotic 
expression systems such as: Drosophila melanogaster (Garcia et al., 1996), myeloma 
cells (Wang et al., 1998), Chinese hamster ovary cells (Reiser et al., 2000) and 
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Spodoptera frugiperda cells (Hahn et al., 2005). However, prokaryotic expression as 
inclusion bodies using E. coli strains, followed by artificial refolding, remains the 
most popular and robust system because it produces high yields of homogenous non-
glycosylated protein (Cole et al., 2008; Cole et al., 2007; Cole et al., 2009). This last 
method was used for the generation of recombinant TCRs and MHCs in my 
laboratory. 
 
3.1.2 Methods for improving TCR stability 
Contrary to antibodies, TCRs are not naturally expressed in a soluble form but are 
anchored to the T-cell membrane and are stabilized by an extracellular, membrane 
proximal, inter-chain disulphide bond. However, the production of soluble TCRs 
incorporating this native bond has been very poor (Garboczi et al., 1996; van Boxel 
et al., 2009). Different TCR cloning methods have been designed to improve soluble 
TCR stability including: (i) expression of the variable domains only in a form of a 
single chain Fv fragment (scFv) to form a scTCR (Gregoire et al., 1996; Housset et 
al., 1997); (ii) expression of TCR α and β chains carrying 30 residue-long BASE-p1 
(α) and ACID-p1 (β) leucine-zipper heterodimerization motifs at their carboxyl 
termini (Chang et al., 1994); (iii) expression of TCR α and β chains carrying c-Jun 
(α) and c-Fos (β) leucine-zipper heterodimerization motifs at their carboxyl termini 
(Kalandadze et al., 1996; Willcox et al., 1999b); (iv) introduction of a carboxy-
terminal flanking sequence to the full length V and C ectodomains to promote the 
formation of an interchain disulphide bridge (Stewart-Jones et al., 2003); and, (v) 
introduction of non-native disulphide bond into the interface between the TCR 
constant domains by mutating residues threonine 48 (α chain) and serine 57 (β chain) 
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into cysteines (Boulter et al., 2003) to form “dsTCRs” (Figure 3.1). The ‘Boulter-
disulphide’ method has been the preferred choice in my laboratory.  
 
3.1.3 Generating crystals for high resolution X-ray diffraction 
Once expressed and purified, the last challenge is to generate TCR/pMHC complex 
protein crystals capable of high resolution X-ray diffraction. Even when pure soluble 
protein is available, producing high-quality crystals remains a major bottleneck in 
structure determination (Chayen and Saridakis, 2008). Crystallization requires large 
quantities of protein, highly concentrated solutions, filtration of the protein solutions 
and "neutral" pHs (4-9) that did not cause proteins to break down (McCoy, 2009). 
There are, of course, an infinite number of crystallization conditions. Parameters to 
vary include the type of precipitant (salts, polymers, and organic solvents), 
precipitant concentration, buffer type and pH of buffer, temperature, and the 
presence or absence of divalent cations (Asherie, 2004; Blundell and Johnson, 1976). 
In order to achieve the crystallisation of TCR/pMHC complexes, a number of 
commercial screens, not tailored specifically for T-cell-associated proteins, have 
been used by different laboratories with some success (evidenced by the modest 
number of TCR/pMHC complexes published). Van Boxel et al. designed a crystal 
screen for isolated TCRs (van Boxel et al., 2009) but no screen was specifically 
developed for the TCR/pMHC complexes crystallization. 
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Figure 3.1. Schematic representations of the different methods to increase 
soluble TCRs stability. 
(A) Variable domains of the TCR expressed in the form of a single chain Fv 
fragment (scFv) to form a scTCR. (B) TCR α and β chains carrying 30 residue-long 
BASE-p1 (α) and ACID-p1 (β) leucine-zipper heterodimerization motifs at their 
carboxyl termini. “Leucine-zipper” motifs (dash lines), acidic residues (green) and 
basic residues (red) are shown. (C) TCR α and β chains carrying c-Jun (α) and c-Fos 
(β) leucine-zipper heterodimerization motifs at their carboxyl termini. Leucine-
zipper” motifs (dash lines) are shown. (D) Introduction of a carboxy-terminal 
flanking sequence to the full length V and C ectodomains to promote the formation 
of an interchain disulphide bridge (yellow). (E) Introduction of non-native 
disulphide bond (yellow) into the interface between the TCR constant domains by 
mutating residues threonine 48 (α chain) and serine 57 (β chain) into cysteines to 
form “dsTCRs”. 
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3.1.4 Aim 
My PhD project involved the crystallization of melanoma specific TCRs (MEL5 and 
α24β17) complexed with HLA-A2 when presenting different melanoma peptides 
(ELAGIGILTV, EAAGIGILTV and AAGIGILTV). I failed to successfully 
crystallize these complexes with the commercially available crystal screens after 
several attempts. I therefore decided to develop my own TCR/pMHC Optimized 
Protein crystallization Screen (TOPS) by analysing the crystallization conditions of 
previously published TCR/pMHC complexes. This Chapter will highlight the design 
of TOPS and will determine the optimal conditions for the generation of 
TCR/pMHC complex crystals. 
 
3.2 RESULTS 
3.2.1 Design of a TCR/pMHC Optimized Protein crystallization Screen  
TCR/pMHC complex structures have previously been solved by a number of 
different groups using individually determined crystallization conditions. In order to 
combine these data to generate a comprehensive TCR/pMHC Optimized Protein 
crystallization Screen (TOPS), I investigated the crystallization conditions of 16 
previously published TCR/pMHC complexes (Adams et al., 2005; Chen et al., 2005; 
Cole et al., 2009; Colf et al., 2007; Ding et al., 1998; Garboczi et al., 1996; 
Hennecke et al., 2000; Hennecke and Wiley, 2002; Kjer-Nielsen et al., 2003; Li et 
al., 2005a; Maynard et al., 2005; Reiser et al., 2000; Sami et al., 2007; Stewart-Jones 
et al., 2003; Tynan et al., 2005; Tynan et al., 2007) (Table 3.1) (Figure 3.2). 
Although there was substantial variation in the crystallization conditions identified 
for different TCR/pMHC complexes, certain trends were noticed. The pH lay 
112 
 
between 5.6 and 8.5 in all cases, with the TCR/pMHC complexes tending to 
crystallize at the higher end of this pH range (Figure 3.2A); with 25%, 19% and 
19% of complexes crystallizing in the pH range 7.0-7.5, 7.5-8.0 and 8.0-8.5, 
respectively. Six conditions (38%) contained glycerol as cryoprotectant (Figure 
3.2B). All conditions contained PEG (polyethylene glycol), although the weight 
(550-8000 g/mol) and percentage (10-25%) were very variable. The best PEG 
concentration, representing 31% of the previous structures reported, was between 
15% and 17.5%. Molecular weight PEG 3350, 4000 and 8000 were most successful 
(Figure 3.2C&D) evidenced by 31%, 13% and 44% of all structures being obtained 
with each additive, respectively. Another common component of successful 
conditions were various salts, with concentrations ranging from 0 to 1 M, the 
absence of salt (38%) and 0.2 M (31%) being most popular (Figure 3.2E). Based on 
these findings I developed a crystallization screen for TCR/pMHC complexes (Table 
3.2). The screen consisted of two 48 well PEG/pH screens. Each PEG/pH screen 
consisted of four buffer systems (C2H6AsO2Na, MES, HEPES and TRIS) at a 
concentration of 0.1 M in combination with PEG 4000, or PEG 8000 at 15, 20 and 
25%. These buffers allowed scanning the pH range from 6.0 to 8.5. 15% glycerol 
was added to the first subscreen, whereas 0.2 M ammonium sulphate was added to 
the second subscreen.  
 
In some cases, TOPS generated several crystal hits that were of lower quality, i.e. the 
crystals were very small, contained cracks or impurities, or did not diffract to high 
resolution. In these cases, we extended the conditions that yielded crystals to 
generate a number of other fine screens that proved useful for specific TCR/pMHC 
complexes.  
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Table 3.1. Crystallization conditions of 16 previously published TCR/pMHC 
complexes. 
TCR/pMHC 
complex 
Buffer pH 
PEG 
(%) 
PEG 
(g/mol) 
Glycerol 
(%) 
Salt Reference 
ha1G4/A2-
NY-ESO-1 
85mM 
HEPES 
8.5 17 4000 15  
(Sami et al., 
2007) 
1G4/A2-
NY-ESO-1 
0.1M Na 
Nitrate 
6.8 20 3350 10  
(Chen et al., 
2005) 
G8/T22 
0.1M Na 
Citrate 
5.6 15 4000  
2mM Zinc 
Acetate 
(Adams et al., 
2005) 
HA1.7/DR1
-HA 
0.1M 
HEPES 
7 14 8000  1M NaCl 
(Hennecke et 
al., 2000) 
HA1.7/DR4
-HA 
0.1M 
HEPES 
7 13 8000  1M NaCl 
(Hennecke 
and Wiley, 
2002) 
3A6/DR2A-
MBP 
0.1M Na 
Citrate 
6 10 8000  
0.2M Ammonium 
Sulphate 
(Li et al., 
2005a) 
ELS4/B35 
0.1M Na 
Cacodylate 
6.4 16 3350  0.2M CaCl2 
(Tynan et al., 
2007) 
A6/A2-tax 50mM TRIS 8.5 14 8000 20 0.1M Mg Acetate 
(Garboczi et 
al., 1996) 
JM22/A2-
MP(58-66) 
50mM MES 6.5 14 8000 10  
(Stewart-
Jones et al., 
2003) 
B7/A2-tax 
0.1M Mg 
Acetate 
7.1 12 8000   
(Ding et al., 
1998) 
LC13/B8-
EBV 
0.2M 
Ammonium 
Acetate 
7.5 25 8000   
(Kjer-Nielsen 
et al., 2003) 
MEL5/A2-
ELA 
0.1M TRIS 7.4 23 550 15  
(Cole et al., 
2009) 
SB27/B350
8-LPEP 
0.1M Na 
Cacodylate 
6.7 16 3350  0.2M K Iodide 
(Tynan et al., 
2005) 
BM3.3/H-
2Kb-pBM1 
0.1M 
HEPES 
7.5 15 6000  0.1M Na Acetate 
(Reiser et al., 
2000) 
ha2C/H-
2Ld-QL9 
0.1M TRIS 8.5 20 3350 25 
0.2M Ammonium 
Phosphate 
(Colf et al., 
2007) 
172.1/I-Au-
MBP 
0.1M 
HEPES 
7.5 21 3350  
0.2M Lithium 
Sulphate 
(Maynard et 
al., 2005) 
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Figure 3.2. Analysis of the crystallization conditions of 16 previously published 
TCR/pMHC complexes. 
(A) The pH of the conditions lay between pH 5.6 to pH 8.5, with a preference for the 
higher end of this pH range. (B) Glycerol was used as a cryoprotectant in 38% of 
cases. (C) The molecular weight of the PEG varied from 550 g/mol to 8000 g/mol 
(PEG 3350, 4000 and 8000 being the most successful). (D) The best PEG 
concentration was between 15% and 17.5%, with a PEG concentration range from 
10% to 25%. (E) Various salts, with concentrations from 0 to 1 M, were used, with a 
preference for 0.2 M. 
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TOPS1 (Table 3.3) was designed by extending the lower range of pH with 
C2H6AsO2Na pH 5.0 and 5.5 of the A07 condition of the TOPS screen. In addition, 
PEG 3350 was compared versus PEG 4000 in this screen. TOPS2 (Table 3.4) was 
designed by extending the lower range of PEG concentration (10, 12.5, 15, 17.5, 20 
and 22.5%) of the second subscreen of the TOPS screen. In addition, one of the 
buffer systems (C2H6AsO2Na pH 6.0) was replaced by a non-buffered condition and 
supplemented by another precipitant (0.2 M sodium sulphate) as some good hits 
were obtained using a commercially available screen (PACT Premier, condition E08; 
0.2 M sodium sulphate and 20% PEG 4000). TOPS3 (Table 3.5) was designed by 
reducing the range of pH (from 6.5 to 7.5) and increasing the number of buffer 
system (MES pH 6.5, BIS TRIS propane pH 7.0 and TRIS pH 7.0) as well as the 
range of glycerol concentrations (0, 4.4, 8.7 and 17.4%). PEG 4000 was the PEG of 
choice in this screen. The only difference between TOPS3 and TOPS4 (Table 3.6) 
was that TOPS4 contained 0.2 M ammonium sulphate. These screens generated 5 
TCR/pMHC complexes as detailed in Table 3.7. 
 
3.2.2 Comparison of TOPS efficiency with commercially available screens 
High-throughput crystallization trials were performed using 3 commercially 
available screens (PACT Premier, JBScreen and JCSG-plus (Molecular Dimensions 
Ltd)) and/or 5 different “homemade” screens (TOPS, TOPS1, TOPS2, TOPS3 and 
TOPS4), the last four screens being derivatives of the TOPS screen. Crystallization 
conditions were successfully identified for 25 TCR/pMHC complexes, 14 of which 
were derivatives from a common parent complex.   
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Table 3.2. TOPS conditions. 
Buffer (pH) 
0.1 M 
15% glycerol 0.2 M ammonium sulphate 
PEG 4000 (%) PEG 8000 (%) PEG 4000 (%) PEG 8000 (%) 
15 20 25 15 20 25 15 20 25 15 20 25 
C2H6AsO2Na 
(pH 6) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
C2H6AsO2Na 
(pH 6.5) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 
MES (pH 7) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
HEPES (pH 
7) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 
HEPES (pH 
7.5) E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
TRIS (pH 7.5) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
TRIS (pH 8) G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
TRIS (pH 8.5) H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
 
 
Table 3.3. TOPS1 conditions. 
Buffer (pH) 
0.1 M 
0.2 M ammonium sulphate  
C2H6AsO2Na 
(pH 5.5) A1 A2 A3 A4 A5 A6 
15% PEG 3350 
C2H6AsO2Na 
(pH 6) B1 B2 B3 B4 B5 B6 
C2H6AsO2Na 
(pH 5) C1 C2 C3 C4 C5 C6 
15% PEG 4000 C2H6AsO2Na 
(pH 5.5) D1 D2 D3 D4 D5 D6 
C2H6AsO2Na 
(pH 6) E1 E2 E3 E4 E5 E6 
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Table 3.4. TOPS2 conditions. 
Buffer (0.1 
M) or non 
buffered 
component 
(0.2 M) 
0.2 M ammonium sulphate 
PEG 4000 (%) PEG 8000 (%) 
10 12.5 15 17.5 20 22.5 10 12.5 15 17.5 20 22.5 
Na2SO4 A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
C2H6AsO2Na 
(pH 6.5) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 
MES (pH 7) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
HEPES (pH 
7) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 
HEPES (pH 
7.5) E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
TRIS (pH 7.5) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
TRIS (pH 8) G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
TRIS (pH 8.5) H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
 
 
Table 3.5. TOPS3 conditions. 
Buffer (pH) 
0.1 M 
No ammonium sulphate 
PEG 4000 (%) 
15 20 25 15 20 25 15 20 25 15 20 25 
C2H6AsO2Na 
(pH 6.5) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
MES (pH 6.5) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 
MES (pH 7) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
HEPES (pH 
7) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 
TRIS propane 
(pH 7) E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
TRIS (pH 7) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
TRIS (pH 7.5) G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
HEPES (pH 
7.5) H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
 0 4.4 8.7 17.4 
 Glycerol (%) 
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Table 3.6. TOPS4 conditions. 
Buffer (pH) 
0.1 M 
0.2 M ammonium sulphate 
PEG 4000 (%) 
15 20 25 15 20 25 15 20 25 15 20 25 
C2H6AsO2Na 
(pH 6.5) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
MES (pH 6.5) B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 
MES (pH 7) C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
HEPES (pH 
7) D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 
TRIS propane 
(pH 7) E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
TRIS (pH 7) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
TRIS (pH 7.5) G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
HEPES (pH 
7.5) H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
 0 4.4 8.7 17.4 
 Glycerol (%) 
 
Table 3.7. Successfully crystallized TCR/pMHC complexes, TCRs and pMHCs 
in my laboratory. 
TCR/pMHC complex Screen 
Resolution 
(Å) 
pH 
PEG 
(%) 
PEG 
Glycerol 
(%) 
Salt 
(M) 
α24β17/A2-ELA TOPS4 2.4 7.0 20 4000 0 0.2 
α24β17/A2-AAG TOPS 2.8 7.0 20 4000 15 0 
α24β17/A2-ELA-4A TOPS3 2.7 7.0 15 4000 17.4 0 
α24β17/A2-ELA-7A TOPS4 2.6 7.0 20 4000 17.4 0.2 
α24β17/A2-EAA TOPS4 2.1 7.5 15 4000 8.7 0.2 
MEL5/A2-EAA TOPS 3.0 6.5 15 4000 15 0 
MEL5/A2-AAG TOPS 3.2 7.5 25 4000 15 0 
P1/A2-CLG TOPS 2.6 6.0 15 4000 15 0 
SB7/A2-FLY TOPS 2.6 6.5 15 4000 0 0.2 
868/A2-SLY TOPS 2.9 6.0 15 4000 0 0.2 
868/A2-6I TOPS 2.9 6.0 15 4000 0 0.2 
868/A2-3F6I8V TOPS1 2.8 5.5 15 4000 0 0.2 
1E6/A2-ALW TOPS 2.6 6.0 15 4000 15 0 
1E6/A2-AQW PACT 3.0 6.5 20 4000 0 0.2 
1E6/A2-RQW PACT 2.3 6.0 20 6000 0 0.2 
1E6/A2-YQF PACT 2.1 7.0 20 6000 0 0.2 
1E6/A2-WQY TOPS 1.9 7.0 25 8000 0 0.2 
1E6/A2-KLP TOPS 2.9 6.5 15 8000 0 0.2 
1E6/A2-YLG TOPS 2.5 6.5 15 4000 0 0.2 
1E6/A2-MVW TOPS 2.0 7.5 15 4000 0 0.2 
1E6/A2-RQF(I) TOPS 1.9 7.5 15 4000 0 0.2 
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1E6/A2-RQF(A) TOPS 1.9 7.0 15 4000 0 0.2 
GP100/A2-YLE JBS 2.0 7.0 20 4000 0 0.2 
ILA/A2-ILA TOPS 2.6 7.0 20 8000 0 0.2 
AS01/A2-GLC TOPS 2.6 6.0 20 4000 0 0.2 
TCR Screen 
Resolution 
(Å) 
pH 
PEG 
(%) 
PEG 
Glycerol 
(%) 
Salt 
(M) 
α24β17 TOPS 2.4 6.5 20 8000 0 0.2 
P1 TOPS 1.5 6 20 4000 0 0.2 
HA1.7 TOPS 2.7 7.5 25 8000 0 0.2 
F11 PACT 1.5 7.5 20 3350 0 0.2 
1E6 PACT 2.6 7.5 20 3350 0 0.2 
pMHC Screen 
Resolution 
(Å) 
pH 
PEG 
(%) 
PEG 
Glycerol 
(%) 
Salt 
(M) 
A2-ELA-4A TOPS 2.0 6 20 8000 0 0.2 
A2-RQW TOPS 1.5 8 20 8000 15 0 
A2-YQF TOPS 1.5 8 25 4000 15 0 
A2-FLY TOPS 1.8 7 25 4000 0 0.2 
A2-6I TOPS 1.7 7 20 4000 15 0 
A2-3F6I8V TOPS 1.8 6 25 4000 0 0.2 
A2-FAT TOPS 2.8 6.5 25 8000 0 0.2 
A2-CLG TOPS 2.4 7.0 25 4000 0 0.2 
A2-ALW PACT 1.7 6.5 20 3350 0 0.2 
A2-AQW PACT 1.7 6.5 20 3350 0 0.2 
A2-KLP PACT 1.8 7.5 20 3350 0 0.2 
A2-YLG PACT 1.4 6.5 20 3350 0 0.2 
TCR, pMHC and TCR/pMHC complexes I obtained are in bold and underlined 
 
 
Figure 3.3. Comparison of TCR/pMHC structures obtained in my laboratory in 
TOPS and TOPS screen-derived versus commercially available screens. 
15 structures out of 25 were exclusively obtained in TOPS, 21 being obtained in total 
in TOPS or TOPS screen-derived. 3 TCR/pMHC structures were exclusively 
obtained in PACT Premier, 1 in JBScreen and no structures were obtained with the 
JCSG-plus screen.  
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Among these 25 unique complexes, 21 were obtained from the TOPS screen or 
TOPS screen-derived conditions while only 3 were obtained exclusively from the 
PACT Premier screen and 1 from the JBScreen. No complexes were obtained from 
the JCSG-plus screen. Thus, TCR/pMHC structures that crystallized in TOPS screen 
represented more than 80% of the total number of complexes solved (Table 3.7 and 
Figure 3.3). Although the TOPS screen was designed for TCR/pMHC complexes, a 
selection of uncomplexed TCR and pMHC proteins were generated in the laboratory 
based on our ongoing research interests, to test the efficacy of TOPS. This approach 
directly resulted in structures of 3 uncomplexed TCRs and 8 pMHCs proteins (Table 
3.7). 
 
3.2.3 Optimal conditions for the generation of TCR/pMHC complex crystals 
The total number of 25 complexes and 53 datasets (we collected datasets from 
different conditions for a particular complex) (Appendix 2) allowed us to perform an 
analysis in order to define the most optimal conditions for growing crystals of 
TCR/pMHC complexes. One dataset represents a full diffraction dataset obtained 
from one particular crystal growing condition for a given complex and usable to 
solve, analyze and publish the structure. We often collected several datasets from the 
same condition for a particular complex but only one is included in the Appendix 2 
in order to avoid any redundancy in the analysis. The results of the analysis are 
presented in Figure 3.4. In all cases, the pH was within a range of 5.0 to 8.5. 
However, a great majority of crystals (90%) were obtained around a neutral pH of 
6.0 to 7.5, and more than a third (35%) at pH 7.0 (Figure 3.4A). The presence of 
salt, a precipitating agent, at 0.2 M was required as 79% of crystals successfully 
grew in such conditions (Figure 3.4B). The best PEG concentrations, another 
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precipitating agent, were 15% and 20%, resulting in 51% and 40% of the datasets, 
respectively. In contrast, higher precipitant concentrations produced only 9% of the 
datasets (Figure 3.4C). The most popular PEG size was around 4000 g/mol with 
79% of datasets obtained in this condition (13% PEG 3350 and 66% PEG 4000). 
PEG at smaller molecular weight only generated 2% of the datasets, whereas PEG at 
higher molecular weight generated 19% of the datasets (6% and 13% of PEG 6000 
and 8000 respectively) (Figure 3.4D). Although glycerol was a good cryoprotecting 
agent, the absence of this component was essential in 72% of the cases. However, 
when the presence of glycerol was required, 15% appeared to be the best 
concentration (Figure 3.4E). 
 
Although this analysis suggested the optimal conditions for obtaining TCR/pMHC 
complexes, it was performed by taking each variable independently. In order to 
verify if a given condition was more representative than the others, the frequency of 
appearance of each particular condition was calculated (Figure 3.5 and Appendix 
3). The conditions producing less than 5% of the datasets were combined together. 
This combined fraction of 23 different conditions correlated to 51% of all datasets. 
The remaining 6 conditions (pH 6.5 20% PEG 3350 0.2 M salt, pH 6.0 15% PEG 
4000 0.2 M salt, pH 6.5 15% PEG 4000 0.2 M salt, pH 7.0 15% PEG 4000 0.2 M 
salt, pH 7.5 15% PEG 4000 0.2 M salt and pH 7.0 20% PEG 4000 0.2 M salt), 
surprisingly, produced nearly half of all datasets (Figure 3.5).  
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Figure 3.4. Analysis of crystallization conditions obtained from 25 TCR/pMHC 
complexes. 
(A) The pH was within a range of 5.0 to 8.5, with 91% of the datasets obtained 
around a neutral pH from 6.0 to 7.5. (B) The presence of 0.2 M salt was required in 
79% of the conditions. (C) The best PEG concentrations were 15% and 20%, 
representing 91% of the datasets. (D) The most popular PEG molecular weight was 
around 4000 g/mol, representing 79% of the datasets (13% PEG 3350 and 66% PEG 
4000). (E) The absence of glycerol was dominant (72%), but the best concentration 
of glycerol when this component was required was 15%. 
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This analysis completely correlated with the previous independent analysis with a 
pH range from 6.0 to 7.5, a required presence of 0.2 M salt, a preferred PEG size 
around 4000 g/mol and PEG concentrations of 15% and 20%. Based on these 
analyses, it could be possible to significantly restrain the crystallization conditions of 
TCR/pMHC complexes. 
 
3.2.4 TOPS efficiency correlated to the datasets obtained in this screen 
Based on the analysis presented in Figure 3.4, a scoring system associated to the 
percentage of datasets obtained per condition of pH, PEG concentration, PEG size 
and presence of salt or glycerol was designed (Table 3.8). This scoring system 
allows the generation of a score for each condition of TOPS based on the number of 
TCR/pMHC complexes crystallized in each condition (Table 3.9). For example, 
condition A1 of TOPS was attributed the score 9 ([score pH 6 = 3] + [score 15% 
PEG 4000 = 5] + [score glycerol = 1]). Scores were transposed into a colour system  
(scores <2.5 in dark blue, 2.5-5 in light blue, 5-7.5 in green, 7.5-10 in yellow, 10-
12.5 in orange and >12.5 in red) and each datasets obtained in TOPS-like conditions 
were plotted (Figure 3.6). The vast majority of TCR/pMHC complexes crystallized 
in the conditions with a high score, but a number of complexes crystallized in the 
low range of this scoring system. Thus, although it is tempting to limit the number of 
conditions in a protein crystal screen to improve efficiency and reduce protein 
consumption, broader screens are required to ensure that crystallization conditions 
are not missed for important proteins. 
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Figure 3.5. Analysis of the frequency of appearance of a particular condition. 
The conditions producing less than 5% of the datasets were combined together. The 
53 datasets were obtained in a total of 29 different conditions. Among these 29 
conditions, 6 conditions (pH 6.5 20% PEG 3350 0.2 M salt, pH 6.0 15% PEG 4000 
0.2 M salt, pH 6.5 15% PEG 4000 0.2 M salt, pH 7.0 15% PEG 4000 0.2 M salt, pH 
7.5 15% PEG 4000 0.2 M salt and pH 7.0 20% PEG 4000 0.2 M salt) produced 
nearly half of all datasets. 
 
Table 3.8. Scoring system. 
pH Score PEG concentration and type  Score Salt or glycerol Score 
6.0 3.0 15% PEG 4000 5.0 Presence salt 4.0 
6.5 3.0 20% PEG 4000 3.0 Presence glycerol 1.0 
7.0 6.0 25% PEG 4000 1.0   
7.5 6.0 15% PEG 8000 2.0   
8.0 0.5 20% PEG 8000 0.5   
8.5 0.5 25% PEG 8000 0   
Based on Figure 3.4, a scoring system related to the percentage of datasets obtained 
per condition of pH, PEG concentration and size and presence of salt or glycerol was 
implemented. 
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Table 3.9. TOPS conditions correlated to the scoring system. 
Buffer (pH) 
0.1 M 
15% glycerol 0.2 M ammonium sulphate 
PEG 4000 (%) PEG 8000 (%) PEG 4000 (%) PEG 8000 (%) 
15 20 25 15 20 25 15 20 25 15 20 25 
C2H6AsO2Na 
(pH 6) 9.0 7.0 5.0 6.0 4.5 4.0 12.0 10.0 8.0 9.0 7.5 7.0 
C2H6AsO2Na 
(pH 6.5) 9.0 7.0 5.0 6.0 4.5 4.0 12.0 10.0 8.0 9.0 7.5 7.0 
MES (pH 7) 12.0 11.0 8.0 9.0 7.5 7.5 15.0 13.0 11.0 11.0 10.0 10.0 
HEPES (pH 
7) 12.0 11.0 8.0 9.0 7.5 7.5 15.0 13.0 11.0 11.0 10.0 10.0 
HEPES (pH 
7.5) 6.5 10.0 8.0 9.0 7.5 7.5 15.0 13.0 11.0 12.0 10.5 10.0 
TRIS (pH 7.5) 6.5 10.0 8.0 9.0 7.5 7.5 15.0 13.0 11.0 12.0 10.5 10.0 
TRIS (pH 8) 6.5 4.5 2.5 3.5 2.0 1.5 9.5 7.5 5.5 6.5 5.0 4.5 
TRIS (pH 8.5) 6.5 4.5 2.5 3.5 2.0 1.5 9.5 7.5 5.5 6.5 5.0 4.5 
 
 
 
Figure 3.6. Representation of the expected TOPS efficiency correlated to the 
datasets obtained with that screen based on the implemented scoring system. 
Scores <2.5, 2.5-5, 5-7.5, 7.5-10, 10-12.5 and >12.5 were represented in dark blue, 
light blue, green, yellow, orange and red, respectively. Each dark circle represents a 
successful dataset. The vast majority of TCR/pMHC complexes crystallized in the 
conditions with a high score, but a number of complexes crystallized in the low 
range of this scoring system. 
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3.3 DISCUSSION 
The ability of T-cells to respond to antigen depends on the productive interaction 
between the TCR and pMHC. The crystal structures of a number of TCR/pMHC 
complexes have been solved and show that the TCR has a relatively conserved mode 
of binding to pMHC in which the TCR lines up approximately diagonally to the 
MHC peptide binding groove, with the TCR α chain contacting the MHC α2 domain 
and the TCR β chain contacting the MHC α1 domain. The antigen specific portion of 
the TCR/pMHC interaction occurs between the pMHC surface and the TCR 
complementarity determining region loops (CDR-loops) (Rudolph et al., 2006). 
These CDR-loops serve different roles during TCR binding to pMHC; the variable 
(V)-gene encoded CDR2-loops contact mainly the conserved helical region of the 
MHC surface, the V-gene encoded CDR1-loops can contact both the MHC and the 
peptide and the more variable somatically rearranged CDR3-loops contact mainly 
the antigenic peptide. Although the general features of TCR/pMHC binding have 
been defined, there are a number of conflicting models that describe the structural 
basis of T-cell MHC-restriction, cross-reactivity, autoimmunity and alloreactivity. 
Furthermore, each previous TCR/pMHC complex has been governed by a unique set 
of contacts that enable T-cell antigen recognition. Thus, there is still a pressing need 
to increase the number of TCR/pMHC complex structures in the literature in order 
to: (i) determine an accepted set of rules that describe the generalities of T-cell 
specificity, and (ii) understand the unique features of individual TCR/pMHC 
interactions that allow T-cells to target different disease epitopes. 
 
The study of TCR/pMHC complexes has been limited by the challenges in 
expression, purification and successful crystallization of these soluble proteins. Here, 
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a new systematic and directed approach for the design of a TCR/pMHC Optimized 
Protein crystallization Screen (TOPS) that has proved to be useful for the 
crystallization of this family of immuno-proteins is reported. With this novel 
crystallization screen, my laboratory and I have successfully generated the majority 
of the current portfolio of structures that includes 21 TCR/pMHC complexes (13 
derived from a common parent complex), 3 TCRs and 8 pMHCs. These structures 
have already enabled a better understanding of T-cell antigen recognition of viral 
(Miles et al., 2010), autoimmune (Bulek et al., 2012a) and cancer (Cole et al., 2009) 
epitopes, as well as a number of so far unpublished observations. I found that 
TCR/pMHC complex crystals most commonly formed at neutral pH, with 15% to 
20% of PEG 4000 and 0.2 M ammonium sulphate. In addition, results from the 
crystallization trials indicated that it might be possible to significantly restrain the 
crystallization conditions of TCR/pMHC complexes to around 6 different conditions 
(rather than 96) thereby saving valuable protein.  
 
In conclusion, TOPS will greatly contribute to a better understanding of molecular 
basis for T-cell recognition of self, foreign (microbial/viral/parasitic) and 
autoimmune antigens by providing an improved method for generating TCR/pMHC 
complex protein crystals capable of high quality X-ray diffraction. Furthermore, 
TOPS may be useful for the determination of TCR structures in complex with 
classical and non-classical MHC ligands that are less well characterized, including: 
pMHC class II, MR1, CD1c and HLA-E. Structural information, detailing the 
precise atomic contacts that mediate T-cell immunity, can provide clear insights into 
various immune dysfunctions and could accelerate the rational design of T-cell based 
therapies and vaccines.  
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Chapter background 
The work presented in this Chapter mainly results from the generation of TOPS as 
well as collaborations with Professor Brian Baker laboratory (University of Notre 
Dame, Indiana, USA) and with a biotechnology company (Immunocore, Ltd). 
Immunocore generated the high-affinity variant sequences of MEL5 TCR used in 
this study from a TCR that was originally described by my primary supervisor, 
Professor Sewell. Professor Baker’s laboratory provided the datasets for solving two 
unligated pMHC structures and TOPS allowed the generation of the other structures 
reported here. This study is a continuation of the work started in my laboratory on 
MEL5 TCR and follows the publication of the in-depth crystallographic and 
thermodynamic analyses of the MEL5 TCR interaction with the heteroclitic 
melanoma-derived HLA-A2-restricted MART-126/35 peptide (Cole et al., 2009) 
published shortly before I started my PhD. The high-affinity TCR variant was 
produced by Immunocore using a phage display technique originally described by 
our late Cardiff University colleague Jonathan Boulter (Li et al., 2005b). Such high-
affinity TCRs are in development for soluble TCR therapy (Liddy et al., 2012). 
Detailed analysis of a high-affinity MEL5 variant TCR and its peptide specificity 
was deemed to be an important step in understanding these molecules. The data 
presented here were subsequently submitted for publication shortly before the 
submission of this thesis. 
 
4.1 INTRODUCTION 
Monoclonal antibodies (mAbs) are being used as therapeutic agents for a wide range 
of pathologies and more than 30 mAbs and mAbs-derived molecules are currently 
registered as approved drugs with hundreds more in clinical trial (Adler and 
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Dimitrov, 2012; Brekke and Sandlie, 2003). Generally, mAbs are unable to target 
internal cellular infections or aberrations. In contrast, TCRs can exploit the MHCI 
presentation pathway to scan the internal proteome for such anomalies and thereby 
gain access to a much wider range of targets, including tumour associated antigens 
(TAAs), that are not readily available for antibody-mediated therapies. Unlike 
antibodies which bind to their cognate antigens with high affinity (KD = nM-pM), 
TCRs bind to their cognate pMHC with relatively low affinity (KD = 0.1-270 µM) 
(Bridgeman et al., 2012; van der Merwe and Davis, 2003). This weak binding 
affinity correlates to a half-life of binding of 0.1-12 seconds ruling out efficient cell 
targeting with soluble TCRs. The weak binding affinity and short half-life of 
TCR/pMHC interactions can be circumvented using several different methods (e.g. 
phage display) as described in Chapter 1. Previous structural studies revealed that 
TCR affinity-enhancements were due to contacts made between the TCR and both 
the peptide and MHC surface, but primary resulted from contact associations with 
peptide antigen rather than MHC (Dunn et al., 2006; Sami et al., 2007). It is 
currently unknown how improving the interaction between TCR and MHC (self-
interaction) could affect TCR specificity for the peptide component of the bipartite 
antigen. Loss of TCR specificity could result in recognition of self-derived peptides 
and precipitate autoimmunity. It is critically important that we gain an understanding 
of the binding specificity of enhanced affinity TCRs before these molecules are put 
to widespread use in clinical applications. I will begin by describing the therapeutic 
use of monoclonal antibodies. 
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4.1.1 Therapeutic application of monoclonal antibodies 
Therapeutic monoclonal antibodies (mAbs) (Kohler and Milstein, 1975) are 
currently being used in hundreds of clinical trials for conditions ranging from cancer 
and autoimmunity to cardiovascular disease and transplant rejection (Gura, 2002; 
Waldmann, 2003). These molecules represent the next wave of medicines and are 
likely to form the basis of a number of therapies over the coming years. The huge 
success of these molecules can be partly attributed to their high level of specificity 
and strong binding affinity (nM–pM). In combination, these attributes allow the 
specific targeting of important disease epitopes using soluble proteins to deliver 
therapeutic benefit. There are three categories of antibodies generated for use in 
therapeutics: (i) “naked” mAbs; (ii) conjugated mAbs; and, (iii) bispecific mAbs. 
 
4.1.1.1 “?aked” or unconjugated monoclonal antibody therapy 
“Naked” or unconjugated monoclonal antibodies such as the clinically effective 
therapeutic agents Trastuzumab (Herceptin®), Rituximab (Rituxan®) or the more 
recently approved anti-melanoma Ipilimumab (Yervoy®) elicit an antibody-
dependent cell-mediated cytotoxicity (ADCC) (Sapoznik et al., 2012). Fc portions of 
mAbs specifically bound to target cells are engaged by the Fc receptors of the 
effector cells (most commonly CD16/FcɣRIII). These receptors then activate NK 
cells or macrophages, leading to the lysis and/or phagocytosis of the target cells 
(Clynes et al., 2000). 
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4.1.1.2 Conjugated monoclonal antibody therapy 
Various conjugated antibodies have been designed to enhance the ADCC process by 
inducing toxicity via agents such as radioisotypes, cytotoxic drugs and as prodrugs. 
These conjugated antibodies are constituted by a recombinant antibody covalently 
bound by a synthetic linker to a given cytotoxic chemical (Chari, 2008). The main 
objective is to combine the pharmacological potency of cytotoxic drugs and the high 
specificity of monoclonal antibodies (Beck et al., 2010a). However, the clinical 
success of these “immuno-conjugates” has been limited compared to the 
unconjugated mAbs (Haeuw et al., 2009). To date, only one conjugated mAb has 
been approved by the FDA, namely gemtuzumab ozogamicin (GO) (Mylotarg®) in 
2000 (Jurcic, 2012). This anti-CD33 mAb conjugated to calicheamycin was 
approved for the treatment of patients with acute myeloid leukaemia (AML) but was 
never approved in Europe and was withdrawn from the US market in June 2010. The 
reasons for the withdrawal included high level of off-target toxicity and failure to 
demonstrate improved survival during required post-approval studies combining 
chemotherapy and Mylotarg.  In addition, protease-mediated degradation of the 
linker joining the mAb to the cytotoxic drug was identified as a further issue (Beck 
et al., 2010a; Jurcic, 2012). However, there are currently discussions for the reversal 
of the decision to withdraw GO. It has been shown that AML is not a homogeneous 
disease but rather a group of diseases, some of which are particularly sensitive to the 
drug, and the compelling data available from the more recently reported trials 
strongly suggested that the reversal of the decision might be the correct way forward 
(Ravandi et al., 2012). 
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4.1.1.3 Bispecific antibody therapy 
Bispecific antibodies (or bifunctional antibodies) are mAbs that bind to two different 
epitopes. These epitopes can be on the same antigen or two different antigens, 
thereby triggering two different functions (Beck et al., 2010b). As for most diseases 
several mediators contribute to pathogenesis, the simultaneous blockade of several 
targets might yield to better therapeutic efficacy than the inhibition of a single target. 
After years of unsuccessful trials, catumaxomab (Removab®) was the first, and to 
date the only, approved bispecific antibody (Seimetz, 2011). This bifunctional mAb 
binds to both epithelial cell adhesion molecule (EpCAM) on tumour cells and CD3 
on effector T-cells and was approved in Europe in 2009 for the treatment of 
malignant ascites (Linke et al., 2010). Another promising example of this class of 
mAbs is the Bispecific T-cell Engaging (BiTE) antibody (Wolf et al., 2005). The 
BiTE construct blinatumomab (MT103) has a dual specificity for the tumour-
associated CD19 and the T-cell expressed CD3. It has shown promising results in 
Phase I (non-Hodgkin’s lymphoma) and Phase II (acute lymphoblastic leukaemia) 
clinical trials by instigating the lysis of CD19+ lymphoma and leukaemia cells by 
CD3+ T-cells (Beck et al., 2010b). 
 
Although antibodies are able to target disease particles or pathogens, they are not 
able to detect internal cellular infections or aberrations. Like antibodies, T-cells have 
the potential to be used to target specific disease markers (Liddy et al., 2012; Morgan 
et al., 2006; Varela-Rohena et al., 2008). Additionally, because of their ability to 
detect deleterious proteins that are only expressed inside of cells, T-cells can access 
disease targets that are hidden from antibody detection. This “X-ray vision”, that T-
cells utilize through cell surface antigen recognition via the TCR-pMHC interaction, 
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offers exciting new possibilities for developing disease specific therapies. A number 
of strategies have been used to overcome the weak binding affinity of TCRs (see 
Chapter 1). The resultant soluble high affinity T-cell receptors have been called 
“monoclonal TCRs”. 
 
4.1.2 Monoclonal TCRs 
Antibodies undergo affinity maturation in vivo via a somatic hypermutation and a 
selection process where the progeny with highest affinity for antigen win out to 
receive a survival signal. This process ensures that antibodies bind with high affinity. 
In contrast, TCRs are fixed at the protein sequence level and do not change in 
affinity for antigen. TCRs are required to bind to self-antigens during thymic 
selection so any process that allowed TCRs to “home in” on antigens would rapidly 
result in autoimmunity. 
 
TCRs are selected in the thymus to bind with a weak affinity (KD = 0.1-270 µM) 
(Bridgeman et al., 2012; Cole et al., 2007). However, the combination of advances in 
soluble TCR technology (described in Chapter 3) and molecular affinity evolution 
systems (described in Chapter 1) have enabled the production of soluble high 
affinity “monoclonal TCRs” that can be coupled to a variety of payloads in a same 
way that therapeutic mAbs are being used. Despite showing great promise in certain 
situations, the success of therapeutic mAbs is limited by the nature of antigens that 
antibody are designed to recognize. Whereas antibodies can only bind to secreted or 
surface bound antigens (typically in the form of whole proteins), TCRs have access 
to all antigens when presented by the MHC, regardless of cellular localisation. Since 
the majority of TAAs and other pathogenic antigens are intracellular, soluble TCRs 
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(when armed with immune stimulators or cytotoxic agents) are ideal candidates for 
immunotherapy (Figure 4.1) (Molloy et al., 2005). One of the earliest successful 
soluble TCR immunotherapy studies was reported by Card et al. (Card et al., 2004). 
This group produced a single-chain TCR-interleukin-2 (IL-2) fusion protein, namely 
264scTCR/IL-2, specific for an epitope of the p53 tumour suppressor protein (Card 
et al., 2004). This TCR-like fusion protein reduced lung metastases in an 
experimental HLA-A2+ mouse tumour model and inhibited the growth of primary 
tumours derived from the A375 human melanoma cell line (HLA-A2+ and p53+) in 
these humanized mice (Belmont et al., 2006). It would be also possible to fuse other 
immunomodulatory molecules that have been used with conjugated mAbs, including 
the cytokines tumour necrosis factor (TNF-α) and interleukin-12 (IL-12) (Halin et 
al., 2003) or an anti-CD3 antibody (Wolf et al., 2005), to TCRs. Recently, high-
affinity variants of several anti-tumour TCRs were used in monoclonal TCR therapy 
models to induce regression of established tumours. These TCRs were fused to an 
anti-CD3 antibody Fab fragment and have been called ImmTACs (immune-
mobilizing monoclonal TCRs against cancer) (Liddy et al., 2012). This development 
represents exciting milestones in both TCR-mediated therapy and the range of 
potential treatments available for cancer. 
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Figure 4.1. Differences in antigen recognition between mAbs and TCRs. 
Cytoplasmic proteins, in this case tumour-associated antigens (TAAs) comprise 
intracellular antigens (shown in pink), cell-surface-bound antigens (shown in red) 
and secreted antigens (shown in green). These proteins are degraded into short 
peptides by the proteasome and the peptide fragments are transported to the lumen of 
the endoplasmic reticulum where they can bind MHCI. The pMHC complex is then 
displayed on the cell surface with their intracellularly derived peptide fragments 
(pink, red and green). Whereas antibodies can only bind to secreted or surface bound 
antigens (typically in the form of whole proteins), TCRs have access to all antigens 
when presented by the MHC, regardless of cellular localisation. Since the majority of 
TAAs and other pathogenic antigens are intracellular, soluble TCRs (when armed 
with immune stimulators or cytotoxic agents) are ideal candidates for 
immunotherapy (Figure taken from (Molloy et al., 2005)). 
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4.1.3 Aim 
Using phage display (Li et al., 2005b), several high affinity TCRs derived from the 
MEL5 TCR that is specific for the heteroclitic version of the primary melanoma 
antigen recognized by T-cells 1 (MART-126-35) peptide presented by HLA-A*0201 
(A2-ELA) were generated. This Chapter focuses on one of the high-affinity TCRs 
specific for melanoma, namely α24β17. The aims of this Chapter were to provide a 
molecular explanation for the high affinity TCR binding observed by solving the 
structure of α24β17 in complex with A2-ELA and comparing this structure with the 
previously published MEL5/A2-ELA complex (Cole et al., 2009) and to analyse and 
understand the peptide specificity of this high-affinity TCR by using biophysical 
analysis and structural data. These results have importance for the therapeutic use of 
soluble high-affinity TCRs. 
 
4.2 RESULTS 
4.2.1 Production and purification of soluble TCRs and pMHCs for this study 
In this Chapter, I solved the structures of the high-affinity TCR α24β17 unbound to a 
pMHC and in complex with the heteroclitic version of MART-126-35 presented by 
HLA-A*0201 (A2-ELAGIGILTV, A2-ELA), with ELA mutants ELAAIGILTV 
(A2-ELA4A) and ELAGIGALTV (A2-ELA7A) as well as the structures of A2-
ALAGIGILTV (A2-ELA1A), A2-ELA4A and A2-ELAGIGIATV (A2-ELA8A) 
unbound to a TCR (unligated). I also performed biophysical analyses of the 
interaction between Melan A-specific TCRs and various antigens. These experiments 
required the manufacture of considerable amounts of soluble, refolded pMHC and 
TCR. Protein was produced by expression as inclusion bodies in E. coli, purification 
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of inclusion bodies and then refolding by the dilution of denaturing conditions as 
described in Chapter 2 (section 2.3). An example of the process of manufacture of 
the α24β17 TCR is shown in Figure 4.2A. Briefly, the process involved: (i) 
expression of protein chains as inclusion bodies in E. coli; (ii) purification of 
inclusion bodies; (iii) refolding by dilution of denaturing conditions; (iv) an anion 
exchange purification step (e.g. Figure 4.2B&C); and, (v) several gel filtration 
purification steps (e.g. Figure 4.3) in order to obtain enough pure proteins to 
perform the different experiments (Figure 4.3). For the biophysical analysis by 
Surface Plasmon Resonance (SPR) using BIAcore® machinery, biotin-tagged 
pMHC were biotinylated and purified by gel filtration (Figure 4.3) before analysis. 
The biotin group allowed coupling of pMHC to a streptavidin-coated sensor chip 
(BIAcore®). Conveniently, the antibody-like affinity of α24β17 binding to A2-ELA 
made it possible to co-purify the α24β17/A2-ELA complex by gel filtration before 
setting up crystallization plates (Figure 4.4). Conventionally, TCRs and pMHCs, or 
antibodies and recombinant antigens, are mixed in an equimolar ratio prior to 
crystallization trials (Bossi et al., 2010) as described in Chapter 2. The co-
purification step of the α24β17/A2-ELA complex coupled to the optimization of the 
crystallization conditions detailed in the previous Chapter (Bulek et al., 2012b) could 
explain the generation of high-quality crystals > 200 µm long (Figure 4.4) for this 
particular complex. The size of the protein crystal is important for the generation of 
high resolution X-ray diffraction as the strength of the scattering (or Bragg spot) 
depends on several factors such as X-ray exposure time or crystal volume (Holton 
and Frankel, 2010). Bigger crystals will produce stronger patterns and suffer less 
damage (Garman, 1999).   
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Figure 4.2. Example of inclusion bodies purity and anion exchange purification 
step. 
(A) α24 (left panel) and β17 (right panel) chains were produced as inclusion bodies 
(IB) in E. coli. Although the protein of interest was over-expressed (black rectangle), 
several contaminants remained in the IB preparation. (B) An anion exchange 
purification step (7.9 mL POROS® 10/100 HQ 50 µm column) after refolding of 
α24β17 TCR shows three different peaks (1, 2 and 3). TCR, TCR α24 and β17 
chains aggregation as well as contaminants from the IB preparation are eluted by 
gradually increasing the NaCl gradient (green line) from 0 mM to 500 mM and all 
the proteins bound on the column are eventually eluted with 1 M NaCl to regenerate 
the column (waste fraction). The analysis of several fractions of each peak by SDS-
PAGE and Coomassie staining was required to discriminate the peak containing the 
protein of interest. (C-D) SDS-PAGE under non reducing (C) and reducing (D) 
conditions followed by Coomassie staining reveals that the α24β17 TCR was located 
in the second peak, namely fractions B9-C4. The refold before anion exchange (load 
fraction, L) and the flow though (FT) were also analysed. Non-refolded α24 or β17 
chains were eluted in the first peak, TCR aggregation was eluted in the third peak 
and most of the contaminants from the IB preparation were eluted with 1 M NaCl in 
the waste fraction. No proteins were detected in the L and FT fractions because of 
the low protein concentration.  
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Figure 4.3. Gel filtration examples and purity of proteins for crystallography 
and biophysical analysis. 
(A) After anion exchange, fractions containing the protein of interest were pooled, 
concentrated and purified by gel filtration (24 mL Superdex 200 10/300 GL column). 
For α24β17 TCR, two peaks were obtained and fractions A7-A12 were analysed by 
(B) SDS-PAGE and Coomassie staining under non reducing and reducing 
conditions. The first peak contains TCR aggregation and the second peak contains 
relatively pure TCR. (C) After pMHC biotinylation, pMHC-bt were purified by gel 
filtration to remove the excess biotin (second peak). (D) Analysis by SDS-PAGE and 
Coomassie staining under non reducing conditions showed that relatively pure 
pMHC-bt (here A2-ELA-bt) was located in the first peak, namely fractions A11-
A15. After several rounds of gel filtration, the purity of (E) α24β17 and (F) pMHCs 
(here A2-ELA for crystallography) was analysed SDS-PAGE and Coomassie 
staining under non reducing and reducing conditions and no contaminants were 
detectable.  
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Figure 4.4. Gel filtration, protein crystal and high-resolution diffraction pattern 
of the α24β17/A2-ELA complex. 
(A) Due to the high-affinity of α24β17 for A2-ELA, the complex was co-purified by 
gel filtration for crystallography and two peaks were obtained between fractions A9 
and A12. Analysis by SDS-PAGE and Coomassie staining under (B) non reducing 
and (C) reducing conditions showed that the first peak (A9-A10) contains pure 
α24β17/A2-ELA complex whereas the second peak (A11-A12) contained the excess 
A2-ELA. (D) Pure gel filtrated α24β17/A2-ELA complex was used to generate high 
quality crystals, here ~210 µm long, leading to a high resolution X-ray diffraction 
pattern with ~2.43 Å maximum resolution.  
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Finally, crystals of A2-ELA1A and A2-ELA8A were grown in MES 25 mM pH 6.5, 
24% PEG 3350 and 10 mM NaCl by our collaborator Professor Brian Baker and 
diffraction datasets were obtained at the Advanced Photon Source at Argonne 
National Labs, USA. 
 
4.2.2 α24β17 TCR binds to A2-ELA with high affinity due to an extended off-
rate 
The high-affinity α24β17 TCR varied from the MEL5 TCR parental sequence at 19 
amino acids located within the CDR1α, CDR2α, FWα, CDR3α, CDR2β and CDR3β 
loops as well as in the β chain between residues 41 and 45 (Table 4.1). My group 
has previously demonstrated that the MEL5 TCR has a binding constant (KD) of 16-
20 µM (Cole et al., 2010; Cole et al., 2007; Cole et al., 2009) for A2-ELA (Figure 
4.5A). The high-affinity α24β17 TCR bound to A2-ELA ~30,000-fold stronger 
affinity than the wildtype MEL5 parent receptor (KD = 600 pM) (Figure 4.5B). 
Similar to previously reported high-affinity engineered TCRs (Dunn et al., 2006; Li 
et al., 2005b; Sami et al., 2007; Varela-Rohena et al., 2008), the enhancement in 
affinity was due primarily to an extended off-rate of 1.09 x 10-4 sec-1. The off-rate 
for the MEL5 TCR was too fast to measure (>0.1 sec-1) (Figure 4.5). 
 
4.2.3 MEL5 and α24β17 TCRs use a similar binding mode to engage A2-ELA 
Previous structures of high-affinity TCRs have shown that, although these mutated 
TCRs can bind with many orders of magnitude stronger affinity than their wildtype 
progenitors, they bind in the same overall conformation (Dunn et al., 2006; Sami et 
al., 2007).  
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Table 4.1. Sequence alignment of the α24β17 TCR and the wildtype MEL5 
progenitor. 
TCR CDR1α27-32 CDR2α50-54 FWα67-71 CDR3α89-100 
MEL5 DRGSQS IYSNG KASQY CAVNVAGKSTFG 
α24β17 FLGSQS TYREG KASQH CAVNDGGRLTFG 
TCR CDR1β27-32 β chain41-45 CDR2β50-54 CDR3β91-106 
MEL5 GTSNPN  GRGLQ SVGIG CAWSETGLGTGELFFG 
α24β17 GTSNPN GRGPQ WGPFG CAWSETGLGMGGWQFG 
Mutations from wildtype sequence are bold and underlined. 
 
 
Figure 4.5. Binding affinity and kinetic analysis of the HLA A2-ELAGIGILTV 
specific wildtype MEL5 TCR and the high-affinity TCR, α24β17. 
These data were produced on a BIAcore T100TM using surface plasmon resonance 
and were then analyzed using (A) equilibrium analysis and (B) single cycle kinetic 
analysis. The raw data and the fits are shown in each panel. These data illustrate the 
binding capabilities of (A) the HLA A2-ELAGIGILTV specific wildtype MEL5 
TCR (data from the previously published work (Cole et al., 2007)) and (B) the HLA 
A2-ELAGIGILTV specific high-affinity mutant TCR, α24β17. The α24β17 TCR 
binds to HLA A2-ELAGIGILTV with 30,000-times stronger affinity than MEL5. 
 
  
145 
 
This observation is important because this conserved binding mode increases the 
likelihood that high-affinity modified TCRs can maintain the rules that govern T-cell 
antigen recognition (self-tolerance). In order to determine the structural basis of the 
high-affinity binding for the α24β17 TCR, I solved the α24β17/A2-ELA complex 
structure to 2.43 Å. Molecular replacement was successful only in space group P41 
and the resolution was sufficiently high to show that the interface between the two 
molecules was well ordered and contained well defined electron density (Figure 
4.6). The crystallographic R/Rfree factors were 21% and 26.3%. The ratio was 
within the accepted limits shown in the theoretically expected distribution (Tickle et 
al., 2000) (Table 4.2). The overall buried surface area (BSA) of 2705 Å2 
(TCR/pMHC) for α24β17/A2-ELA was slightly higher than for the previously 
published structure of MEL5/A2-ELA (Cole et al., 2009) (BSA = 2327.8 Å2) (Table 
4.3) but was within the observed range (Rudolph et al., 2006). The high affinity 
α24β17 TCR bound with a diagonal docking geometry to A2-ELA and showed one-
to-one stoichiometry as previously reported of other TCR/pMHC complexes (Figure 
4.7A) (Rudolph et al., 2006). As with previously reported high-affinity TCR 
structures (Dunn et al., 2006; Sami et al., 2007), a high level of similarity between 
the MEL5/A2-ELA and α24β17/A2-ELA complexes was observed, suggesting that 
the overall conformation was not substantially affected by the mutations in α24β17. 
The crossing angles of both TCRs (Figure 4.8A) and the positioning of the 
complementarity determining region (CDR) loops (Figure 4.8B) were similar (47.6° 
for MEL5 and 42.2° for α24β17) and fell within the previously observed range 
(Rudolph et al., 2006). Importantly, the ELA peptide conformation was virtually 
identical in both complexes, discounting the possibility that changes in the peptide 
contributed to the high affinity observed (Figure 4.8C&D).   
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Figure 4.6. 2Fo-Fc electron density maps for all structures reported in this 
Chapter. 
2Fo-Fc electron density maps (shown in cyan) for (A) α24β17 free, (B) α24β17/A2-
ELA complex, (C) α24β17/A2-ELA4A complex, (D) α24β17/A2-ELA7A complex, 
(E) A2-ELA1A, (F) A2-ELA4A and (G) A2-ELA8A. All maps shown are within 2 
Å from the atoms to which they relate. Positive density is shown in green and 
negative density is shown in red. 
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Table 4.2. Data collection and refinement statistics for unligated α24β17 TCR 
and complex structures (molecular replacement). 
Data set 
statistics 
α24β17 
α24β17/ 
A2-ELA 
α24β17/ 
A2-ELA4A 
α24β17/ 
A2-ELA7A 
Space Group P3221 P41 P41 P41 
Unit Cell 
parameters (Å) 
a=97.14, 
b=97.14, 
c=123.08,γ=12
0 
a=121.44, 
b=121.44, 
c=82.3 
a=121.49, 
b=121.49, 
c=82.96 
a=121.52, 
b=121.52, 
c=82.15 
Radiation Source 
DIAMOND 
I24 
DIAMOND 
IO3 
DIAMOND 
IO3 
DIAMOND 
IO3 
Wavelength (Å) 0.9778 0.9763 0.9763 0.9763 
Resolution (Å) 2.4 2.43 2.46 2.7 
Unique 
reflections 
26783 45232 44185 35640 
Completeness 
(%) 
100 100 100 99.9 
Multiplicity 10.9 8.3 8.2 8.1 
I/Sigma(I) 16.6 14.8 17.1 13.5 
Rmerge (%) 0.192 0.091 0.073 0.103 
Refinement statistics (highest resolution shell in parenthesis) 
No reflections 
used 
25403 42931 41936 31318 
No reflections in 
Rfree set 
1346 2278 2225 1674 
Rcryst (no 
cutoff) (%) 
20.1 21 20.2 20.2 
Rfree (%) 24.6 26.3 24.8 25 
RMSD from ideal geometry (target values in parenthesis) 
Bond lengths 
(Å) 
0.022 (0.022) 0.021 (0.021) 0.021 (0.021) 0.019 (0.021) 
Bond Angles (°) 1.206 (1.956) 1.246 (1.94) 1.174 (1.94) 1.134 (1.934) 
Wilson B-factor 
(Å2) 
37.4 47 58.9 54.4 
Overall ESU 
based on 
Maximum 
Likelihood (Å) 
13 14.5 14.4 22.4 
One crystal was used for data collection.  
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Table 4.3. Summary of co-complex structures of MEL5/A2-ELA (Cole et al., 
2009), α24β17/A2-ELA, α24β17/A2-ELA4A and α24β17/A2-ELA7A. 
 
MEL5/ 
A2-ELA 
α24β17/ 
A2-ELA 
α24β17/ 
A2-ELA4A 
α24β17/ 
A2-ELA7A 
H-bondsa (≤3.2Å) 6 16 15 16 
H-bondsa (≤3.4Å) 1 6 6 1 
vdWa (≤3.5Å) 23 21 11 15 
vdWa (≤4Å) 65 95 109 105 
Total contacts 95 138 141 136 
Number of α chain 
CDR1/CDR2/CDR3 
contacts (≤4Å) 
26/11/13 37/12/21 38/16/18 31/8/20 
Number of β chain 
CDR1/CDR2/CDR3 
contacts (≤4Å) 
3/6/36 1/38/30 1/41/27 1/46/30 
TCR/Peptide 
contacts 
39 42 39 41 
TCR/MHC contacts 56 97 102 95 
BSAb (Å2) 2327.8 2705 2650.4 2781.6 
SCc (TCR/MHC) 0.55 0.71 0.65 0.66 
SCc (TCR/peptide) 0.71 0.59 0.58 0.62 
SCc (TCR/pMHC) 0.6 0.66 0.62 0.63 
Crossing angle (°) 47.6 42.2 41.9 42 
a Number of hydrogen bonds (H-bond) / van der Waals (vdW) contacts calculated 
with CONTACT program from the CCP4 package (Collaborative Computational 
Project, 1994) 
b Buried surface area (BSA) (Å2) of TCR/pMHC calculated with PISA program from 
the CCP4 package (Collaborative Computational Project, 1994) 
c Shape complementarity (SC) of TCR/MHC / TCR/peptide / TCR/pMHC calculated 
with SC program from the CCP4 package (Collaborative Computational Project, 
1994) 
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Figure 4.7. Structural analysis of the binding mode implemented by MEL5 
versus α24β17 when interacting with A2-ELA. 
(A) Overall binding mode of MEL5 (data from the previously published work (Cole 
et al., 2009)) (green cartoon) and α24β17 (cyan cartoon) interaction with HLA 
A*0201 (grey cartoon) and the ELAGIGILTV peptide (yellow sticks). Generally, the 
two TCRs bind in a very similar orientation, with some differences in the CDR loops 
and more flexible regions of the TCR variable and constant domains. (B&C) Surface 
representation of the A2-ELA complex looking down at the peptide. MHC residues 
that are contacted by the TCR are colored in red. Peptide residues that are contacted 
by the TCR are colored yellow. From this analysis, it is clear that although (B) 
MEL5 and (C) α24β17 make a similar contact footprint with the peptide (yellow), 
α24β17 make substantially more interactions with the MHC surface (red). 
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Figure 4.8. Structural differences between the MEL5 TCR versus α24β17 TCR 
when interacting with A2-ELA. 
(A) The α24β17 (cyan) and MEL5 (green) crossing angles when interacting with A2-
ELA (grey surface and cartoon, peptide shown as yellow sticks), A2-ELA4A (red 
cartoon) and A2-ELA7A (orange cartoon) are very similar. (B) Positions of the 
α24β17 TCR CDR loops when interacting with A2-ELA (cyan cartoon) are similar, 
but not identical to the positions of the MEL5 TCR CDR loops (green cartoon) when 
binding to A2-ELA. (C&D) The ELAGIGILTV peptide does not undergo any 
substantial structural changes when in complex with MEL5 (yellow) compared to 
α24β17 (red). 
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Thus, differences in binding affinity between the MEL5 and α24β17 TCRs could not 
be explained by a large conformational change in geometry, in agreement with our 
previously published observations (Dunn et al., 2006; Sami et al., 2007). 
 
4.2.4 Enhanced TCR-MHC interactions govern the high affinity binding of 
the α24β17 TCR 
Previous structures of high-affinity TCRs have shown that just a small number of 
additional contacts at the binding interface can mediate the high affinity binding 
interaction observed (Dunn et al., 2006; Sami et al., 2007). In order to delineate the 
mechanism behind the high affinity binding of the α24β17 TCR, I investigated the 
binding interface in atomic detail. Although the overall conformations of the MEL5 
and α24β17 TCRs were similar, there were a number of important differences at the 
binding interface that probably contributed to the divergent binding affinities 
between the two TCRs. The interactions with the ELAGIGILTV peptide were very 
similar for MEL5 and α24β17, with the TCRs making 39 and 42 contacts 
respectively (Table 4.3). However, the α24β17 TCR made a substantial number of 
new contacts with the MHC surface, making 97 MHC contacts compared to only 56 
for MEL5 (Table 4.3, Figure 4.7B&C). This increase in interactions with the MHC 
was consistent with the increased BSA for α24β17 (Table 4.3) and was probably the 
main mechanism enabling α24β17 to bind with an affinity 30,000-fold stronger than 
MEL5. The majority of the new contacts were directly attributable to the mutated 
residues in the α24β17 TCR. For instance, MEL5 TCR α chain residue Asp27 made 
no contacts with the MHC surface. However, when mutated in the α24β17 TCR α 
chain, the longer aromatic side chain of residue Phe27 was able to make 4 vdW 
contacts with MHC residue Glu58 (Table 4.4, Figure 4.9A).   
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Table 4.4. Direct contacts made by the wild-type or mutant TCR residues. 
 TCR residue vdW (≤4 Å) H-bonds (≤3.4 Å) 
Wild-type 
MEL5 TCR 
αAsp27 0 0 
αArg28 2 MHC 1 MHC 
αSer52 0 0 
αVal93 0 0 
αAla94 6 MHC 1 MHC 
αLys96 2 MHC 0 
βVal51 4 MHC 0 
βGly52 0 0 
βIle53 0 0 
βThr100 7 MHC 1 MHC 
Total  21 3 
Mutant 
α24β17 TCR 
αPhe27 4 MHC 0 
αLeu28 5 MHC 0 
αArg52 3 MHC 0 
αAsp93 4 MHC 2 MHC 
αGly94 6 MHC 1 MHC 
αArg96 7 MHC 0 
βGly51 3 MHC 0 
βPro52 4 MHC 1 MHC 
βPhe53 18 MHC 1 MHC 
βMet100 2 MHC 1 ELA 1 MHC 
Total  68 6 
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Figure 4.9. The α24β17 mutated residues make an increased number of contacts 
with the MHC surface compared to MEL5 wildtype residues. 
MEL5 residues are shown on the left hand side of each panel in green. The 
equivalent α24β17 residues are shown on the right hand side of each panel in cyan. 
Hydrogen bonds (<3.4Å) are shown as red dotted lines and van der Waals 
interactions (<4.0Å) are shown as black dotted lines. In all cases, an increased 
number of interactions was observed between α24β17 and the MHC surface 
compared to MEL5. (A) Position 27 in the TCR CDR1α loop. (B) Position 52 in the 
TCR CDR2α loop. (C) Position 93 in the TCR CDR3α loop. (D) Position 96 in the 
TCR CDR3α loop. (E) Position 52 in the TCR CDR2β loop. (F) Position 53 in the 
TCR CDR2β loop. 
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Similarly, the mutation from MEL5 TCR α chain residue Val93 to Asp93 in the 
α24β17 TCR α chain resulted in 4 new vdW contacts and 2 new hydrogen bonds, 
and the mutation from MEL5 TCR β chain residue Ile53 to Phe53 in the α24β17 
TCR β chain resulted in 18 new vdW contacts and 1 new hydrogen bond (Table 4.4, 
Figure 4.9). Overall, mutated residues in the α24β17 TCR accounted for 36 new 
vdW contacts and 3 new hydrogen bonds with the MHC surface (Table 4.4). Thus, 
the vast majority of the 44 new contacts formed by the α24β17 TCR, compared to 
the MEL5/A2-ELA complex, were made directly by mutated residues with only a 
small number of new contacts made through indirect effects of the high affinity 
mutations on non-mutated residues (Table 4.3, Appendix 4). This observation, that 
the α24β17 TCR mediated enhanced affinity through an increase in MHC contacts, 
substantially altered the ratio of TCR:peptide contacts vs. TCR:MHC contacts 
compared to MEL5. For instance, the MEL5 TCR made 41% of the total contacts 
with the peptide, compared to just 30% for the α24β17 TCR. These new contacts 
contributed to a 30,000-fold increase in affinity (Figure 4.5). This change in focus, 
from peptide interactions to MHC interactions, raised the possibility that the α24β17 
TCR could bind in a peptide independent manner. In order to investigate this 
possibility further, the ability of α24β17 to tolerate changes in the ELAGIGILTV 
peptide was probed. 
 
4.2.5 The α24β17 TCR is highly sensitive to peptide substitutions 
The α24β17/A2-ELA structure demonstrated that new MHC contacts were central to 
the 30,000-fold stronger affinity observed, compared to the MEL5/A2-ELA 
complex. Thus, in order to investigate the ability of α24β17 to tolerate changes in the 
peptide, I performed an alanine (Ala) mutagenesis scan across the peptide backbone 
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and evaluated the capacity of the A2-ELA mutants to bind α24β17 using surface 
plasmon resonance (SPR) (Table 4.5, Figure 4.10). As peptide positions P2 and P10 
were buried and are known to be important for MHC binding (Borbulevych et al., 
2007), I focused on assessing the solvent exposed positions P1, P4, P5, P6, P7, P8 
and P9. I did not assess P3, as this residue is Ala in the native sequence. I observed a 
striking and unexpected result. Modification of any peptide residue to Ala reduced 
the binding of α24β17 to wildtype-like affinities, or lower (Table 4.5). For example, 
α24β17 bound A2-ELA with Gly substituted for Ala at position 4 (A2-ELA4A) with 
36 µM, 60,000-fold weaker affinity than for A2-ELA (∆∆G -6 kcal/mol) (Table 
4.5). In the α24β17/A2-ELA structure, 4 hydrogen bonds and 8 vdW were made 
between the TCR and peptide residue Gly4 (Appendix 4). Thus, although Ala and 
Gly are similar in terms of size, this mutation could result in the disruption of an 
important network of TCR-peptide contacts that would explain the reduction in 
binding affinity. Similarly, α24β17 bound A2-ELA with Ile substituted for Ala at 
position 7 (A2-ELA7A) with 31 µM, 51,667-fold weaker affinity than for A2-ELA 
(∆∆G -6.1 kcal/mol) (Table 4.5). The α24β17/A2-ELA structure showed that 3 
hydrogen bonds and 8 vdW were made between the TCR and peptide residue Ile7 
(Appendix 4). Thus, the reduction in binding affinity observed for α24β17 binding 
to the Ala7 mutant again could be accounted for because of the potential disruption 
to TCR-peptide contacts. However, substitution of Ala for Ile at position 5 in the 
peptide completely abrogated binding (Table 4.5). The α24β17/A2-ELA structure 
demonstrated that only 4 vdW contacts were made between α24β17 and the peptide 
residue Ile5. Thus, the observed effect on binding affinity was surprising and was 
likely due to indirect effects on TCR binding.  
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Table 4.5. Kinetic binding analysis of α24β17 to alanine substituted peptides. 
TCR Peptide 
Peptide 
sequence 
Affinity (KD)  
∆G° 
(kcal/mol) 
∆∆G° 
(kcal/mol) 
MEL5 ELA ELAGIGILTV 18µM -6.5 Nm 
α24β17 
ELA ELAGIGILTV 0.6nM -12.1 Nm 
ELA1A ALAGIGILTV 140µM -5.3 -4.2 
ELA4A ELAAIGILTV 36µM -6.1 -6 
ELA5A ELAGAGILTV No binding Nm Nm 
ELA6A ELAGIAILTV 41µM -6 -6.1 
ELA7A ELAGIGALTV 31µM -6.1 -6 
ELA8A ELAGIGIATV 21µM -6.4 -5.7 
ELA9A ELAGIGILAV 37µM -6 -6.1 
Nm = not measured 
 
 
Figure 4.10. α24β17 is extremely sensitive to alanine substitutions within the 
ELAGIGILTV peptide. 
Ten serial dilutions of α24β17 were measured in three separate experiments (with 
different protein preparations) for each alanine-substituted peptide; representative 
data from these experiments are plotted. Alanine substitutions in any position within 
the peptide reduced binding from 600 pM down to wildtype like affinities (µM). The 
equilibrium binding constant (KD) values were calculated using a nonlinear curve fit 
(y= (P1x)/P2 + x)); mean plus SD values are shown. In order to calculate each 
response, α24β17 was also injected over a control sample (HLA-A*0201 in complex 
with ILAKFLHWL peptide) that was deducted from the experimental data. (A) 
α24β17 binding to A2-ALAGIGILTV (B) α24β17 binding to A2-ELAAIGILTV (C) 
α24β17 binding to A2-ELAGIAILTV (D) α24β17 binding to A2-ELAGIGALTV 
(E) α24β17 binding to A2-ELAGIGIATV (F) α24β17 binding to A2-
ELAGIGILAV. I observed no signal for α24β17 binding to A2-ELAGAGILTV 
(data not shown). 
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Importantly, the MEL5 TCR was also very sensitive to Ala substitutions and no 
binding to the MEL5 TCR with Ala substituted across the ELAGIGILTV peptide 
was observed (data not shown, experiments performed by Dr David Cole). These 
data demonstrate that, even though the α24β17 TCR bound with 600 pM, primarily 
through new contacts made with the MHC, the TCR was still very sensitive to 
changes in the antigenic peptide. These data have important implications for high 
affinity TCR antigen recognition and show that TCR-peptide contacts play a 
dominant role in governing high affinity TCR/pMHC binding.  
 
4.2.6 Peptide substitutions do not alter the overall conformation of the 
α24β17/A2-ELA complex 
My discovery, that the high affinity α24β17 TCR was sensitive to small changes in 
the peptide, was highly unanticipated based on the observation that: (i) additional 
contacts between α24β17 and A2-ELA were mainly with the MHC surface, not the 
peptide; and, (ii) single peptide mutations, with the potential to directly disrupt only 
a small number of TCR/pMHC contacts, could have such a dramatic impact on 
binding affinity. Thus, in order to gain an atomic perspective on how such small 
changes at the interface could impact binding, I solved the co-complex structures of 
α24β17 with two of the A2-ELA Ala mutants: A2-ELAAIGILTV (A2-ELA4A) and 
A2-ELAGIGALTV (A2-ELA7A). I attempted to crystallize a number of other co-
complexes with the other Ala mutants, but these attempts were unsuccessful. The 
α24β17/A2-ELA4A and α24β17/A2-ELA7A complex structures were solved to a 
resolution of 2.46 Å and 2.70 Å respectively, enabling a detailed view of the atomic 
structure. Molecular replacement was successful only in space group P41 for both 
complexes and the resolution was sufficiently high to show that the interface 
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between the two molecules was well ordered and contained well-defined electron 
density (Figure 4.6). The crystallographic R/Rfree factors were 20.2% and 24.8% 
for α24β17/A2-ELA4A and 20.2% and 25% for α24β17/A2-ELA7A (Table 4.2). 
Compared to α24β17/A2-ELA, the overall BSA was virtually identical across the 
three co-complex structures (α24β17/A2-ELA BSA = 2705 Å2, α24β17/A2-ELA4A 
BSA = 2650.4 Å2, α24β17/A2-ELA7A BSA = 2781.6 Å2) (Table 4.3). Furthermore, 
the docking geometry and the positions of the TCR CDR loops were 
indistinguishable between the three complexes (Table 4.3, Figure 4.11). Thus, large 
conformational changes could not explain the difference in binding affinity between 
α24β17/A2-ELA and the Ala mutants.  
 
4.2.7 Peptide substitutions do not directly alter the contact interface between 
the α24β17 TCR and A2-ELA 
In order to further probe the effects of the Ala substitutions on α24β17 binding, I 
investigated the direct effects of these mutations on binding. The structure of α24β17 
bound to A2-ELA demonstrated that peptide residue Gly4 made 4 hydrogen bonds 
and 8 vdW and Ile7 made 3 hydrogen bonds and 8 vdW with the TCR (Figure 
4.12A&B, Appendix 4). The α24β17/A2-ELA4A structure revealed that the number 
of contacts was very similar between peptide residue Ala4 and α24β17 (3 hydrogen 
bonds and 10 vdW contacts) and the α24β17/A2-ELA7A structure revealed that the 
number of contacts was very similar between peptide residue Ala7 and α24β17 (2 
hydrogen bonds and 8 vdW contacts) (Figure 4.12C&D, Appendices 5&6). Thus, it 
was unlikely that the Ala peptide substitutions could directly explain the large 
difference in binding affinity between α24β17 binding to A2-ELA compared to A2-
ELA4A and A2-ELA7A.  
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Figure 4.11. Structural comparison of the binding mode implemented by 
α24β17 when interacting with A2-ELA, A2-ELA4A and A2-ELA7A. 
A2-ELA is shown in grey cartoon, peptide as yellow sticks. (A) Overall binding 
mode of α24β17 when interacting with A2-ELA (cyan cartoon), A2-ELA4A (red 
cartoon) and A2-ELA7A (orange cartoon). α24β17 binds in a virtually identical 
mode to all three epitopes. (B&C) Surface representation of the A2-ELA complex 
(colored as in (A)) looking down at the peptide. (B) Positions of the α24β17 TCR 
CDR loops when interacting with A2-ELA (cyan cartoon), A2-ELA4A (red cartoon) 
and A2-ELA7A (orange cartoon). (C) α24β17 TCR crossing angle when interacting 
with A2-ELA (cyan cartoon), A2-ELA4A (red cartoon) and A2-ELA7A (orange 
cartoon). The positions of the CDR loops and the TCR crossing angles are virtually 
identical across all three complexes. 
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Figure 4.12. Interactions between α24β17 and modified residues in the 
ELAGIGILTV peptide at positions 4 and 7. 
Hydrogen bonds (<3.4Å) are shown as red dotted lines and van der Waals 
interactions (<4.0Å) are shown as black dotted lines and water molecules are shown 
as grey spheres. α24β17 (cyan sticks) interactions with (A) peptide residues (yellow 
sticks) Gly4 and (B) Ile7. (C) α24β17 (red sticks) interacting with A2-ELA4A, 
residue Ala4 (red sticks). (D) α24β17 (orange sticks) interacting with A2-ELA7A, 
residue Ala7 (orange sticks). Contacts between α24β17 and the three epitopes (A2-
ELA, A2-ELA4A and A2-ELA7A) are virtually identical and cannot explain the 
reduced affinity between α24β17 and the modified peptides.  
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4.2.8 Peptide substitutions do not alter the overall conformation of unligated 
A2-ELA molecules 
Although the overall conformation of the α24β17/A2-ELA complex was similar with 
the Ala substituted peptides, the possibility that Ala substitution could alter the 
structure of the unligated A2-ELA molecules had to be explored. If α24β17 TCR 
binding required a conformational shift in the peptide more energy would be 
required to reach the same final bound state and this could explain the loss of 
binding affinity. To this end, our collaborator Professor Brian Baker, obtained 
crystals and diffraction datasets for A2-ELA1A and A2-ELA8A at 2.11 Å and 1.9 Å 
resolution, respectively, while I obtained crystals and a diffraction dataset for A2-
ELA4A at 1.91 Å resolution (Table 4.6). I solved the three structures by molecular 
replacement in space groups P1, C121 and P1211 for A2-ELA1A, A2-ELA4A and 
A2-ELA8A, respectively, and the resolution was sufficiently high to show that the 
interface between the two molecules was well ordered and contained well-defined 
electron density (Figure 4.6). A comparison of these Ala mutant structures with the 
unligated structure A2-ELA (Sliz et al., 2001), that does not substantially alter its 
structure when in complex with different TCRs (Borbulevych et al., 2011; Cole et 
al., 2009), showed that there was no difference in the overall conformation of the 
different peptides (Figure 4.13). These data discounted the possibility that 
alterations in the unligated conformation of the Ala substituted A2-ELA peptides 
could explain the sensitivity of the α24β17 TCR to these single peptide mutations. 
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Table 4.6. Data collection and refinement statistics for A2-ELA peptide alanine 
substitution structures (molecular replacement). 
 
Data set statistics A2-ELA1A A2-ELA4A A2-ELA8A 
Space Group P1 C121 P1211 
Unit Cell 
parameters 
a=50.283Å, 
b=63.255Å, 
c=75.098Å, 
α=81.96°, 
β=76.09°,  
γ=77.98° 
a=202.59Å, 
b=49.11Å, 
c=117.6, 
γ=123° 
a=84.096Å, 
b=58.359Å, 
c=89.432Å, 
β=109.82° 
Radiation Source 
ADSC Quantum 
210r CCD 
DIAMOND 
IO3 
ADSC Quantum 
210r CCD 
Wavelength (Å) 0.98 0.9763 0.98 
Resolution (Å) 2.11 1.91 1.9 
Unique reflections 42338 73975 64858 
Completeness (%) 78.8 98 97 
Multiplicity 2.1 3.5 3.4 
I/Sigma(I) 18.9 10.7 16.5 
Rmerge (%) 0.10 0.052 0.07 
Refinement statistics (highest resolution shell in parenthesis) 
No reflections used 40179 70233 61271 
No reflections in Rfree 
set 
2159 3730 3275 
Rcryst (no cutoff) (%) 21.8 20.5 21.9 
Rfree (%) 29.6 23.9 29.6 
RMSD from ideal geometry (target values in parenthesis) 
Bond lengths (Å) 0.021 (0.021) 0.026 (0.021) 0.20 (0.21) 
Bond Angles (°) 1.497 (1.930) 1.688 (1.937) 1.845 (1.938) 
Wilson B-factor (Å2) 25.336 37.759 18.057 
Overall coordinate ESU 
based on ML (Å) 
0.169 0.101 0.157 
 
One crystal was used for data collection.  
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Figure 4.13. Alanine substitutions do not alter the overall conformation of the 
unligated A2-ELA related pMHCs. 
Structural comparison of the A2-ELA unligated crystal structure (1JF1) (Sliz et al., 
2001) with: (A) A2-ELA from the α24β17/A2-ELA complex structure, (B) A2-
ELA1A, (C) A2-ELA4A and (D) A2-ELA8A. These structures show that the 
conformation of the peptide backbone is not altered by TCR binding, or by alanine 
substitutions. Furthermore, the positions of the solvent exposed side chains is 
virtually identical in all of the structures, showing that large alterations in peptide 
conformation in unligated state cannot account for the difference in binding affinity 
observed between α24β17 binding to A2-ELA compared to the alanine substituted 
peptides. 
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4.2.9 Peptide specificity is governed by a distinct thermodynamic signature 
and a reduction in water bridges 
From the previous in-depth structural analysis, the underlying mechanism for the 
dramatic reduction in binding affinity for α24β17 binding to the alanine substituted 
peptides was unclear. Thus, I investigated the changes in enthalpy (∆H°) and entropy 
(T∆S°) in order to examine the energetic differences between the binding interaction 
between α24β17 binding to A2-ELA (Figure 4.14, Figure 4.17A) compared to A2-
ELA4A (Figure 4.15, Figure 4.17B) and A2-ELA7A (Figure 4.16, Figure 4.17C).  
 
The α24β17/A2-ELA interaction (Figure 4.17A) was entropically driven (T∆S° 
~18.1 kcal.mol-1) and enthalpically unfavourable (∆H° ~6 kcal.mol-1). While ∆H° 
was within the range of enthalpy described for a TCR/pMHC interaction, T∆S° was 
one of the highest entropy reported so far in the literature (from -30 to 18 kcal.mol-1 
for ∆H° and from -23.8 to 23.8 kcal.mol-1 for T∆S°) (Armstrong et al., 2008a; 
Holland et al., 2012). I also crystallized and solved the structure of the unligated 
α24β17 TCR (Table 4.2). This structure solved in space group P3221 at 2.4 Å 
resolution demonstrated that the change in energy was accompanied by a relatively 
large conformational shift in the TCR CDR loops upon ligand engagement (Figure 
4.18). The TCR CDR3β loop underwent a hinge movement of 8.06 Å in order to 
accommodate residues towards the C-terminus of the peptide. These observations 
suggest that, similarly to the MEL5/A2-ELA complex (T∆S° ~8.3 kcal.mol-1) (Cole 
et al., 2009), an entropically favourable transition from order to disorder was key for 
driving the high affinity interaction, probably through the expulsion of ordered 
solvent during binding rather than a loss of order at the TCR/pMHC interface.  
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Figure 4.14. Thermodynamic analysis of the α24β17/A2-ELA interaction. 
Kinetic titration analysis was used to determine the affinity of the α24β17-A2-ELA 
interaction at: (A) 5°C, (B) 7°C, (C) 12°C, (D) 15°C, (E) 19°C, (F) 22°C, (G) 25°C, 
(H) 30°C, (I) 32°C, (J) 35°C, (K) 37°C and (L) 40°C. The raw data and the fits are 
shown in each panel. These data were used to fit thermodynamic parameters shown 
in Figure 4.17A. 
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Figure 4.15. Thermodynamic analysis of the α24β17/A2-ELA4A interaction. 
Ten serial dilutions of α24β17 were measured in triplicate at each temperature; 
representative data from these experiments are plotted. The equilibrium binding 
constant (KD) values were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)); 
mean plus SD values are shown. (A) 5°C, (B) 13°C, (C) 15°C, (D) 20°C, (E) 25°C 
and (F) 30°C. These data were used to fit thermodynamic parameters shown in 
Figure 4.17B. 
 
 
Figure 4.16. Thermodynamic analysis of the α24β17/A2-ELA7A interaction. 
Ten serial dilutions of α24β17 were measured in triplicate at each temperature; 
representative data from these experiments are plotted. The equilibrium binding 
constant (KD) values were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)); 
mean plus SD values are shown. (A) 5°C, (B) 13°C, (C) 15°C, (D) 20°C and (E) 
25°C. These data were used to fit thermodynamic parameters shown in Figure 
4.17C.  
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Figure 4.17. Thermodynamic analysis of α24β17 binding to A2-ELA, A2-
ELA4A and A2-ELA7A. 
The thermodynamic parameters were calculated according to the Gibbs-Helmholtz 
equation (∆G° = ∆H − T∆S°). The binding free energies, ∆G° (∆G° = RTlnKD), 
were plotted against temperature (K) using non-linear regression to fit the three-
parameters Van’t Hoff equation, (RT ln KD = ∆H° –T∆S° + ∆Cp°(T-T0) – T∆Cp° ln 
(T/T0) with T0=298 K), as previously reported (Cole et al., 2009). Thermodynamic 
measurements of (A) α24β17 binding to A2-ELA, (B) α24β17 binding to A2-
ELA4A and (C) α24β17 binding to A2-ELA7A. α24β17 uses a distinct 
thermodynamic strategy when binding to each of the three different epitopes. 
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Figure 4.18. α24β17 undergoes large TCR CDR movement during ligand 
engagement. 
Comparison of the conformation of the α24β17 TCR CDR1, CDR2 and CDR3 loops 
in the α24β17/A2-ELA complex (α24β17lig) versus α24β17 unligated (α24β17free). 
(A) Superposition of the free (purple cartoon) and complexed (cyan cartoon) TCRs. 
(B) Superposition of the free (purple lines) and complexed (cyan lines) α24β17 TCR 
looking down on the peptide (yellow sticks). (C) Superposition of the free (purple 
lines) and complexed (cyan cartoon) α24β17 CDR1α, CDR3α, CDR2β and CDR3β 
loops from the side. The CDR3β loop has to move in order to avoid a clash with the 
peptide (yellow sticks) during binding. (D) Superposition of the free (purple lines) 
and complexed (cyan lines) α24β17 TCR CDR loops during binding showing 
backbone shifts in Å (orientation as in (B)). The CDR2β and CDR3β loops undergo 
the largest conformational change upon binding. 
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In contrast, this energetic mechanism was reversed for the α24β17/A2-ELA4A and 
α24β17/A2-ELA7A interactions (∆H° ~-15.6 and ~-5.9 kcal.mol-1, respectively) 
(Figure 4.17B&C) with favourable enthalpy driving the interaction. Thus, the loss 
of binding affinity observed for the interaction between the α24β17 TCR and the 
alanine modified peptides seemed to be governed by a change in the order-disorder 
balance during binding, possibly due to differences in the interaction between the 
unligated molecules and solvent (Holland et al., 2012). To further explore this 
possibility, the role of water molecules during antigen recognition was examined and 
some changes in the number of water bridges between the different complexes were 
noticed. For instance, in the α24β17/A2-ELA complex, 9 water bridges were formed 
between the TCR and pMHC compared to only 7 for α24β17/A2-ELA4A and 5 for 
α24β17/A2-ELA7A (Figure 4.19). Although this reduction in water bridges, hence a 
reduction in hydrogen bonds, could partly explain the reduction in binding affinity to 
the alanine substituted peptide mutants, the difference in water bridges also 
suggested that the interaction between the TCR, pMHC and solvent was different in 
the three complexes. For instance, the less favourable entropic values, that were the 
main driving force governing the weaker binding affinity observed for the 
α24β17/A2-ELA4A and α24β17/A2-ELA7A interactions, were most likely due a 
reduction in the expulsion of ordered solvent during binding. This notion is the best 
explanation for the sensitivity of the TCR to alanine substitutions, considering the 
similar binding modes and the distinct thermodynamic signatures observed for the 
α24β17 TCR interacting with A2-ELA compared to A2-ELA4A and A2-ELA7A. 
Overall, these data support the idea that TCR specificity can be mediated by changes 
in solvent interactions between the TCR and pMHC that can occur through a knock-
on effect in modifications to the peptide sequence.  
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Figure 4.19. α24β17 makes more water bridges with A2-ELA than with A2-
ELA4A and A2-ELA7A. 
α24β17 binding to A2-ELA is shown in cyan sticks, peptide in yellow sticks. α24β17 
binding to A2-ELA4A is shown in red sticks, peptide in red sticks. α24β17 binding 
to A2-ELA7A is shown in orange sticks, peptide in orange sticks. The MHC is 
shown in grey sticks and water molecules are shown as grey spheres. Hydrogen 
bonds (<3.4Å) are shown as red dotted lines and van der Waals interactions (<4.0Å) 
are shown as black dotted lines. Water bridges between the TCR and peptide in (A) 
the α24β17/A2-ELA complex, (B) the α24β17/A2-ELA4A complex and (C) the 
α24β17/A2-ELA7A complex. Water bridges between the TCR and MHCα1 helix in 
(D) the α24β17/A2-ELA complex, (E) the α24β17/A2-ELA4A complex and (F) the 
α24β17/A2-ELA7A complex. Water bridges between the TCR and MHCα2 helix in 
(G) the α24β17/A2-ELA complex, (H) the α24β17/A2-ELA4A complex and (I) the 
α24β17/A2-ELA7A complex.  
 
171 
 
4.3 DISCUSSION 
CD8+ T-cells have the ability to detect intracellular deleterious proteins and deliver a 
cytotoxic payload that can destroy cells that pose a threat to host health. T-cell “X-
ray vision” is controlled via the TCR/pMHC interaction. The capacity of TCRs to 
see internal anomalies from the cell surface offers exciting new possibilities for 
developing disease-specific therapies. However, unlike antibodies that undergo 
somatic hypermutation and bind with a relatively strong affinity, TCRs are selected 
in the thymus to bind with a weak affinity (KD = 0.1-270 µM) (Bridgeman et al., 
2012; Cole et al., 2007). This effect is magnified during cancer-specific T-cell 
responses because cancer-specific TCRs bind at the weaker end of this scale. The 
weak affinity of natural TCR/pMHC interactions imposes limitations on the use of 
TCRs for targeting cell surface expressed pMHCs. 
 
Using phage display, several high affinity TCRs directed against a range of antigens 
were generated (Li et al., 2005b; Liddy et al., 2012; Varela-Rohena et al., 2008). 
Herein, I investigated the interaction between a high-affinity TCR, α24β17, derived 
from the MEL5 TCR that is specific for the HLA-A*0201 restricted MART-126-35 
antigen. The α24β17 TCR bound to A2-ELA with an enhanced affinity 30,000 times 
stronger than the MEL5 TCR that could be primarily attributed to a longer off-rate. 
In order to better understand the consequences of high-affinity TCR binding, I 
solved the atomic structure of α24β17 in complex with A2-ELA. Although α24β17 
used a similar overall binding mode to MEL5 during engagement of A2-ELA, finer 
examination of the structure demonstrated that 3 new contacts were made between 
α24β17 and the ELA peptide, compared to 41 new MHC contacts. Thus, the 
enhanced affinity was mediated primarily through additional interactions with the 
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surface of the MHC molecule. This observation raised the possibility that the α24β17 
TCR might be capable of recognizing HLA-A*0201 independently of the bound 
peptide and such peptide-independent recognition would be deleterious for a 
potential use in soluble TCR therapy. In order to investigate the ability of α24β17 to 
tolerate changes in the peptide, I performed a biophysical investigation of the effect 
of alanine mutations scan across the peptide backbone. Surprisingly, the α24β17 
TCR was highly sensitive to changes in the peptide with some single mutations 
capable of completely abrogating binding, supporting the notion the TCR-peptide 
contacts are required to enable TCR-MHC binding. The finding that α24β17 was 
highly sensitive to alanine peptide mutations was unexpected and warranted further 
investigations to uncover the molecular mechanism behind this observation. Thus, I 
solved the structure of α24β17 in complex with two alanine mutants; A2-ELA4A 
and A2-ELA7A. Additionally, I solved the structure of the unligated α24β17 TCR 
and unligated A2-ELA1A, A2-ELA4A and A2-ELA8A molecules. These structures 
demonstrated that α24β17 used a virtually identical structural strategy to engage the 
alanine mutants compared to A2-ELA and that the alanine mutations did not alter the 
peptide conformation of the unligated pMHCs. The total number of contacts made in 
the α24β17/A2-ELA complex compared to the α24β17/A2-ELA4A and α24β17/A2-
ELA7A complexes was also very similar (138, 141 and 136 respectively) and could 
not explain the weaker binding affinity. Next, I conducted a thermodynamic 
investigation of α24β17 binding to A2-ELA and the alanine substituted variants. I 
found that α24β17 used a distinct thermodynamic signature to engage A2-ELA 
compared to A2-ELA4A and A2-ELA7A involving a marked decrease in favourable 
entropy. This observation suggested that differences in ordered solvent molecules 
involved during α24β17 binding could have an important role in governing antigen 
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sensitivity. In support to this notion, I observed a reduction in the number of water 
bridges for α24β17 binding to A2-ELA4A and A2-ELA7A compared to A2-ELA. 
Overall, these data support the idea that TCR specificity can be mediated by changes 
in solvent interactions between the TCR and pMHC that can occur through a knock-
on effect in modifications to the peptide sequence. 
 
One interesting characteristic of the TCR that is not fully understood is its natural 
weak binding affinity for pMHC, especially considering the similarity in TCR 
structure to antibodies. If generated, T-cells bearing TCRs that bind to pMHC with 
antibody-like affinity must be removed during thymic selection as they have never 
been detected in peripheral responses. How and why these T-cells are removed is 
unclear. There are, at least, three obvious possibilities. First, high affinity TCRs are 
self-reactive and are removed during negative selection (Palmer and Naeher, 2009). 
Second, the thymic auditioning may require that TCRs exhibit specific biophysical 
properties that are consistent with serial triggering by pMHC in the periphery (Irving 
et al., 2012; Valitutti et al., 1995). Third, it has recently been shown that T-cells 
must, and do, confer a high level of cross-reactivity in order to fully protect the host 
against all potential pathogens (Mason, 1998; Wooldridge et al., 2012). Thus, it is 
possible that T-cells with high-affinity TCRs are culled in the thymus because they 
are too “focused” on a limited number of potential foreign peptides. In other words, 
T-cells with TCRs that bind too strongly could be focused on a small number of 
antigens rendering them unable to provide adequate cross-protection. However, 
despite my data supporting this notion, more work (particularly on cellular 
experiments and on testing the high-affinity TCR specificity toward different 
peptides) is required to add support to this idea. Whilst this characteristic would be 
174 
 
deleterious in the context of a natural immune response where a high level of T-cell 
cross-reactivity may be essential for effective immunity, a high level of specificity is 
desirable for epitope targeting during drug delivery. Although more work, 
particularly cellular experiments, are required to add support to these ideas, these 
findings here suggest that high-affinity TCRs may be more “focused” on their 
cognate target antigens, which is a promising discovery in context of the 
development of specific tools and therapies for targeting human diseases. 
 
In summary, my data show that TCR affinity can be enhanced by increasing 
interactions between the TCR and the MHC surface without obvious concomitant 
loss of peptide specificity. Although this strategy of affinity enhancement has 
potential to lead to peptide-independent TCR/pMHC binding, I showed that the 
high-affinity α24β17 TCR was highly sensitive to single alanine mutations in the 
peptide backbone at every position. My data supports the notion that the TCR must 
contact the peptide to enable optimal TCR docking with MHC. The mechanism for 
this sensitivity to peptide modifications was unclear based on the structural evidence, 
which showed that TCR binding was virtually identical for the alanine modified and 
natural peptide variants. However, the in depth biophysical and thermodynamic 
analysis revealed an unexpected and novel mechanism for TCR specificity in which 
different interactions with solvent molecules seemed to govern the reduction in 
affinity for the high-affinity TCR when single alanine mutations were introduced 
into the peptide. Overall, these data highlight the complex and unpredictable nature 
of T-cell antigen recognition and have important implications for the development of 
high-affinity TCRs as therapeutic agents.  
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Chapter background 
The results in this Chapter follow on from Chapter 3 and Chapter 4. The HLA-A2-
restricted MART-126/35 system is the best-studied human cancer antigen to date and 
has been used in thousands of published studies. These efforts and at least 4 peptide 
vaccine trials have largely focussed on an MHC anchor-modified “heteroclitic” 
version of the natural peptide. Recent work from my laboratory has questioned this 
approach by showing that TCRs can distinguish between the heteroclitic and the 
natural sequence (Cole et al., 2010). Thus, T-cells primed with the heteroclitic 
sequence often do not recognise melanoma cells well (Cole et al., 2010). The MEL5 
TCR exhibits a strong preference for the natural sequence over the anchor-modified 
sequence. In this Chapter, I aimed to solve the structure of MEL5 complexed with 
this natural decameric peptide in order to understand the reason why a TCR could 
distinguish between these two peptides that differ only at a buried MHC anchor 
residue. Studies of MART-1-derived peptides presented at the melanoma cell surface 
suggest that a nonamer version of the peptide is more common than the natural 
decamer (Skipper et al., 1999; Valmori et al., 1998). Thus, the nonameric antigen 
might be the best peptide to target. I therefore also set out to solve the structure of 
MEL5 complexed with the natural nonameric peptide and found some unanticipated 
and novel findings.  
 
5.1 INTRODUCTION 
The clonotypic αβ T-cell receptor (TCR), expressed on the surface of T-cells, can 
bind to peptide-Major Histocompatibility Complex (pMHC) molecules on the 
surface of target cells (Jenkins et al., 2010). Thymic TCR affinity editing produces a 
population of peripheral T-cells with TCRs that bind to their cognate pMHC ligands 
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relatively weakly (KD = 0.1-270 µM), with self-reactive T-cells towards the weaker 
end of this range (Bridgeman et al., 2011). Because the majority of cancer epitopes 
are derived from self-proteins, robust immune responses to cancer epitopes have not 
been commonly observed. In support of this notion, my laboratory has recently 
shown that TCRs bind to cancer epitopes with around ten times weaker affinity than 
to viral epitopes (Cole et al., 2007). I described the MEL5 TCR and its high-affinity 
variant α24β17 in Chapter 4. MEL5 TCR binding to the heteroclitic version of the 
melanoma antigen MART1 (A2-ELA) is relatively weak (KD ~18 µM) (Cole et al., 
2007). However, the MEL5 TCR can recognise the natural decamer epitope 
EAAGIGILTV (A2-EAA) with a substantially stronger affinity (~6-8 µM). Thus, I 
decided to investigate the molecular rules governing this relatively strong affinity 
anti-cancer TCR recognition. I extended the study to determine the ability of MEL5 
to recognise the native nonamer epitope, AAGIGILTV. This nonamer peptide is 
thought to represent the dominant species on the surface of melanoma cells (Skipper 
et al., 1999). I also investigated the recognition of these two natural epitopes by the 
high-affinity variant α24β17. 
 
5.1.1 Conformational changes observed upon TCR recognition 
The crystal structures of several TCR/pMHC complexes have been solved and 
reviewed (Rudolph et al., 2006). In some cases there is also a corresponding 
structure of the uncomplexed TCR allowing observation of the molecular 
movements that take place upon ligand engagement. While some TCRs bind in a 
rigid ‘lock-and-key’ mechanism (Bulek et al., 2012a), most exhibit a degree of 
plasticity at the TCR/pMHC interface. So far, three main types of conformational 
changes have been observed when TCRs bind to pMHCs: (i) Changes in the TCR; 
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(ii) Changes in the MHC; and (iii) Changes in the central ‘bulge’ region of the 
peptide. 
 
5.1.1.1 TCR flexibility on pMHC engagement 
TCR complementarity determining region (CDR) loops can exhibit considerable 
plasicity upon binding pMHC (Armstrong et al., 2008b). The types of loop shift can 
be placed into three major classes: (i) Loop remodelling facilitated by multiple φ/ψ 
bond angle changes; (ii) Hinge-bending motions; and, (iii) Rigid-body shifts 
(Armstrong et al., 2008b). Kjer-Nielsen et al. have also shown that pMHC ligation 
can lead to a conformational change within the TCR constant domain, an observation 
that was recently confirmed by Beddoe et al. (Beddoe et al., 2009; Kjer-Nielsen et 
al., 2002). Overall, the plasticity of the TCR allows engagement of a wide range of 
different pMHC “landscapes”. 
 
5.1.1.2 MHC flexibility on pMHC engagement 
The MHC α-helices flanking the peptide-binding groove can shift upon TCR 
binding. Such movements have been observed in the recognition of pBM8/H-2Kbm8 
(MHCI) by the BM3.3 TCR (Auphan-Anezin et al., 2006) and MBP/HLA-DR2a 
(MHCII) by the 3A6 TCR (Li et al., 2005a). In both cases, rigid-body shifts of 
approximately 1Å were distributed across both the α1 and α2 helices (Armstrong et 
al., 2008b). More unusual HLA-A2 α2-helix conformational changes have also been 
observed. Upon the recognition of Tel1p/HLA-A2 by the A6 TCR, a conformational 
“switch” occurred at the hinge of the short and long helical elements that shortened 
the short arm and extended the long arm of the α2-helix (Borbulevych et al., 2009).  
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5.1.1.3 Peptide flexibility on pMHC engagement 
There have been several reports that TCR binding can induce conformational 
changes in the solvent exposed central peptide residues, mediating TCR docking and 
T-cell recognition (Rudolph et al., 2006; Ruppert et al., 1993). Small backbone shifts 
have been observed upon recognition of the Tax and NY-ESO peptides presented by 
HLA-A2 (Chen et al., 2005; Garboczi et al., 1996; Khan et al., 2000; Webb et al., 
2004), whereas binding of the ELS4 TCR dramatically “squashed” the EPLP 
backbone (peptide from the BZLF1 antigen of Epstein-Barr virus) presented by 
HLA-B35, with a large shift of 5 Å occurring in the centre of the peptide (Tynan et 
al., 2007). Another large shift occurred upon recognition of the malignant melanoma 
MART-127-35 nonamer peptide by the DMF4 TCR, with the amide nitrogen of Gly5 
moving 2.7Å toward the HLA-A2 α2-helix (Borbulevych et al., 2011). My work has 
focussed on TCR binding of two HLA-A2-restricted peptides from Melan-A/MART-
1. Observations in this system are detailed below. 
 
5.1.2 Structural observations of the common HLA-A2-restricted melanoma 
antigens 
Melan-A (for melanoma antigen A)/MART-1 (for melanoma antigen recognised by 
T-cells 1) is a tumor differentiation antigen which is expressed by melanocytes and 
malignant melanoma cells from tumours in >95% of patients (Derre et al., 2007). 
There are two natural peptide variants derived from Melan-A presented by 
HLA*0201 and recognized by Melan-A specific T-cells. Initial studies identified the 
MART-127-35 nonamer AAGIGILTV (referred to herein as AAG) as the numerically 
dominant epitope at the melanoma cell surface from the MART-1 protein (Skipper et 
al., 1999), although the MART-126-35 decamer EAAGIGILTV (referred to herein as 
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EAA) has also been reported at the surface of melanoma cells (Held et al., 2007; 
Valmori et al., 1998). Several studies suggest that the majority of Melan-A-specific 
T-cells preferentially recognise the minority decamer rather than the nonamer (Cole 
et al., 2010; Romero et al., 1997). The atomic structures of both peptides complexed 
to HLA*0201 have been solved previously (Borbulevych et al., 2007) and showed a 
bulged conformation and an extended conformation for EAA and AAG, respectively, 
which could explain the difference in recognition by Melan-A specific T-cells 
(Figure 5.1A). In both cases the peptide position 2 (P2) anchored in the B pocket of 
the MHC groove and the C-terminus (P10 for EAA and P9 for AAG) anchored in the 
F pocket (Figure 5.1B). The crystallographic structures of DMF4 and DMF5, the 
first TCRs used in cancer gene therapy (Morgan et al., 2006), in complex with both 
the nonamer AAG and a heteroclitic form of the decamer (ELAGIGILTV, referred 
to as ELA) have been solved recently (Borbulevych et al., 2011), but there remains 
no atomic structure of the natural decamer EAA in complex with a TCR. This is an 
important omission because work from my host laboratory recently showed that 
TCRs can distinguish between A2-EAA and A2-ELA peptides (Cole et al., 2010). 
This difference offers a potential molecular reason for why all the clinical trials with 
the ELAGIGILTV peptide have been a universal failure (Bins et al., 2007; Cole et 
al., 2010; Rosenberg et al., 2004). Borbulevych et al. showed that there were no 
major changes in either peptide or MHC conformation upon TCR recognition of the 
A2-ELA (Borbulevych et al., 2011).   
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Figure 5.1. Atomic structures of AAGIGILTV and EAAGIGILTV complexed 
to HLA-A2. 
(A) When complexed to HLA-A2, EAAGIGILTV (orange stick) displays a “bulged” 
and “zig-zagged” conformation whereas AAGIGILTV (blue stick) displays a 
“stretched” (also referred as “extended”) conformation. The dissimilar 
conformations result, for example, in a significant 2.6 Å distance between IleP4 
(AAG) and IleP5 (EAA). (B) For both peptides, the peptide position 2 (P2) anchors in 
the B pocket of the MHC groove (grey) and the C-terminus (P10 for EAA and P9 for 
AAG) anchors in the F pocket. 
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However binding of TCRs to the nonamer A2-AAG induced a shift in the peptide 
conformation, bringing the centre of AAG closer to that seen with A2-ELA. 
Nevertheless, due to the presence of the additional amino acid in the decamer, there 
were still conformational differences between A2-AAG and A2-ELA, with the 
peptides out of alignment at Ile4 (AAG) and Ile5 (ELA). 
 
5.1.3 Aim 
The MEL5 affinity for A2-EAA and A2-AAG has been described previously (Cole 
et al., 2010; Ekeruche-Makinde et al., 2012). This particular melanoma-specific TCR 
binds to both natural MART-1 peptides with a stronger affinity compared to 
previous published MART-1-specific TCRs and within the affinity range normally 
associated with TCR response to non-self peptides (Cole et al., 2007). The MEL5 
TCR is thus the best natural TCR for the natural HLA-A2-restricted MART-1 
antigens described to date. The aims of this Chapter were to provide a molecular 
explanation for MEL5 ability to interact with a greater affinity with MART-1, 
particularly the physiologically relevant MART-127-35 nonamer, and to investigate 
the interaction between the high-affinity variant α24β17 and the two clinically 
relevant natural MART-1 peptides. 
 
5.2 RESULTS 
5.2.1 Production and purification of soluble TCRs and pMHCs 
This work required the production of substantial amounts of the proteins listed in 
Table 5.1. Protein production and purification are described in Chapter 2 (section 
2.3) and Chapter 4 (section 4.2.1) of this thesis.   
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Table 5.1. List of the proteins produced for the work reported in this Chapter. 
 Protein produced for SPR and crystallography analyses 
Inclusion bodies 
HLA-A2 
HLA-A2-bt 
β2m 
MEL5 α chain 
MEL5 β chain 
α24 chain 
β17 chain 
TCRs 
MEL5 
α24β17 
pMHCs 
HLA-A2-EAA 
HLA-A2-EAA-bt 
HLA-A2-AAG 
HLA-A2-AAG-bt 
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5.2.2 MEL5 and α24β17 TCR binding to natural MART-1 antigens 
The affinities of MEL5 for A2-EAA (Cole et al., 2010) and A2-AAG (Ekeruche-
Makinde et al., 2012) have been described previously and were confirmed here 
(Figure 5.2A&B). With a KD ~8.4 ± 0.2 µM and ~18.4 ± 2.2 µM toward A2-EAA 
and A2-AAG, respectively, the affinity was within the range described previously 
for TCR interactions with a tumor antigen (Cole et al., 2007). Interestingly, MEL5 
bound to both natural MART-1 peptides with a stronger affinity than other MART-1 
specific TCRs (Table 5.2). I also analyzed here the interaction of α24β17 with A2-
EAA and A2-AAG by surface plasmon resonance (SPR) using the single-cycle 
kinetics method (Karlsson et al., 2006) (Figure 5.2C&D). α24β17 TCR bound to 
A2-EAA and A2-AAG with KDs of ~750 pM and ~19.7 nM, respectively. This 
represented a 11,200-fold enhancement in binding to A2-EAA and a 934-fold 
enhancement in A2-AAG binding compared to MEL5. As with previously published 
high-affinity TCRs (Jones et al., 2008; Li et al., 2005b; Sami et al., 2007), the 
enhanced binding of α24β17 TCR was attributed to a substantially slower off-rate 
compared to the wild-type progenitor (Figure 5.2A-D). In order to further 
understand the mechanism underlying the difference in the recognition of the two 
natural MART-1 peptides, I solved the crystal structure of MEL5 and α24β17 
complexed to A2-EAA and A2-AAG.  
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Figure 5.2. Binding affinities of the MEL5 and α24β17 TCRs with A2-EAA and 
A2-AAG. 
(A&B) Ten serial dilutions of MEL5 were measured in triplicate at 25°C. 
Representative data from these experiments are plotted. The equilibrium binding 
constant (KD) values were calculated using a nonlinear curve fit (Langmuir binding 
equation AB = (B x ABmax)/(KD + B)); mean plus SD values are shown. The 
MEL5/A2-EAA KD (A) was ~8.4 µM and the MEL5/A2-AAG KD (B) was ~18.4 
µM. (C&D) Five serial dilutions of α24β17 were measured in triplicate at 25°C. 
Representative data from these experiments are plotted. Association constant (kon), 
dissociation constant (koff) and affinity constant (KD) were estimated by global fitting 
of the data using the single-cycle kinetics method (Karlsson et al., 2006). The raw 
data and the fits are shown in each panel. The α24β17/A2-EAA KD (C) was ~750 
pM and the α24β17/A2-AAG KD (D) was ~19.7 nM. 
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Table 5.2. MEL187.c, DMF4, DMF5, MEL5 and α24β17 binding analysis and 
thermodynamics toward A2-EAA and A2-AAG. 
TCR/ 
pMHC 
kon
a koff
a KD
a
  ∆G°
b ∆G°c ∆H°c T∆S°c Reference 
MEL187.
c5/A2-
EAA  
nd nd 
42 ± 
0.3 
µM 
-5.97 nd nd nd 
(Cole et al., 
2010) 
MEL187.
c5/A2-
AAG  
nd nd 
94 ± 
22 µM 
-5.49 nd nd nd 
(Ekeruche-
Makinde et 
al., 2012) 
DMF4 
/A2-AAG  
nd >0.5 
170 ± 
11 µM 
-5.14 nd nd nd 
(Borbulevych 
et al., 2011) 
DMF5 
/A2-EAA  
nd nd 
11.3 ± 
0.3 
µM 
-6.75 nd nd nd 
(Insaidoo et 
al., 2011) 
DMF5 
/A2-AAG  
nd nd 
68 ± 4 
µM 
-5.65 nd nd nd 
(Borbulevych 
et al., 2011; 
Insaidoo et 
al., 2011) 
MEL5/ 
A2-EAA 
nd nd 
8.4 ± 
0.2 
µM 
-6.92 -6.75 -14.0 -7.2  
MEL5/ 
A2-AAG 
nd nd 
18.4 ± 
2.2 
µM 
-6.46 -6.62 -6.1 0.49  
α24β17/ 
A2-EAA 
2.8x105 2.1x10-4 
0.75 
nM 
-12.44 -12.0 11.1 23.1  
α24β17/ 
A2-AAG 
8.6x104 1.7x10-3 
19.7 
nM 
-10.51 -10.72 33.6 44.1  
a kon (M
-1.s-1), koff (s
-1) and KD were measured at 25°C. 
b ∆G° (kcal.mol-1) calculated from ∆G°=RT0ln(KD) with R=1.987 cal.K
-1.mol-1 and 
T0=298 K. 
c ∆G° (kcal.mol-1), ∆H° (kcal.mol-1) and T∆S° (kcal.mol-1) calculated from the non-
linear van’t Hoff equation with T the reference temperature (T=298 K) 
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5.2.3 Protein crystallization 
As for the purification of α24β17/A2-ELA (Chapter 4, section 4.2.1), it was also 
possible to co-purify α24β17/A2-EAA for crystallography because of the TCR 
antibody-like affinity (Figure 5.2). However, the α24β17 affinity toward A2-AAG 
was not high enough and the complex dissociated during the gel filtration (Figure 
5.3) probably because of a shorter half-life compared to A2-EAA binding (Figure 
5.2). The α24β17/A2-AAG complex was therefore crystallized using the “classical 
method” where TCR and pMHC are mixed in equimolar ratio before setting up 
crystallization trials (Chapter 2, section 2.5.1). Crystallization of MEL5/A2-AAG 
and MEL5/A2-EAA was not straightforward. After unsuccessful attempts at growing 
crystals with the classical method for both complexes, I tried the “seeding” method 
where crystals of the same lattice and symmetry as the crystals one wants to grow 
are used to initiate crystal formation (McCoy, 2009). I attempted to seed MEL5 
crystals using the relevant α24β17/pMHC complex crystals (α24β17/A2-AAG and 
α24β17/A2-EAA to seed MEL5/A2-AAG and MEL5/A2-EAA, respectively). These 
attempts were unsuccessful. I eventually crystallized MEL5/A2-AAG with a method 
never described before but related to seeding (Chapter 2, section 2.5.2.1). Seeding is 
used to initiate crystal formation in conditions where critical nuclei do not 
spontaneously form, or only form slowly (McCoy, 2009). In order to allow the 
formation of critical nuclei and to avoid the generation of high-affinity TCR/pMHC 
complex crystals, a very low quantity of equimolar α24β17/A2-AAG was added to a 
large excess of equimolar MEL5/A2-AAG (Chapter 2, section 2.5.2.1). This 
approach successfully facilitated the generation of MEL5/A2-AAG crystals. These 
MEL5/A2-AAG crystals were then used to successfully seed MEL5/A2-EAA 
crystallisation.
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Figure 5.3. Co-purification by gel filtration of α24β17/A2-EAA and α24β17/A2-
AAG complexes for crystallography. 
α24β17/A2-EAA complex (blue line) was successfully co-purified before setting up 
crystallization trials, the first peak being the complex (~95 kDa) and the second peak 
being the excess of TCR (~50 kDa). α24β17/A2-AAG complex (red line) could not 
be co-purified by gel filtration with the first peak being the TCR (~50 kDa) and the 
second peak being the pMHC (~45 kDa). 
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5.2.4 Structures of MEL5 and α24β17 complexed to A2-EAA and A2-AAG 
The structures of MEL5 bound to MART-127-35 natural nonamer (AAGIGILTV) and 
MART-126-35 natural decamer (EAAGIGILTV) were determined at resolutions of 
3.16 Å and 3.00 Å, respectively (Table 5.3). I also solved the structures of α24β17 
bound to A2-AAG and A2-EAA at a better resolution: 2.81 Å and 2.10 Å, 
respectively (Table 5.3). These higher resolution structures with the α24β17 TCR 
were useful for confirming results with the wildtype TCR. In all four complex 
structures, the TCR bound in a canonical diagonal docking mode to the pMHCI. 
MEL5 bound at a crossing angle of ~47° for both complexes and the α24β17 bound 
with a crossing angle of ~42°. The crossing angles, as well as other structural factors 
such as shape complementarity (SC) or buried surface area (BSA) (summarized in 
Table 5.4), were within the range described for other TCR/pMHC interactions 
(Miles et al., 2010; Rudolph et al., 2006). I first analysed the reasons for the affinity 
enhancement of α24β17 toward the natural MART-1 antigens. 
 
5.2.5 The high affinity of α24β17 toward MART-126/27-35 is due to an increase 
in the interaction between the TCR and the MHC 
As I observed before (Chapter 4), the increased affinity compared to MEL5 was 
mainly due to an increase in interactions between the α24β17 TCR and the MHC. 
Indeed, there was a gain of 2 H-bonds, 1 salt bridge and 59 vdW contacts with the 
MHC when presenting AAG and a gain of 2 H-bonds and 39 vdW with the MHC 
when presenting EAA (Table 5.4).  
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Table 5.3 Data collection and refinement statistics (molecular replacement). 
Data set 
statistics 
MEL5/A2-
AAG 
MEL5/A2-
EAA 
α24β17/A2-
AAG 
α24β17/A2-
EAA 
Space Group P41 P41 P41 P41 
Unit Cell 
parameters (Å) 
a=121.40, 
b=121.40, 
c=82.32 
a=121.44, 
b=121.44, 
c=82.3 
a=120.77, 
b=120.77, 
c=82.25 
a=121.49, 
b=121.49, 
c=82.68 
Radiation 
Source 
DIAMOND 
I04-1 
DIAMOND 
I24 
DIAMOND 
I03 
DIAMOND 
I02 
Wavelength (Å) 0.9173 0.9778 0.9363 0.9795 
Resolution (Å) 3.16 3.00 2.81 2.10 
Unique 
reflections 
20733 23795 29094 69920 
Completeness 
(%) 
100 99.9 100 99.4 
Multiplicity 6.6 7.5 8.0 8.3 
I/Sigma(I) 13.4 12.8 9.9 16.0 
Rmerge 0.119 0.122 0.146 0.084 
Refinement statistics 
No reflections 
used 
19653 22556 27589 66386 
No reflections in 
Rfree set 
1062 1588 1478 3532 
Rcryst (no 
cutoff) (%) 
18.6 20.3 20.0 17.3 
Rfree (%) 26.3 26.2 25.7 20.9 
RMSD from ideal geometry (target values in parenthesis) 
Bond lengths 
(Å) 
0.013 (0.021) 0.013 (0.020) 0.016 (0.021) 0.016 (0.021) 
Bond Angles (°) 1.431 (1.936) 1.452 (1.933) 1.597 (1.937) 1.556 (1.941) 
Wilson B-factor 
(Å2) 
58.1 56.3 61.0 40.3 
Overall ESU 
based on 
Maximum 
Likelihood (Å2) 
46.2 16.3 29.72 6.78 
 
One crystal was used for data collection.  
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Table 5.4 Summary of co-complex structures of Mel5/A2-AAG, Mel5/A2-EAA, 
α24β17/A2-AAG and α24β17/A2-EAA. 
 
MEL5/ 
A2-EAA 
MEL5/A2-
AAGbulged 
MEL5/A2-
AAGstretched 
α24β17/ 
A2-EAA 
α24β17/A2
-AAGbulged 
α24β17/A2
-AAGstretched 
Total No. 
TCR/ 
pMHC 
contacta 
9/3/116 8/1/84 8/1/84 11/1/143 12/2/156 11/2/146 
No. Vα 
contactsa 
5/2/57 3/1/35 3/1/38 5/1/68 6/2/67 5/2/64 
No. Vβ 
contactsa 
4/1/59 5/0/49 5/0/46 6/0/75 6/0/89 6/0/82 
No. TCR/ 
peptide 
contactsa 
6/1/43 4/0/29 4/0/29 6/1/31 6/0/42 5/0/32 
No. TCR/ 
MHC 
contactsa 
3/2/73 4/1/55 4/1/55 5/0/112 6/2/114 6/2/114 
No. 
peptide/ 
MHC 
contacts 
≤4Åb 
147 107 122 154 97 113 
BSAc (Å2) 
1684/682/
2366 
1620/655/ 
2275 
1625/545/ 
2170 
1833/695/ 
2528 
1944/682/ 
2626 
1951/662/ 
2613 
SCd (%) 
59.9/74.5/
64 
53.8/63.4/ 
56.8 
53.8/57.9/ 
53.5 
73.1/56/   
66.6 
73.2/61.1/ 
70.9 
73.2/42/    
62 
Crossing 
angle (°) 
46.9 48.0 48.0 42.6 42.3 42.3 
The structures involving A2-AAG have been divided into a bulged and a stretched 
model. 
a Number of hydrogen bonds (H-bond) (≤4Å) / salt bridges (≤4Å) / van der Waals 
(vdW) (3.2-4Å) contacts calculated with CONTACT program from the CCP4 
package (Collaborative Computational Project, 1994) 
b Peptide/MHC contacts ≤4Å calculated with CONTACT program from the CCP4 
package (Collaborative Computational Project, 1994) 
c Buried surface area (BSA) (Å2) of TCR-MHC / TCR-peptide / TCR-pMHC 
calculated with PISA program from the CCP4 package (Collaborative 
Computational Project, 1994) 
d Shape complementarity (SC) (%) of TCR-MHC / TCR-peptide / TCR-pMHC 
calculated with SC program from the CCP4 package (Collaborative Computational 
Project, 1994) 
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The mutations and the different binding angle between MEL5 and α24β17 induced a 
shift between the TCR Vα domains (Figure 5.4). These shifts brought the α24β17 
CDR loops closer to the MHC, increasing the binding network and allowing some 
mutated residues to greatly interact with the MHC helices compared to MEL5 
(Table 5.4 and Appendices 7-10).  
 
5.2.6 Binding mechanisms of two melanoma-specific TCRs to the HLA-A2-
restricted EAAGIGILTV MART-1 antigen 
The structure of several TCRs with the heteroclitic ELA peptide have been solved 
(Borbulevych et al., 2011; Cole et al., 2009) but to date there are no TCR structures 
with the natural EAA peptide, an omission that has hampered the understanding of 
TCR recognition to this relevant MART-1 antigen. The newly solved MEL5/A2-
EAA showed similarities with the previously solved MEL5/A2-ELA structure (Cole 
et al., 2009) in that the Vα domain of MEL5 made predominant contacts with 
peptide residues P1 to P5 via the CDR1α. The use of a germline-encoded CDR loop 
for peptide discrimination is in opposition with the long-held belief that contacts 
with peptide are dominated by the hypervariable CDR3 loops. The MEL5 Vβ 
domain contacted residues P5 to P9 with CDR3β aligning alongside the C-terminal 
half of the peptide as seen with the DMF4 TCR (Borbulevych et al., 2011). A 
comparison of the previously solved structure of EAAGIGILTV complexed to HLA-
A2 (Borbulevych et al., 2007) with the newly solved ternary complex MEL5/A2-
EAA showed that the peptide conserved its overall “bulged” conformation upon the 
recognition by the TCR (Figure 5.5A).   
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Figure 5.4. Structural differences in the TCR Vα domain between MEL5 and 
α24β17 bound to A2-AAG and A2-EAA. 
The mutations and the different binding angle to the pMHCI (shown in grey) 
between MEL5 and α24β17 induced a shift between the TCR Vα domains. (A) The 
comparison of α24β17/A2-AAG (deep purple) with MEL5/A2-AAG (forest green) 
showed an average shift of ~ 2.3 Å with the CDR1α, CDR2α, FWα and CDR3α 
shifting of 2.7 Å, 1.7 Å, 2.4 Å and 2.2 Å. (B) The comparison of α24β17/A2-EAA 
(light pink) with MEL5/A2-EAA (green) showed an average shift of ~ 2.1 Å, with 
the CDR1α, CDR2α, FWα and CDR3α shifting of 2.1 Å, 1.4 Å, 2.3 Å and 2.4 Å, 
respectively. 
 
 
 
 
Figure 5.5. Peptide contacts between the MEL5 TCR and A2-EAA. 
(A) Upon MEL5 TCR binding, EAA (green) conserved the bulged and “zig-zagged” 
conformation observed with the unligated EAA (orange) in the peptide binding 
groove of the MHC (grey cartoon). (B) MEL5 (green cartoon, upper left panel) 
bound to EAA (green) in the MHC peptide binding groove (grey cartoon). Compared 
with EAA unligated (orange), there was a 2.9 Å shift of the GluP1 side chain when 
ligated with MEL5 allowing more contacts with αGly29 and αGln31 (green, lower 
left panel). IleP5 (green) was contacted by TCR residues αGln31, αSer32, αAsn92, 
βLeu98 and βGly99 (green) making a total of 10 vdW (upper right panel, lower 
middle panel and lower right panel). 
 
.   
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The mechanism of recognition of the EAAGIGILTV peptide involved a 2.9 Å shift 
in the side chain of the peptide residue GluP1 enabling contacts between residues 
Gly29 and Gln31 of the TCR CDR1α, including: 1 H-bond, 1 salt bridge and 4 vdW 
contacts (Figure 5.5B). One of the key peptide residues was IleP5, contacted by 5 
different TCR residues (αGln31, αSer32, αAsn92, βLeu98 and βGly99) of 3 CDRs 
(CDR1α, CDR3α and CDR3β), and a total of 10 vdW contacts (Figure 5.5B). Two 
other important peptide residues were GlyP4 and IleP7, contacting the TCR with 1 H-
bond and 8 vdW and 2 H-bonds and 12 vdW respectively.  
 
The structure of α24β17 complexed to A2-EAA confirmed the MEL5/A2-EAA 
results. When complexed with α24β17, EAA conserved its bulged conformation 
(Figure 5.6). The P1 shift was also observed upon TCR recognition, the glutamic 
acid side chain shifting by 2.4 Å. However, the shift in the α24β17 Vα led to a 
slightly different binding mechanism (Figure 5.6). Gly29 and Gln31 of the α24β17 
CDR1α loops still contacted GluP1, but IleP5 was contacted by αGln31, αSer32, 
αTyr51 and βLeu98.  
 
5.2.7 The MEL5 TCR distinguishes EAA with ELA due to an enhanced 
flexibility of the natural decamer 
My laboratory recently showed that T-cells can distinguish between A2-ELA and 
A2-EAA (Cole et al., 2010) so that T-cells primed with ELA might not cross-
recognize tumours (Bins et al., 2007; Rosenberg et al., 2004).   
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Figure 5.6. Binding mechanism of α24β17/A2-EAA. 
(A) The structure of α24β17 (forest green cartoon) complexed to EAA (forest green) 
in the binding groove of HLA-A2 (grey cartoon) displayed a bulged conformation 
similar to the EAA unligated conformation (orange) (Borbulevych et al., 2007). (B) 
The P1 glutamic acid side chain shifted by 2.4 Å upon α24β17 binding, allowing 
residues αGly29 and αGln31 to contact GluP1. (C). IleP5 was contacted by βLeu98 
(left panel), αGln31 and αSer32 (middle panel) and αTyr51 (right panel). 
 
 
 
 
  
Figure 5.7. Structural differences between MEL5/A2-EAA and MEL5/A2-ELA. 
(A) MEL5/EAA and (B) MEL5/ELA are shown in green and brown, respectively. 
(A) αGly29 and αGln31 contacted GluP1 with 4 vdW, 1 H-bond and 1 salt bridge. 
(B) αGly29 and αGln31 contacted GluP1 with only 4 vdW. As there were no 
modifications in the CDR1α loop between the two structures, the difference in the 
bonding network was due to the peptide flexibility. The improved anchor position 
LeuP2 reduced the ELA peptide flexibility compared to the natural decamer EAA, 
hence inducing the loss of 1 H-bond and 1 salt bridge.  
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The comparison of the MEL5/A2-ELA structure my laboratory previously solved 
(Cole et al., 2009) with the newly solved MEL5/A2-EAA structure showed that, 
despite MEL5 TCR binding to EAA and ELA displaying similarities, a major 
difference was observed regarding the anchor position P2. MEL5 TCR residues 
αGly29 and αGln31 contacted GluP1 with only 4 vdW contacts in MEL5/A2-ELA, 
hence losing 1 H-bond and 1 salt bridge compared to EAA with no structural 
modifications in the CDR1α loop (Figure 5.7). The improved anchored position 
LeuP2 reduced the ELA peptide flexibility leading to a reduction in the bonding 
network. This loss of flexibility possibly contributes to the T-cells ability to 
distinguish between the two peptides and explains the MEL5 TCR lower affinity for 
A2-ELA (KD = 18 µM) compared to A2-EAA (KD = 8.4 µM). 
 
5.2.8 TCR binding to A2-AAGIGILTV induces a peptide anchor switch 
The numerically dominant HLA-A2-resctricted MART-1-derived peptide at the 
melanoma surface is believed to be the nonamer AAG, but most MART-1-specific 
TCRs bind this peptide poorly and it is an extremely poor antigen (Ekeruche-
Makinde et al., 2012). As MEL5 TCR interacts with a greater affinity with this 
peptide compared to other published TCRs, I aimed to understand the better affinity 
by solving MEL5/A2-AAG complex structure.  
 
The results were highly unexpected as they showed that the TCR recognized two 
different conformations of AAG (bulged and stretched), both conformations being 
present in the crystal (Figure 5.8). It is likely that this observation indicates that the 
N-terminus of the AAG peptide was quite mobile during binding to MEL5. 
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Figure 5.8. 2Fo-Fc peptide electron density maps for all structures reported in 
this Chapter. 
2Fo-Fc peptide electron density maps (shown in grey) in (A) MEL5/A2-EAA, (B) 
α24β17/A2-EAA, (C) MEL5/A2-AAG with AAGbulged shown in light blue, 
AAGstretched shown in light pink and the identical conformation of the last three 
residues at the C-terminal end of the peptide shown in black and (D) α24β17/A2-
AAG with AAGbulged shown in blue, AAGstretched shown in magenta and the identical 
conformation of the last three residues at the C-terminal end of the peptide shown in 
black. All maps shown are within 2Å from the atoms to which they relate. Positive 
density is shown in green and negative density is shown in red. 
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In order to understand the effect of each peptide conformation on TCR binding, I 
separated the structures into two different models: MEL5/A2-AAGstretched (anchor 
position P2) and MEL5/A2-AAGbulged (anchor position P1). In both conformations 
the C-terminal end of the peptide possessed an identical conformation. However, the 
region from AlaP1 to IleP6 was different (Figure 5.9A). 
 
The MEL5/A2-AAGstretched model presented the extended conformation of AAG 
(AAGstretched), the same conformation observed in all previously known A2-AAG 
structures, complexed or uncomplexed with a TCR (Borbulevych et al., 2007; 
Borbulevych et al., 2011; Insaidoo et al., 2011) (Figure 5.9B). Notably, the C-alpha 
of GlyP5 (Gly5Cα) shifted by 1.7 Å between AAGstretched and AAGuncomplexed. Without 
this shift, steric clashes would occur between this peptide residue and the carbonyl 
oxygen of βLeu98 (Figure 5.9B). In the bulged conformation model, the Cα of AlaP1 
executed a large translation of 4.7 Å to become the anchor position AlaP1bulged, thus 
leaving the A pocket empty during recognition by MEL5 (Figure 5.10). An empty A 
pocket has not been seen before during TCR binding to a MHCI-restricted natural 
nonamer. The Cα of the anchor residue AlaP2 of the A2-AAG structure shifted 3.8 Å 
in this model, hence losing its role as anchor in the B pocket of the MHC groove 
(Figure 5.10). The analysis of the peptide/MHC interaction (Table 5.4) showed that 
there were more contacts within A2-AAGstretched (122 contacts) than A2-AAGbulged 
(107 contacts). This was mainly due to the empty A pocket and thus the loss of 
contact between the MHC helices and AlaP1stretched. 
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Figure 5.9. Stretched and bulged conformations of AAG during MEL5 binding. 
(A) When bound to MEL5 (forest green cartoon), AAG displayed two different 
conformations: AAGstretched (light pink) with the anchor position Ala
P2 and AAGbulged 
(light blue) with the anchor position AlaP1. The last 3 residues at the C-terminal end 
of the peptide possessed an identical conformation (black). (B) The comparison of 
the unligated AAG (yellow) with AAGstretched (light pink) when bound to MEL5 
(forest green cartoon) revealed that the peptides conformations are similar. However, 
in order to avoid steric clashes with MEL5 residue βLeu98 (forest green) upon 
MEL5 binding (right panel), Cα of GlyP5 (Gly5Cα) shifted of 1.7 Å between 
AAGstretched and the unligated AAG.  
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Figure 5.10. AAG peptide anchor residue switch during MEL5 binding. 
(A) The comparison of the unligated AAG (yellow) with AAGbulged (light blue) when 
bound to MEL5 (forest green cartoon) revealed a peptide anchor position switch. 
The Cα of AlaP1 executed a large translation of 4.7 Å to become the anchor position 
AlaP1bulged and the Cα of the anchor residue Ala
P2 shifted 3.80 Å in the AlaP2bulged 
structure, hence losing its role as anchor in the MHC groove (lower panel). (B) The 
peptide anchor residue switch between the unligated AAG (yellow) and AAGbulged 
(light blue) left an empty A pocket, a binding mode that has not been observed with 
natural nonameric peptides (Borbulevych et al., 2007). 
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Figure 5.11. Structural differences in the peptide conformation between the 
unligated A2-AAG and α24β17/A2-AAG structures. 
(A) When bound to α24β17 (grey cartoon), AAG displayed two different 
conformations: AAGstretched (magenta) with the anchor position Ala
P2 and AAGbulged 
(blue) with the anchor position AlaP1. The last 3 residues at the C-terminal end of the 
peptide possessed an identical conformation (black). (B) The comparison of the 
unligated AAG (yellow) (Borbulevych et al., 2007) with AAGstretched (magenta) when 
bound to α24β17 (grey cartoon) revealed that the peptides conformations were 
similar. However, in order to avoid steric clashes with βLeu98, C-alpha of GlyP5 
(Gly5Cα) shifted of 1.8 Å between AAGstretched and the unligated AAG. (C) The 
comparison of the unligated AAG (yellow) with AAGbulged (blue) when bound to 
α24β17 confirmed a peptide anchor position switch. The C-α of AlaP1 executed a 
large translation of 4.6 Å to become the anchor position AlaP1bulged. 
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The presence of the two AAG conformations was confirmed by solving α24β17 
complexed to A2-AAG (Figure 5.11A). In this structure, the peptide displayed the 
same features: a stretched conformation close to the unbound conformation but with 
a 1.8 Å shift at Gly5Cα level to avoid a steric clash (Figure 5.11B) and a bulged 
conformation leading to the anchor position switch due to a 4.6 Å shift of AlaP1 and 
resulting in an empty P1 pocket upon α24β17 binding (Figure 5.11C). 
 
5.2.9 Different binding mechanisms of recognition for MEL5/AAGbulged and 
MEL5/AAGstretched 
MEL5 made an identical number of contacts with the peptide in bulged and stretched 
conformations (4 H-bonds and 29 vdW contacts). These contacts were, however, 
distributed differently due to the switch in anchor position (Appendix 10), the most 
striking evidence being GlyP3 which made more contacts in the bulged conformation 
(1 H-bond and 9 vdW contacts) than in the stretched conformation (1 vdW contacts), 
whereas IleP4 made more contacts with the TCR in the stretched conformer (12 vdW 
contacts) than the bulged conformer (5 vdW contacts) (Figure 5.12). MEL5 
stabilized the bulged peptide conformation using hydrophobic TCR residues βLeu98 
and βGly99 to contact hydrophobic peptide residues AlaP2bulged, Gly
P3
bulged, Ile
P4
bulged 
and GlyP5bulged (Figure 5.12A). Compared to the interaction between MEL5 and 
AAGbulged, the binding interface between MEL5 and AAGstretched was distinct. TCR 
residue βLeu98 contacted GlyP3stretched, Ile
P4
stretched and Gly
P5
stretched with longer vdWs 
and did not contact AlaP2stretched. TCR residue αGln31 interacted with Ile
P4
stretched 
making 8 contacts compared to no contacts with IleP4bulged and there was an 
additional H-bond between TCR residue αGln31 and AlaP2stretched (Figure 5.12B).  
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Figure 5.12. Different mechanisms of recognition for MEL5/AAGbulged and 
MEL5/AAGstretched. 
(A) The mechanism of recognition for MEL5 binding to AAGbulged (light blue) 
involved αGln31 (orange) contacting GlyP3 (orange panel) while βLeu98 and βGly99 
(green) were contacting peptide residues AlaP2, GlyP3, IleP4 and GlyP5 (green panel). 
(B) The mechanism of recognition for MEL5 binding to AAGstretched (light pink) 
involved αGln31 (orange) contacting AlaP2stretched with an additional H-bond 
compared to AlaP2bulged and contacting Ile
P4
stretched with 8 contacts compared to no 
contacts with IleP4bulged (orange panel). βLeu98 (green) contacted Gly
P3, IleP4 and 
GlyP5 with longer vdWs compared to MEL5/AAGbulged and did not contact Ala
P2 
(green panel). 
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Despite the same overall number of contacts for the TCR/peptide interaction, the two 
conformations exhibited different BSA and shape complementarity (SC) features 
(Table 5.4 and Appendix 11). Interestingly, both BSA and SC were higher for the 
bulged conformation (655 Å2 and 63.4%) compared to the stretched conformation 
(545 Å2 and 57.9%).  
 
5.2.10 Reduction in interactions between MEL5 TCR and A2-AAG results in 
weaker binding affinity  
I described above the binding mechanisms of MEL5 TCR toward A2-EAA and A2-
AAG. In accordance with the other melanoma-specific TCRs described in the 
literature, MEL5 TCR has a preference for the natural decamer. I thus examined the 
reasons for the difference in affinity by further investigating the MEL5/A2-EAA and 
MEL5/A2-AAG structures. 
 
The overall number of MEL5 contacts with the MHC surface was greater when the 
natural decamer EAA was presented (3 H-bonds, 2 salt bridges and 73 vdW) than 
during the presentation of the natural nonamer AAG (4 H-bonds, 1 salt bridge and 55 
vdW) (Table 5.4). This increase in interactions likely explained the superior affinity 
of MEL5/A2-EAA (KD ~ 8.4 µM) compared to MEL5/A2-AAG (KD ~ 18.4 µM).  
 
The comparison of the TCR/peptide interactions for MEL5/A2-AAG and MEL5/A2-
EAA structures revealed that, independent of the AAG conformation, there was an 
increase of the vdW contacts, H-bonds and an added salt bridge when MEL5 bound 
to the decamer. This was mainly due to the additional glutamic acid at the N 
terminus.   
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Figure 5.13. Structural differences in the MEL5 interaction with the first 
peptide residue of EAA, AAGstretched and AAGbulged. 
(A) Overlay of EAA (green), AAGstretched (light pink) and AAGbulged (light blue) upon 
MEL5 recognition. The additional glutamic acid at the N terminus of EAA (GluP1) 
made 4 vdW, 1 H-bond and 1 salt bridge with MEL5 αGlu29 and αGln31 (green 
panel) whereas AlaP1stretched (light pink panel) and Ala
P1
bulged (light blue panel) did not 
contact these MEL5 residues which contributed to the better affinity of MEL5/A2-
EAA. (B) The anchor residue AlaP1bulged (light blue) was buried 1.2 Å deeper into the 
MHC groove than the anchor residue GluP1 (green), this shift possibly helping the 
stabilisation of AAGbulged into the MHC binding groove. 
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Indeed, GluP1 contacted the TCR with 4 vdW, 1 H-bond and 1 salt bridge (Figure 
5.13A). This salt bridge did not appear in the MEL/A2-AAG (Figure 5.13A) 
interaction and could contribute to the better affinity of MEL5/A2-EAA. 
 
The comparison of AAGbulged and EAA showed that the anchor position Ala
P1 of the 
nonamer was buried 1.2 Å deeper into the MHC groove compared to the anchor 
position AlaP2 of the decamer (Figure 5.13B), this shift possibly helping to stabilize 
AAGbulged in the binding groove. However, MEL5 bound to AAGbulged and EAA with 
the same mechanism: αGln31 and βLeu98 were contacting GlyP3bulged/GlyP
4
EAA 
while βLeu98 and βGly99 were contacting residues IleP4bulged/Ile
P5
EAA and 
GlyP5bulged/Gly
P6
EAA. 
 
5.2.11 The binding of MEL5 and α24β17 to A2-AAG leads to a gain of enthalpy 
and entropy compared to the binding to A2-EAA 
As TCR conformational changes upon pMHC recognition have been found to 
correlate with changes in thermodynamic parameters (Armstrong et al., 2008a; 
Armstrong et al., 2008b), I then analyzed the changes in standard free energy (∆G°), 
enthalpy (∆H°) and entropy (T∆S°) for the binding of MEL5 and α24β17 to A2-
EAA and A2-AAG. I used the KD determined by SPR at different temperatures with 
the thermodynamic equation ∆G = RT ln KD and the standard non-linear van’t Hoff 
equation (∆G° = ∆H° –T∆S° + ∆Cp°(T-T0) – T∆Cp° ln (T/T0)) with T0=298 K 
(Table 5.1 and Figures 5.14 - 5.16).  
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Figure 5.14. Thermodynamic analysis of the MEL5 interaction with A2-AAG 
and A2-EAA. 
(A-L) Ten serial dilutions of MEL5 were measured in triplicate at 5°C, 10°C, 15°C, 
20°C, 25°C and 30°C; Representative data from these experiments are plotted. The 
equilibrium binding constant (KD) values were calculated using a nonlinear curve fit 
(Langmuir binding equation AB = (B x ABmax)/(KD + B)); mean plus SD values are 
shown. (A-F) MEL5/A2-AAG interaction at (A) 5°C, (B) 10°C, (C) 15°C, (D) 20°C, 
(E) 25°C and (F) 30°C. (G-L) MEL5/A2-EAA interaction at (G) 5°C, (H) 10°C, (I) 
15°C, (J) 20°C, (K) 25°C and (L) 30°C. 
These data were used to fit thermodynamic parameters shown in Figure 5.17. 
  
209 
 
 
Figure 5.15. Thermodynamic analysis of the α24β17 interaction with A2-AAG. 
(A-K) Five serial dilutions of α24β17 were measured in triplicate at (A) 5°C, (B) 
7°C, (C) 12°C, (D) 15°C, (E) 19°C, (F) 22°C, (G) 25°C, (H) 30°C, (I) 32°C, (J) 
35°C and (K) 37°C for the α24β17/A2-AAG interaction; Representative data from 
these experiments are plotted. Association constant (kon), dissociation constant (koff) 
and affinity constant (KD) were estimated by global fitting of the data using the 
single-cycle kinetics method (Karlsson et al., 2006).  
These data were used to fit thermodynamic parameters shown in Figure 5.17. 
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Figure 5.16. Thermodynamic analysis of the α24β17 interaction with A2-EAA. 
(A-K) Five serial dilutions of α24β17 were measured in triplicate at (A) 5°C, (B) 
7°C, (C) 12°C, (D) 15°C, (E) 19°C, (F) 22°C, (G) 25°C, (H) 30°C, (I) 32°C, (J) 
35°C and (K) 37°C for the α24β17/A2-EAA interaction; Representative data from 
these experiments are plotted. Association constant (kon), dissociation constant (koff) 
and affinity constant (KD) were estimated by global fitting of the data using the 
single-cycle kinetics method (Karlsson et al., 2006).  
These data were used to fit thermodynamic parameters shown in Figure 5.17. 
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Figure 5.17. Thermodynamic analysis of the MEL5 and α24β17 interactions 
with A2-EAA and A2-AAG.  
(A-B) KDs were measured in triplicate at 5°C, 10°C, 15°C, 20°C, 25°C and 30°C 
with ten serial dilutions of MEL5; representative data from these experiments are 
plotted. (C-D) KDs were measured in triplicate at 5°C, 7°C, 12°C, 15°C, 19°C, 22°C, 
25°C, 30°C, 32°C, 35°C and 37°C with five serial dilutions of α24β17; 
representative data from these experiments are plotted. The binding free energies 
(∆G = RT ln KD) were plotted against temperature and the thermodynamic 
parameters (∆H° and T∆S°) were calculated according to the non-linear van’t Hoff 
equation (RT ln KD = ∆H° –T∆S° + ∆Cp°(T-T0) – T∆Cp° ln (T/T0)) for (A) 
MEL5/A2-EAA, (B) MEL5/A2-AAG, (C) α24β17/A2-EAA and (D) α24β17/A2-
AAG.   
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The MEL5/A2-EAA interaction (Figure 5.17A) was enthalpically driven (∆H° ~-14 
kcal.mol-1) and entropically unfavourable (T∆S° ~-7.2 kcal.mol-1), similar to that 
observed for other TCR/pMHC interactions (from -30 to 18 kcal.mol-1 for ∆H° and 
from -23.8 to 23.8 kcal.mol-1 for T∆S°) (Armstrong et al., 2008a; Holland et al., 
2012). Although the standard free energies were similar for MEL5/A2-EAA (∆G° ~-
6.75 kcal.mol-1) and MEL5/A2-AAG (∆G° ~-6.62 kcal.mol-1) interactions, ∆G° 
being related to the KD at 25°C, MEL5 TCR used different energetic strategies to 
bind to EAA and to AAG (Figure 5.17B). Whereas the binding to A2-EAA was 
entropically unfavored, the binding to A2-AAG was slightly entropically favoured 
(T∆S° ~0.49 kcal.mol-1). Moreover, the binding enthalpy changes differed by ~ 8 
kcal.mol-1 (MEL5/A2-AAG ∆H° ~-6.1 kcal.mol-1) at 25°C, the reaction being less 
enthalpically favorable (Table 5.1). These two different energetic strategies are in 
line with the newly solved structures, the mechanism of recognition of the two 
peptides by MEL5 being markedly different.  
 
The analysis of α24β17/A2-EAA and α24β17/A2-AAG thermodynamics (Figure 
5.17C&D and Table 5.1) followed the trend observed for MEL5 and showed that 
the binding to A2-AAG led to a gain of enthalpy and was more entropically 
favourable. However, with the high affinity TCR, the binding to both peptides was 
entropically driven, with the highest positive ∆H° and T∆S° measured to date for a 
TCR/pMHC interaction (∆H° ~11.1 kcal.mol-1 and T∆S° ~23.1 kcal.mol-1 for 
α24β17/A2-EAA and ∆H° ~33.6 kcal.mol-1 and T∆S° ~44.1 kcal.mol-1 for 
α24β17/A2-AAG).  
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Finally, the fact that the binding to A2-AAG compared to the binding to A2-EAA 
with both TCRs led to a higher enthalpy and entropy was consistent with the 
dynamic movement of AAG and supported the structural differences observed 
between the peptides when bound to MEL5 and α24β17. Indeed, the higher enthalpy 
was probably due to the energy required to break and create bonds when the peptide 
switched from one conformation to the other and the higher entropy was 
representative of the energetically favourable order-disorder transition generated by 
the conformational switch in the AAG peptide. 
 
5.3 DISCUSSION 
The HLA A*0201 MART-1 system has been extensively studied for T-cell-related 
therapies directed against melanoma (Johnson et al., 2009; Liddy et al., 2012; 
Morgan et al., 2006; Rosenberg et al., 2004). This tumour-associated antigen is 
expressed by malignant melanoma cells from tumours in >95% of patients (Derre et 
al., 2007). Two HLA-A2-restricted, MART-1-derived peptides have been found at 
the melanoma surface presented by HLA-A2; EAAGIGILTV (EAA) and 
AAGIGILTV (AAG) (Held et al., 2007; Skipper et al., 1999; Valmori et al., 1998). 
The nonamer AAG peptide has been reported to be the dominant species (Skipper et 
al., 1999). Several studies suggested that the majority of MART-1-specific T-cells 
preferentially recognize the minority-expressed decamer (EAA) rather than the 
nonamer (Cole et al., 2010; Romero et al., 1997). Indeed, the nonamer peptide is a 
very poor antigen (Ekeruche-Makinde et al., 2012). The weak immunogenicity of the 
EAA and AAG peptides (Valmori et al., 1998) has resulted in a preference for using 
the MHC anchor-modified “heteroclitic” form of the decamer ELAGIGILTV (ELA) 
in this system (Valmori et al., 1998). The ELA peptide elicits huge T-cell responses 
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and has been used in all peptide vaccine trials to date (Bins et al., 2007; Panelli et al., 
2000). It was assumed that changes in this buried MHC-anchor residue would not 
result in substantial changes to the TCR docking platform of this antigen. Contrary 
to this assumption, my group recently showed that TCRs bind to A2-EAA and A2-
ELA differently (Cole et al., 2010). The fact that TCR distinguish between these two 
antigens might explain why all vaccine trials with ELA peptide have been a 
universal failure (Bins et al., 2007; Rosenberg et al., 2004). The absence of a 
TCR/A2-EAA structure in this system has not allowed visualization of the molecular 
reason for why TCRs recognise A2-EAA and A2-ELA differently. 
 
My newly solved structures of MEL5 and α24β17 TCRs complexed with A2-EAA 
showed no major peptide conformational change upon TCR binding. EAA displayed 
the bulged conformation observed in the unligated A2-EAA structure (Borbulevych 
et al., 2007). However, MEL5/A2-EAA and α24β17/A2-EAA structures supported 
the findings of our binding biophysics data in this system (Cole et al., 2010) showing 
that peptides with suboptimal anchor residues may be more flexible within the MHC 
binding groove, thereby enabling them to form subtly different conformational 
motifs that T-cells can distinguish between. In the case of MEL5 TCR, my group 
hypothesized that increased flexibility in the P1-P2 region of the peptide could allow 
for stronger, or even new, TCR-peptide contacts that could explain the enhanced 
TCR affinity and preferential antigen sensitivity of MEL5 for A2-EAA (8.4 µM) 
compared with A2-ELA (18 µM) (Cole et al., 2010). My MEL5/A2-EAA structure 
confirmed that increased flexibility in the N-terminus of A2-EAA compared to A2-
ELA could affect TCR binding. Indeed the MEL5/A2-EAA structure shows how the 
P2 alanine residue allows αGly29 and αGln31 to contact GluP1 with an additional H-
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bond and salt-bridge compared to A2-ELA. These new contacts led to the better 
interaction with the natural decamer compared to the heteroclitic decamer that has 
been favoured in this system. 
 
The best published binding affinity of a TCR to A2-AAG is 68 µM (Borbulevych et 
al., 2011; Insaidoo et al., 2011). This weak affinity possibly explains the relatively 
low response rate in adoptive cell therapy trials (Johnson et al., 2009; Morgan et al., 
2006) as it has been shown that weak TCR affinity correlates with poor T-cell 
responses (Irving et al., 2012; Stone et al., 2009). I showed that the MEL5 TCR 
bound with the best affinity to A2-AAG. Thus, I also solved the structure of MEL5 
TCR complexed with the HLA-A2-restricted natural nonamer peptide AAG in order 
to understand the substantially stronger affinity of MEL5 for this natural antigen 
compared to previous published MART-1-specific TCRs (Table 5.2). Unexpectedly, 
the MEL5/A2-AAG structure showed a novel mechanism of TCR/pMHC 
recognition mediated by a peptide conformational change upon TCR ligation and 
described herein as a “peptide anchor residue switch”. The peptide residue AlaP1 was 
in the A pocket of the MHC groove before TCR recognition with the peptide 
anchored at position AlaP2. Upon TCR engagement, the peptide AlaP1 residue 
executed a large translation of 4.7 Å to become anchored in the B pocket of the 
MHC groove thus leaving an empty A pocket, a feature never observed before 
during TCR binding to a MHCI-restricted natural nonamer. The peptide anchor 
residue switch changed the original AAG “extended” conformation into an AAG 
“bulged” conformation, almost perfectly mimicking that of EAA and ELA. These 
results may explain why the MEL5 TCR binds to A2-AAG with stronger affinity 
compared to MEL187.c5 (Ekeruche-Makinde et al., 2012), DMF4 (Borbulevych et 
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al., 2011) and DMF5 (Borbulevych et al., 2011; Insaidoo et al., 2011) MART-1-
specific TCRs. This “molecular switch” during peptide binding was also observed in 
the structure of the high-affinity α24β17 TCR complexed with A2-AAG adding 
further confidence in the finding. The flexibility in N-terminal anchoring when 
MEL5 TCR engages A2-AAG was also consistent with the in-depth thermodynamic 
analysis of this interaction. The thermodynamic parameters obtained for the MEL5 
and α24β17 interactions with A2-AAG and A2-EAA revealed a higher enthalpy and 
entropy when both TCRs bind to the nonamer. The more favourable entropy could 
represent an energetically favourable increase in disorder generated by the 
conformational switch. The less favourable enthalpy when the TCRs bind to A2-
AAG was more likely due to the energy required to disrupt and generate bonds when 
AAG peptide switched conformations.  
 
Sliz et al. solved the structures of the two closely MART-1-related HLA-A2-
restricted peptides, ELAGIGILTV and ALGIGILTV (referred here as ALG) (Sliz et 
al., 2001). This study hypothesized that the native AAG nonamer complexed to 
HLA-A2 would adopt a bulged and “zig-zagged” conformation similar to that of the 
ELA decamer in order to be recognized by T-cells (Sliz et al., 2001). The hypothesis 
was based on the fact that the extended conformation displayed by ALG was not 
recognized by T-cells (Valmori et al., 1998). However, the different structures of the 
unligated A2-AAG (Borbulevych et al., 2007; Insaidoo et al., 2011) showed that the 
peptide always adopted a stretched conformation. Based on the unligated A2-EAA, 
A2-AAG and A2-ALG structures, Insaidoo et al. raised the question of how multiple 
T-cells clones could, on one hand, be highly sensitive to a very small structural 
perturbation (A2-AAG vs A2-ALG) while, on the other, be tolerant of a much more 
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dramatic structural difference (A2-AAG vs A2-EAA) (Insaidoo et al., 2011). 
Borbulevych et al. hypothesized that a possible mechanism for achieving both cross-
reactivity and selectivity in T-cell recognition of MART-126/27-35 antigens is that 
MART-126/27-35-reactive T-cells induce a structural shift in the AAG nonamer upon 
TCR binding, forcing the peptide to adopt a conformation resembling that of the 
EAA and ELA peptides (Borbulevych et al., 2007). A structural shift was recently 
observed in the recognition of AAG by the two melanoma-specific DMF4 and 
DMF5 TCRs (Borbulevych et al., 2011), the nonamer mimicking the heteroclitic 
decamer in a mechanism first described as “peptide induced-fit molecular mimicry” 
(Macdonald et al., 2009). However, the molecular shift was imperfect (peptides out 
of alignment at Ile4 (AAG) and Ile5 (ELA)) because AAG retained its original 
anchor positions (Borbulevych et al., 2011). My findings show that the TCR that 
binds best to the natural A2-AAG antigen of those described to date, MEL5, perfects 
the molecular fit by altering the way the peptide is anchored in the MHC groove. 
This novel observation extends the possibilities of changes that are known to occur 
in the peptide upon TCR engagement (section 5.1.1.3 above). If such a peptide 
anchor residue switch or “induced fit” is obligatory for good TCR binding in this 
system then it might also explain why the AAG peptide is such a poor antigen even 
when there are rare TCRs like MEL5 that appear to be capable of engaging it 
efficiently.  
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Chapter background 
Work from my laboratory has established that anti-self (anti-tumour) TCRs bind 
with ~5-fold weaker affinity than pathogen-specific TCRs (Cole et al., 2007). 
Numerous studies, including several from my own group, have shown that TCR 
affinity and/or half-life is critical to the sensitivity of T-cells to antigen. Thus, 
tumour-specific T-cells are at a distinct disadvantage when compared to their 
pathogen-specific counterparts. As part of these studies I had access to a range of 
well-characterised MART-1-specific TCRs that bound to the cognate antigen with a 
range of affinities and half-lives. My aim in this Chapter was to determine the 
optimal TCR affinity for the most efficient TCR gene therapy approach against 
melanoma. At the outset, I had hoped that these experiments would be 
straightforward but I encountered numerous issues not reported herein regarding 
plasmid constructs or cloning steps. As a result of these difficulties and the 3-year 
time limit to my work, I present here a preliminary study in a Jurkat cell model. 
Unfortunately, I did not have the opportunity to duplicate the experiments in a CD8+ 
T-cell model as I had hoped. 
 
6.1 INTRODUCTION 
Although CD8+ T-cells play an important role during viral infections that typically 
elicit strong CD8+ T-cell responses, cancer specific T-cell mediated immune 
responses are often less effective. As reported in earlier Chapters, because cancer 
cells normally express only self proteins (Voskens et al., 2009), cancer-specific T-
cell clones with strong affinity TCRs are likely to be deleted during negative 
selection in the thymus. In support of this notion, it has been demonstrated that 
cancer specific T-cells express TCRs that generally have a lower binding affinity 
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compared to anti-pathogen specific TCRs (Cole et al., 2007). The low natural 
affinity of cancer-specific TCRs may be a barrier to effective anti-cancer CD8+ T-
cell immunity. Tolerance to self-antigens can be broken by using alloreactive T-cells 
as such cells have undergone thymic selection in the absence of the restricting HLA 
molecule (Kronig et al., 2009; Sadovnikova and Stauss, 1996). Alternatively, it is 
now possible to engineer TCRs by phage display, yeast display or computational 
design as described in the earlier Chapters of this thesis. Such TCRs can then be 
expressed in autologous T-cells in vitro prior to transfer back to patient blood in an 
approach termed “adoptive cell therapy” (ACT) as described below. 
 
6.1.1 TCR gene transfer 
Adoptive cell therapy (ACT) consists of transferring autologous tumour-reactive T-
cells to a patient. Figure 6.1 summarises the main steps involved when using either 
tumour-infiltrating lymphocytes (TILs) or TCR gene transfer (TCR gene therapy). I 
concentrate on TCR gene therapy here as this approach is relevant to my work.  
 
TCR gene transfer consists of reprogramming CD8+ T-cells to effectively bypass T-
cell tolerance to tumour cells (Rosenberg et al., 2004). TCR gene transfer provides 
an effective mechanism for the rapid generation of large numbers of T-cells endowed 
with the desired specificity and affinity (Bobisse et al., 2009). Original proof of 
principle was first demonstrated in 1986 when transfer of TCR α and β genes using a 
cosmid vector transferred T-cell specificity from one T-cell clone to another 
(Dembic et al., 1986).  
  
222 
 
 
Figure 6.1. Schematic representation of adoptive cell therapy process. 
The generation of autologous cancer-specific T-cells for ACT can be obtained either 
from TIL or PBMC. PBMC can be enriched in cancer-specific T-cells by TCR gene 
transfer whereas TIL population can be enriched in cancer-specific T-cells by 
different steps of selection based on antigen specificity or tumour reactivity. Then, 
cancer-specific T-cells can be sorted, cloned and in vitro expanded. After expansion, 
T-cells are tested for sterility and tumour reactivity before being transferred to the 
patient. Figure adapted from (Jotereau et al., 2012). 
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More than 20 years later, the first clinical studies in melanoma patients have recently 
shown promise (Johnson et al., 2009; Morgan et al., 2006). In spite of the low 
response rates after the adoptive transfer of genetically modified autologous 
peripheral blood lymphocytes (PBLs) expressing a melanoma specific TCR (e.g. 
DMF4 or DMF5), these trials have established that TCR gene therapy is achievable 
in a clinical setting.  
 
6.1.2 Vectors for transfer of TCR genes 
TCR gene therapy relies on the transfer of TCR genes to autologous T-cells. TCR 
genes can be transiently transferred using mRNA (Schaft et al., 2006; Zhao et al., 
2007). Such transfer is short-term and often of low efficiency. Most clinical trials of 
the TCR gene transfer have utilized viral transduction technologies. γ-retroviral 
vectors (RVs) have been the preferred transfer vector due to high transduction 
efficiency and stable expression of the transferred gene (Engels and Uckert, 2007). 
This type of vector was used in the two melanoma clinical trials (Johnson et al., 
2009; Morgan et al., 2006). Recently, lentiviral vectors (LVs, a subfamily of RVs) 
have also been used to redirect human T-cell antigen specificity (Joseph et al., 2008; 
Tsuji et al., 2005). As LVs are self-inactivating, they reduce the risk of side effects 
due to insertional mutagenesis (Kieback and Uckert, 2010). LVs can also carry a 
larger transgene cassette compared to RVs, thus enabling expression of TCR α and β 
chains genes and a third gene (e.g. a reporter gene) (Kieback and Uckert, 2010). My 
studies utilized a LV construct. 
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6.1.3 Optimised transfer of an αβ TCR 
6.1.3.1 Choosing a transgene cassette 
Various mechanisms have been used for expression of αβ TCR at the T-cell surface. 
These include the use of single chain TCRs (scTCRs) (Alajez et al., 2006) or 
chimeric antigen receptors (CARs) (Mitsuyasu et al., 2000). I expressed TCRs as 
separate TCR α and β chains. It is preferable to have both chains expressed from the 
same vector to ensure optimal transfer of the required TCR. The two TCR chains can 
be expressed from separate promoters (Emerman and Temin, 1984), or expressed 
from the same promoter and the latter situation is most common. In the transgene 
cassette, genes are either separated by an inter-ribosomal entry site (IRES) or a “self-
cleavage” peptide (Uckert and Schumacher, 2009).  
 
My laboratory’s experience with TCR chains expressed and separated by an IRES 
sequence was that TCR expression was low due to suboptimal expression of the gene 
downstream of the IRES sequence. We have found separation of TCR chains by 
“self-cleavage” peptides (such as 2A peptides) to give the best results. Additionally, 
it has been shown that the efficiency of the 2A-mediated cleavage is close to 100% 
and leads to an equimolar ratio of the gene products (Szymczak et al., 2004). The 
2A-like peptides utilized in this study, T2A (EGRGSLLTCGDVEENPGP) and P2A 
(ATNFSLLKQAGDVEENPGP), are used by members of the picornavirus family 
(Palmenberg, 1990). Such peptides function by a ribosome “skipping mechanism”. 
The transcription of a cassette containing a 2A-like sequence leads to a single 
mRNA encoding both TCR genes (de Felipe et al., 1999; Yang et al., 2008). During 
translation, the ribosome “skips” a peptide bond between the last (here a proline) and 
the second last (here a glycine) amino acid of the 2A peptide sequence (de Felipe et 
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al., 1999; Yang et al., 2008) and this cotranslational cleavage event leads to the 
release of each individual protein product in mammalian cells (Osborn et al., 2005). 
The skipping mechanism generates a 17 (T2A) or 18 (P2A) residue-long tail on the 
upstream gene while the downstream protein starts with a proline instead of a 
methionine. This tail can be cleaved off by including a furin cleavage site (Johnson 
et al., 2009; Yang et al., 2008). However, TCRs expressed without the furin cleavage 
site are fully functional (Holst et al., 2006; Yang et al., 2008), indicating that these 
modifications do not impair TCR function. 
 
6.1.3.2 Choosing a transfer vector 
In this study, I used a “third generation” LV construct derived from the human 
immunodeficiency virus type 1 (HIV-1) (Dull et al., 1998) which is one the safest 
and most efficient vector for gene transfer (He and Falo, 2007). HIV-1 contains nine 
genes that are involved in the life cycle and pathogenicity of the virus. Six accessory 
genes (vif, vpr, vpu, nef, env and tat), that are either related to pathogenesis or not 
necessary for vector production and functionality, are either replaced with another 
gene (for env) or deleted from the vector system (Demaison et al., 2002; Dull et al., 
1998). Three genes (rev, pol and gag) involved in viral packaging are retained in the 
vector system (Demaison et al., 2002; Dull et al., 1998). I describe herein the 
components of the “third generation” LV system that consists of one lentivirus-based 
vector (here pELNSxv, Figure 6.2A) and three packaging plasmids: pRSV.REV 
(Figure 6.2B), pMDLg/p.RRE (Figure 6.2C) and pVSV-G (Figure 6.2D). 
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Figure 6.2. Schematic representation of the “third generation” lentivirus system 
used in this study. 
The “third generation” lentivirus system used in this study is composed of 4 vectors. 
(A) Lentivirus-based pELNSxV contains a partial gag sequence and the env, rev and 
pol genes have been deleted. The plasmid contains the central polypurine tract 
(cPPT) of HIV-1. The gene of interest (GOI) is inserted between the EF-1 alpha 
promoter and the Woodchuck Hepatitis Post-transcriptional Regulatory Element 
(WPRE). HIV-1 delta3’ LTR has been partially deleted to render the lentivirus “self-
inactivating”. Chimeric 5’ LTRs have been constructed by replacing the U3 region 
of the 5’LTR with the Rous sarcoma virus (RSV) U3 sequence. (B) pRSV.REV 
contains RSV rev gene under the CMV promoter and a polyadenylation (pA) 
sequence. (C) pMDLg/p.RRE contains gag and pol genes under the CMV promoter, 
Rev response element (RRE) and pA sequences. (D) pVSV-G contains a pA 
sequence and a gene encoding the vesicular stomatitis virus glycoprotein (VSV-G) 
under the CMV promoter.  
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The backbone of the lentivirus-based vector (Figure 6.2A) is constructed by 
removing the viral genes env, rev, gag (partially removed) and pol from the viral 
genome into packaging plasmids, freeing up space for the insertion of the gene of 
interest (GOI) and a number of elements which function to increase or regulate the 
expression of that gene. For instance, the viral long terminal repeat (LTR) flanking 
the GOI are often unsuitable for efficient expression and are replaced by a stronger 
promoter (here human elongation factor-1 alpha, EF-1 alpha Figure 6.2A) 
(Teschendorf et al., 2002). The U3 region 3’ LTR is dispensable for a replication-
defective vector and has been partially deleted (HIV-1 delta3’ LTR, Figure 6.2A) to 
remove all transcriptionally active sequences, generating “self-inactivating” (SIN) 
LTR (Zufferey et al., 1998). Chimeric 5’ LTRs have been constructed to make the 
LV promoter Tat-independent by replacing the U3 region of the 5’LTR with the 
Rous sarcoma virus (RSV) U3 sequence (Dull et al., 1998) (Figure 6.2A). Finally, 
the central polypurine tract (cPPT) sequence of HIV-1 (Follenzi et al., 2000) and the 
Woodchuck Hepatitis Post-transcriptional Regulatory Element (WPRE) (Zufferey et 
al., 1999) have been added to increase transgene expression (Figure 6.2A). 
 
Genes from the three packaging constructs are expressed under the cytomegalovirus 
(CMV) promoter and contain a polyadenylation site of the human β-globin gene 
(Figure 6.2B-D) (Dull et al., 1998). pRSV.REV contains RSV rev gene encoding a 
protein (Rev) that binds env gene HIV RNA (Rev response element, RRE) and that 
is essential for the export of the viral RNA out of the nucleus (Tang et al., 1999) 
(Figure 6.2B). pMDLg/p.RRE contains gag and pol genes as well as RRE (Dull et 
al., 1998). The gag gene encodes structural proteins that make up the viral core: 
matrix, capsid and nucleocapsid (Tang et al., 1999) (Figure 6.2C). The pol gene 
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encodes viral replication enzymes (protease, reverse transcriptase and integrase) that 
have been engineered for safety reasons so the virus has the ability to complete only 
a single round of the retroviral replication cycle (Demaison et al., 2002; Dull et al., 
1998). Finally, pVSV-G contains a gene replacing env gene and encoding the 
vesicular stomatitis virus glycoprotein (VSV-G) (Dull et al., 1998) (Figure 6.2D). 
env gene from HIV-1 provides host cell specificity such that HIV-1 only infects 
CD4+ T-cells but VSV-G broadens the tropism of the vector and reduces the 
requirement for HIV-1 accessory proteins for infectivity by directing the vector to an 
endocytic pathway (Dull et al., 1998; Tang et al., 1999). 
 
6.1.4 Choosing a tumour antigen to target 
An important parameter to consider in TCR gene therapy is the desired specificity 
and affinity of the exogenous TCR. Two classes of tumour antigens have been 
described: (i) tumour-specific antigens (TSAs) which are uniquely expressed on 
cancer cells, caused by random mutations or virally-induced (Parmiani et al., 2007) 
and (ii) tumour-associated antigens (TAAs) which are overexpressed in tumour cells 
but also expressed, at a lower level, on healthy cells (Novellino et al., 2005). As 
TSAs are rarely shared between patients, TAAs (such as MART-1 in melanoma) 
have been studied more thoroughly in TCR gene transfer (Kieback and Uckert, 
2010).  
 
6.1.5 Enhanced affinity TCRs  
CD8+ T-cells elicit a strong immune response during viral infections (Miles et al., 
2010; Sigal et al., 1999) but are often less effective against tumours (Delves and 
Roitt, 2000a; Rosenberg et al., 2008; Rosenberg et al., 2004). As cancer cells 
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normally express self proteins (Valitutti et al., 1995; Voskens et al., 2009), thymic 
education probably leads to T-cells presenting a relatively low affinity TCR against 
these tumour-associated antigens (TAAs) (average KD = 90 µM) (Boon et al., 2006; 
Bridgeman et al., 2012; Cole et al., 2007). Importantly, weak TCR binding affinity 
can be associated with a less sensitive/effective T-cell response (Irving et al., 2012; 
Stone et al., 2009), hence one way to increase tumour sensitivity would be to 
increase TCR affinity (Bobisse et al., 2009). TCR affinity can be improved by 
technologies such as phage display (Li et al., 2005b) by increasing TCR/peptide 
contacts (Colf et al., 2007; Sami et al., 2007) and by increasing TCR/MHC contacts 
(Chapter 4 and Chapter 5). Affinity-enhanced TCRs can then be used in TCR gene 
transfer. However, a number of potential problems with enhanced affinity TCR gene 
transfer have been raised. For the sake of completeness these are described below. 
 
6.1.6 Potential problems with TCR gene transfer of enhanced TCRs 
The aim of TCR gene transfer is to produce T-cells that are effective at killing 
tumour without destroying healthy tissue. This technology is still in its infancy and a 
number of potential issues have been raised as detailed in turn below. 
 
6.1.6.1 TCR chain mispairing 
When TCR chains are transferred to a T-cell the resulting cell can then potentially 
express 4 different TCRs: (i) Endogenous α chain paired with endogenous β chain; 
(ii) Transduced α chain paired with transduced β chain; (iii) Endogenous α chain 
paired with transduced β chain; and (iv) Transduced α chain paired with endogenous 
β chain as described in Figure 6.3.   
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Figure 6.3. Schematic representation of αβ TCR mispairing after TCR gene 
transfer. 
After TCR gene transfer, transduced T-cell could express the endogenous αβ TCR (α 
and β chains in red and green, respectively), the exogenous αβ TCR (α and β chains 
in blue and black, respectively) and two types of mispaired αβ TCRs (exogenous α 
chain associated to endogenous β chain or endogenous α chain associated to 
exogenous β chain). 
 
Table 6.1. Strategies to eliminate or limit TCR mispairing. 
Strategy Reference 
Transfer of a fully murine TCR or partially 
“murinized” TCR 
(Cohen et al., 2006; 
Sommermeyer et al., 2006) 
Insertion of the additional ‘Boulter-disulphide’ bond 
between the α and β constant regions as described in 
Chapter 3 
(Boulter et al., 2003; 
Kuball et al., 2007) 
Co-transduction of the TCR α and β chains fused to 
the extracellular, transmembrane and intracellular 
domains of CD3ζ 
(Sebestyen et al., 2008) 
Exchanging an amino acid pair that normally forms a 
“knob-into-hole” motif at the interface between the 
constant regions of the α and β chains to create a 
“hole-into-knob” motif 
(Voss et al., 2008) 
Silencing or down-regulating the expression of the 
endogenous TCR by using small interfering RNA 
(siRNA) 
(Okamoto et al., 2009) 
Knocking-out the endogenous TCR expression by 
using zinc-finger nucleases (ZFNs) 
(Provasi et al., 2012) 
Transducing γδ T-cells with an αβ TCR  
(van der Veken et al., 
2006). 
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Combinations (i) and (ii) have known pMHC specificities but the antigen specificity 
of TCRs produced from combinations (iii) and (iv) above are unknown and thereby 
have potential to target self antigens. Murine studies have suggested that such 
mispairing can be highly problematic (Bendle et al., 2009; Bendle et al., 2010). 
Thankfully, clinical trials to date have not reported off-target toxicity due to 
mispaired TCRs, but their formation occurred regularly in several models after 
transduction of polyclonal T-cells (Govers et al., 2010) so this important issue 
should be taken into consideration. Various strategies can be used to limit or 
eliminate TCR chain mispairing as detailed in Table 6.1. The ‘Boulter-disulphide’ 
method has been the preferred method in this study. 
 
6.1.6.2 Engineered TCRs bypass thymic editing 
Natural TCRs have undergone a thymic selection process that culls T-cells bearing 
TCRs with a high affinity for self as described in Chapter 1 (section 1.3.2). 
Engineered TCRs have not been through this editing process and therefore have the 
potential to recognise self-antigens. Although enhanced affinity TCRs have been 
reported to be highly specific in soluble form (Holler et al., 2003; Irving et al., 2012; 
Li et al., 2005b; Liddy et al., 2012; Purbhoo et al., 2006), these molecules only need 
to bind to a single self pMHC with a KD ~100 µM in order to cause a problem if they 
are transduced into autologous T-cells and then adoptively transferred. Several 
studies have highlighted the potential danger of T-cells expressing the affinity-
enhanced TCRs compared to T-cells expressing the wild-type TCR (Holler et al., 
2003; Robbins et al., 2008; Udyavar et al., 2009; Zhao et al., 2007). Gene-modified 
CD8+ T-cells expressing the wild-type HLA-A2-restricted 1G4 TCR were reported 
to retain specificity for HLA-A2-expressing target cells presenting the cognate 
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peptide NY-ESO-1 (KD = 32 µM) but CD8+ T-cells expressing the high-affinity 
variant (KD = 26 pM) lost antigen specificity (Zhao et al., 2007). However, CD8
+ T-
cells expressing 1G4 TCR variants with enhanced affinities in the intermediate range 
(KD = 4µM and 0.45 µM) demonstrated antigen-specific recognition (Zhao et al., 
2007). Moreover, Robbins et al. defined an upper affinity limit between KD = 0.45 
µM and KD = 0.28 µM for these 1G4 TCR variants allowing gene-modified CD8+ T-
cells to retain cognate peptide specificity (Robbins et al., 2008). Collectively, such 
results suggested that TCRs displaying enhanced affinities within the natural range 
(KD = 0.1-270 µM) should be used for TCR gene transfer in order to maintain T-cell 
antigen specificity. Studies to date also suggest that each system will have its own 
optimal TCR affinity as described below. The optimal affinity and half-life for TCR 
binding can only be determined by rigourous testing. 
 
6.1.6.3 TCRs exhibit an affinity/dwell time optimum for T-cell activation 
Based on the serial triggering and kinetic proofreading models described in Chapter 
1 (section 1.7), it has been suggested that long TCR/pMHC interaction half-life 
might impede optimal TCR triggering and T-cell signalling (Coombs et al., 2002; 
Valitutti et al., 1995). As enhanced affinity TCRs display longer half-life of 
interaction with the pMHC than their wild-type equivalent (Li et al., 2005b), 
transferring modified TCRs displaying very long half-lives might be suboptimal for 
T-cell activation. It has been suggested that a TCR/pMHC interaction might reach an 
“affinity ceiling” above which there is no improvement, or a decrease, in T-cell 
activation. Indeed, the existence of a TCR affinity threshold of T-cell activation has 
recently been demonstrated (Irving et al., 2012; Schmid et al., 2010). In summary 
optimal TCR gene therapy most likely requires the transfer of a TCR with an optimal 
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binding affinity and/or half-life. This affinity may differ between different 
TCR/antigen pairings and can therefore only be determined experimentally. 
 
6.1.7 Aim 
I had access to MART-1-specific TCRs with a range of enhanced affinities. My aim 
was to establish the optimal TCR affinity for targeting melanoma cells by TCR gene 
transfer in this system. 
 
6.2 RESULTS 
6.2.1 Testing of MEL5 TCR transduction in Jurkat cells 
Jurkat J.RT3-T3.5 Gluc cells were transduced with a lentiviral vector containing the 
MEL5 TCR sequence and a rCD2 reporter gene (Figure 6.4). After cloning of the 
MEL5-rCD2 cassette into the lentiviral vector pELNSxv (Figure 6.4), I produced 
the lentivirus and transduced Jurkat TCR negative GLuc cells as described in 
Chapter 2 (sections 2.2 and 2.7). Transduced cells were stained with an anti-rCD2-
PE antibody and a positive (ELA-APC, melanoma antigen) and control (SLY-APC, 
HIV antigen) pMHCI tetramer (Figure 6.5). Staining of the transduced cells with 
anti-CD3-FITC antibodies also indicated TCR expression (Figure 6.5). After 
transduction of the cells, ~85% of the cells expressed CD3 and ~58% expressed 
rCD2, thus showing a high transduction efficiency (Figure 6.5B&D). ~76% of the 
transduced cells stained with the positive ELA-APC tetramer, whereas none were 
stained with the control tetramer (Figure 6.5A&B).  
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Figure 6.4. Schematic representation of the vectors and transgene cassette for 
the production of lentivirus. 
(A & B) Schematic representation of the pMA plasmids generated by GeneArt and 
conferring a resistance to kanamycin. (C) Lenti vector pELNSxv with the MEL5-
rCD2 cassette. (D) Representation of the cassette cloned into pELNSxv lenti vector. 
Restriction sites XbaI and BspEI, SmaI and XhoI, and NsiI and SalI, flanked the 
TCR α chain, TCR β chain and rCD2, respectively. The 2A-like sequences, T2A 
(amino acid sequence EGRGSLLTCGDVEENPGP) and P2A (amino acid sequence 
ATNFSLLKQAGDVEENPGP), mediates the cotranslational cleavage of the TCR α 
chain, the TCR β chain and the rCD2 reporter gene. 
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Figure 6.5. Transduction of Jurkat TCR negative GLuc cells with a lentivirus 
for the expression of rCD2 and MEL5 TCR. 
(A-B) Jurkat J.RT3-T3.5 cells were transduced with a lentivirus driving the 
expression of rCD2 (reporter gene) and MEL5 TCR α and TCR α chains. 
Transduced cells were stained with anti-CD3-FITC antibodies and either (A) SLY-
APC tetramer (control HIV-specific tetramer) or (B) ELA-APC tetramer and 
analysed by FACS. The shift in CD3 expression and in positive tetramer binding 
revealed a high transduction efficiency. (C-D) Comparison of (C) untransduced and 
(D) transduced Jurkat J.RT3-T3.5 cells stained with ELA-APC tetramer and anti-
rCD2-PE antibodies confirmed the high transduction efficiency and the expression of 
both the reporter gene rCD2 and the melanoma specific MEL5 TCR.  
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Interestingly, there was a 9% difference between the CD3 and the MEL5 TCR 
expression suggesting the presence of mispaired TCRs not binding to A2-ELA. 
Indeed, the formation of mispaired TCRs has been observed after transfection of 
Jurkat J.RT3-T3.5 cells with a TCR β chain despite a low level of endogenous TCR 
α chain expression (Alajez et al., 2006). The comparison of untransduced and 
transduced Jurkat stained with HLA-A2-ELA-APC tetramer and anti-rCD2-PE 
confirmed the specific staining of MEL5 (Figure 6.5C&D). Untransduced Jurkat did 
not stain with anti-rCD2-PE, whereas ~58% of the transduced Jurkat were rCD2+ 
(Figure 6.5C&D). The lower percentage of rCD2+ staining compared to CD3+ and 
MEL5+ was curious but was thought to be a staining artefact. Staining with different 
anti-rCD2-PE antibody clones from AbD Serotec and BD Biosciences revealed a 
rCD2+ population equivalent to that of CD3+.  
 
6.2.2 Transduction of primary HLA A2
+
 CD8
+
 T-cells with MEL5 TCR  
In order to verify the expression of a fully functional MEL5 TCR after transduction 
of primary T-cells with a lentivirus, primary CD8+ T-cells were obtained from an 
HLA A*0201+ healthy blood donor as described in Chapter 2 (section 2.7.3.1). 
CD8+ T-cells were magnetically sorted from PBMCs after incubation with anti-CD8 
microbeads. Staining of the sorted population with anti-CD8-FITC antibodies 
confirmed that cells were 100% CD8+ (Figure 6.6A). Staining with anti-rCD2-PE 
showed that only ~32% of the population was rCD2+ (Figure 6.6B) highlighting a 
lower transduction efficiency compared with Jurkat J.RT3-T3.5 GLuc cells (~58%) 
(Figure 6.5D).  
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Figure 6.6. Transduction of primary HLA A2
+
 CD8
+
 T-cells with a lentivirus for 
the expression of rCD2 and MEL5 TCR  
(A) Magnetically sorted primary HLA A2+ CD8+ T-cells are 100% CD8+ (B) After 
transduction, ~32% of CD8+ T-cells were rCD2+. (C-D) Transduced T-cells were 
magnetically sorted using anti-rCD2 antibodies and the sorted population was 100% 
rCD2+ with (C) no non-specific binding to the HIV-specific tetramer SLY-APC and 
(D) ~32% of sorted T-cells expressing MEL5 TCR. (E-F) Transduced T-cells were 
sorted a second time using ELA tetramers. (E) The sorted population did not bind 
SLY-APC tetramer. (F) ~96% of the MEL5+ CD8+ T-cells stained with ELA-APC 
tetramer confirming that the vast majority of the cells had the required specificity. 
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In order to test the effector functions of the transduced CD8+ T-cells, a pure 
population expressing MEL5 TCR was required. MEL5 transduced CD8+ T-cells 
were first magnetically sorted with anti-rCD2 antibodies (Figure 6.6C&D). Staining 
with anti-rCD2-PE antibodies showed a population 100% rCD2+. Transduced rCD2+ 
cells did not stain with SLY-APC tetramer (Figure 6.6C). However, ~32% of the 
rCD2-sorted cells stained with ELA-APC (Figure 6.6D). A second sorting step was 
required to obtain a pure population of CD8+ MEL5+ transduced T-cells. This was 
done with ELA tetramer sorting as described in Chapter 2 (section 2.7.3.2) and led 
to ~96% of the transduced T-cells binding to the ELA-APC tetramer (Figure 
6.6E&F). 
 
To determine if the transduced T-cells retained their effector functions, I performed a 
MIP1β activation assay (peptide titration) (Figure 6.7A-C) and a cytotoxicity assay 
(51Cr release assay) (Figure 6.7D-F). MIP1β activation assay of the MEL13 clone 
(expressing MEL5 TCR) with the heteroclitic melanoma decameric peptide antigen 
ELAGIGILTV (ELA) was described previously (Ekeruche-Makinde et al., 2012) 
and was duplicated here as a positive control (Figure 6.7A). First, the untransduced 
cell line was not activated by ELA as there was no production of MIP1β (Figure 
6.7B). ELA activated both MEL13 clone (Figure 6.7A) and the transduced cell line 
with similar sensitivity (Figure 6.7C) with MIP1β production starting when target 
cells were pulsed with ELA at 10-11 M. Maximal MIP1β production was observed 
with concentrations of 10-8 M peptide and higher.   
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Figure 6.7. MEL5 TCR transduced primary T-cells recognise HLA A2
+
 targets 
pulsed with cognate peptide and natural levels of antigen presented on the 
surface of melanoma cells. 
(A-C) 3 x 104 (A) MEL13 clone, (B) untransduced A2+ CD8+ T-cells and (C) MEL5 
transduced A2+ CD8+ T-cells were incubated for 2 hours with 6 x 104 A2 C1R pre-
pulsed with various concentrations of ELA. Supernatants were harvested and 
assayed for MIP1β by ELISA. (D-F) 2 x 103 A2 C1R, A2 C1R pulsed with ELA 
(100 µM final concentration), Mel526 and Mel624 target cells labelled with 51Cr 
were incubated for 4 hours with different concentrations of (D) MEL13 clone, (E) 
untransduced A2+ CD8+ T-cells and (F) MEL5 transduced A2+ CD8+ T-cells 
(effector to target ratio, E:T). Supernatants were harvested and assayed for 51Cr 
release in order to obtain the % of specific lysis. 
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MEL5 transduced, but not untransduced, T-cell lines recognised two A2+ melanoma 
cell lines (Mel526 and Mel624) (Figure 6.7D-F). Importantly, this confirms that 
these cells are able to recognise natural surface densities of the natural antigen(s). 
 
6.2.3 Peptide specificity of HLA A2
+
 CD8
+
 T-cells transduced with MEL5 
TCR  
In order to further investigate the specificity of the MEL5 transduced A2+ CD8+ T-
cells, I performed a PS-CPL activation assay. I compared the output with the PS-
CPL activation assay previously described for the MEL13 clone that was derived 
from the same CTL line as MEL5 at the same time and which expresses an identical 
TCR to MEL5 at the nucleotide level (i.e. this clone is MEL5) (Ekeruche-Makinde et 
al., 2012) (Figure 6.8-6.10).  
 
Briefly, MEL13 PS-CPL activation assay showed that several different residues at 
each position of the peptide can be recognized and some of these residues displayed 
markedly different biochemical properties compared to the corresponding residues in 
the index peptide ELA (Figure 6.8 and Figure 6.10). For example, the PheP1 residue 
of the decapeptide library screen induced the maximal T-cell activation for position 1 
and differs from the native GluP1 residue by possessing an aromatic side chain and 
by being strongly apolar. The recognition requirements appeared to be stringent at 
positions 4, 5, 6 and 7 which is the peptide region mainly contacted by MEL5 TCR 
(Cole et al., 2009) and less stringent at positions 1, 2, 3, 8, 9 and 10 (Ekeruche-
Makinde et al., 2012).  
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Figure 6.8. Decameric peptide PS-CPL activation assay of the MEL13 clone. 
MEL13 cells were stimulated for 2 hours with A2 C1R cells pulsed in duplicate with 
the index peptide or each of the 200 mixtures from the decameric peptide library as 
described in Chapter 2 section 2.10.2. Responses to peptides were quantified in a 
MIP1β ELISA using cell supernatant, stimulation with the index peptide 
representing the maximum MIP1β concentration. Responses are displayed as a 
cluster of 10 histograms plots, each plot representing a set of 20 mixtures having the 
defined residues listed on the x-axis at position (A) P1, (B) P2, (C) P3, (D) P4, (E) 
P5, (F) P6, (G) P7, (H) P8, (I) P9 and (J) P10. The red bars represent the mixture 
with a fixed amino acid that corresponds to the MEL13 index peptide 
(ELAGIGILTV). Adapted from (Ekeruche-Makinde et al., 2012). 
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Figure 6.9. Decameric peptide PS-CPL activation assay of the MEL5 
transduced A2
+
 CD8
+
 T-cells. 
MEL5 transduced A2+ CD8+ T-cells were stimulated for 2 hours with A2 C1R cells 
pulsed in duplicate with the index peptide or each of the 200 mixtures from the 
decameric peptide library as described in Chapter 2 section 2.10.2. Responses to 
peptides were quantified in a MIP1β ELISA using cell supernatant, stimulation with 
the index peptide representing the maximum MIP1β concentration. Responses are 
displayed as a cluster of 10 histograms plots, each plot representing a set of 20 
mixtures having the defined residues listed on the x-axis at position (A) P1, (B) P2, 
(C) P3, (D) P4, (E) P5, (F) P6, (G) P7, (H) P8, (I) P9 and (J) P10. The red bars 
represent the mixture with a fixed amino acid that corresponds to the MEL5 index 
peptide (ELAGIGILTV). 
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Figure 6.10. Box plot summary of the PS-CPL activation assays for MEL13 
clone and MEL5 transduced A2
+
 CD8
+
 T-cells. 
Mixture reactivity is represented by the one-letter nomenclature of the fixed residue 
within the mixture. The colours and size of the letters correspond to the magnitude of 
responses observed in the screen and range from black to red with red representing 
the highest response for (A) MEL13 clone and (B) MEL5 transduced A2+ CD8+ T-
cells. (A) adapted from (Ekeruche-Makinde et al., 2012). 
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The recognition profiles of the MEL13 monoclonal T-cell expressing the MEL5 
TCR and MEL5 transduced CD8+ T-cells were similar although the transduced cells 
were a little less responsive (Figure 6.9 and Figure 6.10). These results do not 
indicate any systemic difference in peptide specificity due to TCR chain mispairing 
at the population level. 
 
Having established that the MEL5 transduction system worked and that transduced 
cells acquired the desired peptide specificity and ability to recognise melanoma 
targets, I next moved to compare different affinity-modified MEL5 TCR variants. 
 
6.2.4 Transduction of Jurkat TCR negative GLuc with a panel of affinity-
enhanced TCRs 
In order to determine the optimal melanoma-specific TCR affinity for maximum T-
cell activation, Jurkat J.RT3-T3.5 GLuc cells were transduced with a lentivirus 
driving the expression of rCD2 (reporter gene) and one of the six MEL5 TCR 
mutants obtained by affinity maturation of MEL5 as described in Chapter 1 (Li et 
al., 2005b). These variants were composed of the MEL5 α chain and a mutated 
version of the MEL5 β chain (Appendix 12 and Table 6.2). The six variants (MEL5 
β5, MEL5 β9, MEL5 β12, MEL5 β13, MEL5 β15 and MEL5 β17) had mutated 
CDR3β loops, MEL5 β15 and MEL5 β17 having additional mutations in the CDR2β 
loop as well as in the β chain between CDR1β and CDR2β (Appendix 12). In 
previous experiments, my laboratory measured the kinetic parameters and the 
affinity of these TCR mutants for A2-ELA binding by SPR (Table 6.2).  
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Table 6.2. MEL5 and MEL5 variants binding analysis toward A2-ELA. 
TCR KD (µM) 
Enhanced MEL5 
affinity 
kon (M
-1s-1) koff (s
-1) 
MEL5 16-20  n/m n/m 
MEL5 β5 29  1.3 x 104 3.9 x 10-1 
MEL5 β9 11 ~2.5 2.4 x 104 2.5 x 10-1 
MEL5 β12 4.4 ~6 3.1 x 104 1.4 x 10-1 
MEL5 β13 2.1 ~12 8 x 104 1.7 x 10-1 
MEL5 β15 2.1 ~12 2.5 x 105 5.2 x 10-1 
MEL5 β17 0.54 ~48 4.6 x 104 2.5 x 10-2 
n/m: non measurable 
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These variants displayed a range of affinities toward ELA from no enhancement 
(MEL5 β5) compared to the wild-type MEL5 to 48 times enhanced (MEL5 β17). 
Even at 48 times enhanced, this affinity was within the physiological range observed 
for the TCR/pMHC interaction (KD = 0.1-270 µM) (Bridgeman et al., 2012; van der 
Merwe and Davis, 2003). The kinetic parameters for MEL5 were too fast to be 
measured but were obtained for the mutants. The binding enhancements were due to 
a combination of a slower off-rate and/or a faster on-rate. Interestingly, MEL5 β13 
and MEL5 β15 displayed the same affinity but possessed different kinetic 
parameters, MELβ15 having a faster on-rate than MEL β13 but the latter having a 
slower off-rate.  
 
In order to transduce Jurkat J.RT3-T3.5 GLuc cells with these variants, I first cloned 
the different TCR-rCD2 cassettes into the lentiviral vector and produced the 
lentiviruses as described in Chapter 2 (sections 2.2 and 2.7). After transduction, 
cells were stained with anti-CD3-FITC and anti-rCD2-PE antibodies and analysed 
by FACS (Figure 6.11). Despite a high transduction efficiency, some variability was 
observed regarding the rCD2 and the CD3 expression between the transduced cell 
lines. As observed above, in all cell lines CD3 expression was superior to rCD2 
expression (section 6.2.1) but CD3 expression varied from ~52% to ~80% and rCD2 
expression varied from ~25% to ~48%. Therefore, transduced cells were 
magnetically sorted with anti-CD3 antibodies in order to obtain a pure population for 
the activation assay. After sorting, the six transduced cell lines were 100% CD3+ 
rCD2+ (Appendix 13).  
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Figure 6.11. Transduction of Jurkat J.RT3-T3.5 GLuc cells with a lentivirus for 
the expression of six MEL5 TCR mutants. 
Jurkat J.RT3-T3.5 GLuc cells were transduced with a lentivirus driving the 
expression of rCD2 (reporter gene) and MEL5 mutants (A) β5, (B) β9, (C) β12, (D) 
β13, (E) β15 and (F) β17. Transduced cells were stained with anti-CD3-FITC and 
anti-rCD2-PE antibodies and analysed by FACS. 
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6.2.5 Jurkat TCR negative GLuc cells transduced with enhanced affinity 
melanoma-specific TCRs reveal an unexpected glycosylation site 
To determine the optimal melanoma-specific TCR affinity for maximum T-cell 
activation I used an activation assay based on the ability of the transduced and 
untransduced Jurkat J.RT3-T3.5 GLuc cells to express Gaussia Luciferase when 
activated. T-cell activation measurements were performed either after addition of 
phytohaemagglutinin (PHA) or after exposure to target cells (pulsed and unpulsed 
with ELA) (Figure 6.12). MEL5 β13 transduced cells failed to respond to pulsed A2 
C1R. A subsequent analysis of the β13 sequence (Appendix 12) revealed the 
presence of one N-linked glycosylation site in the mutated CDR3β sequence 
(tripeptide sequence Asn-(Val)-Ser). Due to the very rare occurrence of post-
translational modifications such as glycosylation in E. coli (Benz and Schmidt, 2001; 
Lindenthal and Elsinghorst, 1999; Sherlock et al., 2006), the glycosylation site was 
undetected during affinity maturation by phage display. However, TCRs undergo 
post-translational modifications before expression at the cell surface (Amon et al., 
2006). Therefore, MEL5 β13 was unable to bind to A2-ELA because the 
glycosylated residue in the CDR3β loop probably blocked the interaction with the 
pMHC. I was therefore unable to perform further experiments with MEL5 β13 
transductants.  
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Figure 6.12. Threshold of melanoma-specific TCR affinity for maximum T-cell 
activation. 
1 x 105 untransduced (UNTR), MEL5, MEL5 β5, MEL5 β9, MEL5 β12, MEL5 β13, 
MEL5 β15 and MEL5 β17 transduced Jurkat J.RT3-T3.5 GLuc cells were activated 
with PHA or incubated for 5 hours with 1 x 105 A2 C1R cells pre-pulsed with ELA. 
Supernatants were harvested and assayed for Gaussia luciferase expression. Jurkat 
activation is represented by the ratio between the luciferase activity when incubated 
with target cells and when activated by PHA. The luciferase activity ratio of each 
variant is displayed above the bar. 
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6.2.6 An affinity optimum for T-cell activation in the MEL5 system 
Untransduced Jurkat cells failed to recognize A2 C1R cells pulsed with ELA 
peptide. Recognition of cognate target cells gradually increased until the TCR 
affinity reached ~6 times the MEL5 TCR affinity (MEL5 β12 KD ~4.4 µM), leading 
to ~15-fold stronger signal compared with MEL5 transduced cells (Figure 6.12). 
Beyond this threshold T-cell activation decreased (Figure 6.12). These results show 
that there is an optimal TCR affinity for the recognition of target cells by T-cells 
transduced with the MEL5 TCR. This optimum is ~6-fold higher than the wildtype 
interaction suggesting that use of enhanced affinity TCRs in the clinic might be 
beneficial. Enhancing TCR affinity beyond this level was detrimental to T-cell 
activation. This result is in accordance with other recent data from other laboratories 
(Irving et al., 2012; Schmid et al., 2010; Stone et al., 2009). 
 
6.3  DISCUSSION 
In the study reported here, I aimed to analyze the specificity of T-cells transduced 
with the melanoma-specific MEL5 TCR and to determine the optimal TCR affinity 
for TCR gene transfer targeting of melanoma using the MEL5 system. I tested a 
panel of affinity-enhanced TCRs derived from the melanoma-specific MEL5 TCR.  
 
I first transduced an in-house modified Jurkat J.RT3-T3.5 cell clone (J.RT3-T3.5 
GLuc) with a lentiviral vector containing MEL5 TCR sequences in order to verify 
that transfer of MEL5 TCR genes produced T-cells with desired specificity. 
Tetramer staining of the transduced cells showed that MEL5 TCR was expressed on 
the cell surface (staining with ELA-APC) and that the transduced cells were 
melanoma-specific (no staining with SLY-APC presenting an HIV derived peptide). 
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Moreover, as observed in other TCR gene transfer studies using Jurkat cells (Provasi 
et al., 2012; Thomas et al., 2011), transduction was efficient as ~76% of the 
transduced cells were stained with the ELA-APC tetramer. However, the difference 
between CD3 and MEL5 TCR expression suggested that either the TCR density on 
some cells was too low for staining with pMHC tetramer (Wooldridge et al., 2009) 
or that there might be a small fraction of mixed TCRs on the cell surface that did not 
bind to the tetramer  (Alajez et al., 2006). 
 
I next transduced the HLA-A2-restricted MEL5 TCR into primary A2+ CD8+ T-cells 
as this situation is analogous to what is done in TCR gene transfer therapy. This 
allowed me to analyse the effector functions and antigen specificity of gene-
modified T-cells in comparison to the parent CD8+ T-cell clone (MEL5 and MEL13 
are identical). The transduction efficiency was lower for CD8+ T-cells than Jurkat 
cells J.RT3-T3.5 GLuc, a result consistent with other studies using retroviral and 
lentiviral vectors (Provasi et al., 2012; Thomas et al., 2011). Moreover, the MEL5 
TCR expression level was relatively low after transduction as measured by tetramer 
staining. This might suggest that some of the MEL5 TCR chains might be mispaired 
with endogenous TCR chains. Recent studies have introduced the concept of 
“strong” and “weak” TCRs when it comes to their ability to pair correctly and 
compete with the endogenous TCR for expression at the T-cell surface (Kieback and 
Uckert, 2010; Sommermeyer et al., 2006). The terms “strong” and “weak” are 
ambiguous when it comes to TCRs. My laboratory therefore prefers the terms 
“competitive” and “uncompetitive” to describe how well individual TCRs express at 
the T-cell surface. This factor is thought to represent the ability of TCR chains to 
pair with each other and then compete for a limited quantity of other molecules 
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required for surface expression of TCR protein. The availability of CD3 (particularly 
CD3ζ chain) is thought to be key to the total amount of TCR expressed at the T-cell 
surface (Koning et al., 1990; Manolios et al., 1994; Minami et al., 1987). 
Competitive (or strong) TCRs appear to pair well with each other and outcompete 
most endogenous TCRs for CD3 components so as to be expressed at the cell surface 
at high density. Conversely, uncompetitive (or weak) TCRs fail to compete well with 
endogenous TCRs and transduction of cells with such TCRs results in poor 
expression of the transduced TCR at the T-cell surface and poor responsiveness to 
the cognate antigen for the transduced TCR. Experiments performed by Dr John 
Bridgeman in my laboratory suggested that MEL5 TCR can be defined as an 
“average” TCR for cell surface expression. This factor may therefore explain the low 
expression of MEL5 TCR in some cells. Also, staining with pMHC multimer 
requires that a second pMHC within a single pMHC multimer molecule binds to a 
TCR during the dwell time of the first TCR/pMHC interaction in order for the 
“avidity effect” to come into play and capture the multimer from solution 
(Wooldridge et al., 2009). TCR density is a critical factor in whether a second TCR 
is available for capture of pMHC multimer from solution and T-cells that express 
low surface density of a cognate natural affinity TCR are unable to stain with pMHC 
tetramer (Wooldridge et al., 2009). 
 
MEL5 transduced CD8+ T-cells were analysed for two effector functions: MIP1β 
production and cytotoxicity towards target cells. The MIP1β activation assay showed 
that the gene-modified T-cells were as sensitive as the MEL13 clone. Moreover, the 
cytotoxicity assay showed that, as for MEL13 clone, the transduced cell line was 
able to lyse HLA-A2+ target cells pulsed with ELA as well as two HLA-A2+ 
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melanoma cell lines (Mel526 and Mel624) (Topalian et al., 1990; Topalian et al., 
1989). Collectively, these assays showed that the MEL5 transduced CD8+ T-cell line 
was fully functional and that the gene-modified T-cells acquired an anti-melanoma 
specificity. Some background activation was detected. This is believed to be due to 
the high sensitivity of the MIP1β assay compared to the cytotoxicity assay sensitivity 
(Laugel et al., 2007; Price et al., 1998). 
 
The precise specificity of MEL5 transduced CD8+ T-cells was probed using 
positional scanning combinatorial peptide library (PS-CPL) screen. PS-CPLs, 
coupled to a mathematical analysis, can determine the cross-reactivity profile of a T-
cell clone (e.g. 1E6) (Wooldridge et al., 2012). These data can then be used to design 
optimal peptide sequences that enhance functional activation of a T-cell clone (e.g. 
MEL13) (Ekeruche-Makinde et al., 2012). Comparison of the MEL13 clone PS-CPL 
assay (Ekeruche-Makinde et al., 2012) with the MEL5 transduced CD8+ T-cells PS-
CPL assay revealed an identical specificity profile despite the potential for 
expression of endogenous TCRs and transduced/endogenous mixed chain paired 
TCRs. These experiments showed that there was no dominant, systemic change in 
TCR specificity of MEL5 transduced CD8+ T-cells although it remains possible that 
individual cells in the population expressed different TCRs and exhibited a different 
peptide-specificity profile. Such events would be in vast numeric minority and 
would therefore not be visible at the population level. 
 
Having demonstrated that T-cells retained their effector functions and displayed 
melanoma specificity after transduction with a lentiviral vector containing MEL5 
TCR sequences, I then aimed to determine the optimal TCR affinity for maximal T-
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cell activation. J.RT3-T3.5 GLuc cells were transduced with different lentiviral 
vectors expressing a panel of affinity-enhanced, melanoma-specific TCRs. T-cell 
activation was measured after recognition of HLA-A2 C1R pulsed with ELA 
peptide. We had failed to anticipate that phage display in E. coli might introduce 
mutations that would interfere with protein folding or post-translational 
modifications in eukaryotic cells. The MEL5 β13 TCR failed to recognise antigen. 
Closer inspection of the modified TCR sequence revealed that the phage display 
process had introduced an N-linked glycosylation site (tripeptide sequence Asn-
(Val)-Ser) in the CDR3β sequence of this TCR. In future, sequences generated by 
phage display should be systematically analysed for the occurrence of glycosylation 
sites and other motifs that might interfere with protein expression or function prior to 
expression in T-cells. I was unable to examine the MEL5 β13 TCR in activation 
assays. Thankfully, the other TCRs expressed well and I was able to analyse how 
cells expressing these TCRs responded to cognate antigen.  
 
Jurkat activation assays revealed a “bell shape” curve of T-cell activation depending 
on TCR affinity. Maximal T-cell activation was achieved when T-cells expressed a 
TCR (MEL5 β12) with a KD ~4.4 µM (~6-fold enhancement compared to MEL5 
TCR affinity). This optimal affinity is close to pathogen-specific TCR affinities 
(average KD ~8 µM) (Bridgeman et al., 2012; Cole et al., 2007), possibly explaining 
the better T-cell activation. The “bell shape” curve strongly supports the existence of 
an “affinity ceiling” above which T-cells become less effective (Irving et al., 2012; 
Schmid et al., 2010; Sewell, 2002). Thus, tumour-specific TCRs may only need 
modest affinity enhancement for optimal results in for TCR gene therapy.  
 
255 
 
Collectively, the results of this study suggested that MEL5 TCR gene transfer can 
lead to a rapid generation of fully functional and highly specific T-cells for targeting 
melanoma in TCR gene therapy. TCR affinity can be optimized to improve T-cell 
activation but a TCR “affinity ceiling” exists that seems to be within the range for 
natural TCR affinities (KD = 0.1-270 µM) (Bridgeman et al., 2012; Cole et al., 2007; 
Schmid et al., 2010).  
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The work outlined in my thesis aimed to investigate the structural and biophysical 
features of TCR/pMHCI interactions as well as explore the potential use of affinity-
matured TCRs for gene therapy. Specifically, I aimed to: 
 
1. Develop an optimized screen for the crystallization of TCR/pMHC 
complexes (Chapter 3) 
2. Analyse the specificity of a high-affinity TCR directed against a melanoma 
antigen (Chapter 4) 
3. Investigate the structural and biophysical differences between TCRs with 
different affinities in the recognition of melanoma antigens (Chapter 5) 
4. Determine the optimal TCR affinity for adoptive cell therapy directed against 
melanoma (Chapter 6) 
 
7.1 IMPLICATIONS OF MY RESULTS 
7.1.1 	ew crystallization screening improves study of TCR/pMHC recognition 
X-ray crystallography has revolutionised our understanding of the molecular events 
that govern TCR/pMHC recognition (Armstrong et al., 2008b; Rudolph et al., 2006). 
However, the relatively small number of TCR/pMHC structures (<25 unique human 
TCR/pMHC complexes in total and just 6 unique TCR/pMHCII complexes) 
(Broughton et al., 2012; Deng et al., 2007; Rudolph et al., 2006), has hampered the 
determination of an accepted set of rules that describe the generalities of T-cell 
specificity. Indeed, there are now several TCRs that fail to obey any of the original 
“rules of engagement” that were based on just the first 6 interactions described (Gras 
et al., 2012) and there is a pressing need for further structures to advance our 
understanding of what is possible. 
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A major obstacle in using X-ray crystallography to study T-cell antigen recognition 
has been finding an optimal set of crystallization conditions to produce high quality 
TCR/pMHC crystals that diffract well and the crystallization step is generally 
considered to be the limiting factor in structural studies of proteins (Segelke, 2001). 
As a given condition contains multiple parameters (e.g. type of buffer, temperature, 
pH, salt), there is an almost limitless number of crystallization conditions. Over 1500 
conditions are commercially available alone (McCoy, 2009). Testing a wide range of 
crystallization conditions is time consuming and requires the production of a large 
amount of protein. Therefore, the generation of a screen containing the optimal 
conditions for the crystallization TCRs, pMHCs and complexes was important to 
enable a more directed approach to the crystallization of these proteins. In Chapter 
3, I report the development of a new 96-well “sparse matrix” crystallization screen 
designed specifically for the generation of TCR/pMHC complex structures (TOPS). 
The “sparse matrix” screening method, such as TOPS or most of the commercially 
available screens (Wooh et al., 2003), involves screening conditions based on 
previous successful crystallization experiments (Jancarik and Kim, 1991). However, 
sparse matrix screens have an intentional bias towards combinations of conditions 
that have worked previously. The wide use of such screens continually further biases 
the set of conditions used for screening. This focussing can have a deleterious effect 
on the development of further matrix screens (McCoy, 2009). Indeed, such a bias 
was observed in the last section of Chapter 3 where some complexes crystallized in 
the low range of the scoring system. Thus, although it is tempting to limit the 
number of conditions in a protein crystal screen to improve efficiency and reduce 
protein consumption, broader screens are required to ensure that crystallization 
conditions are not missed. Nonetheless, the screening I perfected used a relatively 
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low number of conditions and resulted in the generation of a high number of human 
TCR/pMHC structures. The resultant TOPS screen has already produced 21 
TCR/pMHC, 3 TCR and 8 pMHCI structures. Notably, the use of TOPS has 
furthered our knowledge of TCR cross-reactivity to different pMHCIIs (Holland et 
al., 2012). Only 6 TCR/pMHCII structures have been described to date. It is 
important that this very limited database is expanded and my TOPS screen has 
already helped in this respect. Analysis of successful crystallisation conditions used 
by other groups show that the Class II MHC molecule HLA-DR1 presenting the 
phosphopeptide MART-1100-114 was crystallized in 20% PEG 8000 and 0.1 M 
sodium cacodylate pH 6.5 (Li et al., 2010), corresponding to TOPS conditions B5 or 
B11. Recently, the non-classical MHC-related molecule 1 (MR1) presenting a 
vitamin B9 metabolite (6-formylpterin) was crystallized in 25% PEG 3350, 0.2 M 
salt and 0.1 M HEPES pH 7.5 (Kjer-Nielsen et al., 2012), an equivalent of TOPS 
condition E9. The KK50.4 TCR complexed to the MHC class Ib molecule HLA-E 
presenting a UL40 peptide of the human cytomegalovirus (CMV) was crystallized in 
18-22% PEG 3350 and 0.2 M potassium iodide pH 6.4-7.4 (Hoare et al., 2006), a 
condition extremely close to some of the conditions contained in TOPS1. A human 
NKT TCR (NKT15) complexed to the human CD1d presenting the glycolipid α-
galactosylceramide (α-GalCer) was crystallised in 13% PEG 10000, 0.1M bis-tris 
propane pH 8.5 and 0.2 M tri-sodium citrate (Borg et al., 2007), a condition close to 
TOPS H10. Hence, TOPS is, by far, the best screen for the crystallization of 
TCR/pMHCI complexes described to date and it has already saved our laboratory 
several grams of protein. This screen could also prove to be really useful for other T-
cell-associated proteins or non classical T-cell protein targets as indicated by the 
successes described above. Finally, the use of TOPS and the determination of 
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immune-protein structures might lead to a better understanding of different 
pathologies as suggested by our recently published study on the autoimmune type 1 
diabetes (Bulek et al., 2012a) or by the studies reported here on melanoma. Relevant 
TCR/pMHC structures could also be useful for the development of T-cell based 
therapies, vaccines or soluble TCR therapy. Indeed, our collaborators have now 
made a high affinity variant of the 1E6 insulin-specific TCR (Immunocore, 
unpublished data). Initial attempts to obtain such a reagent failed. Our recent crystal 
structure of this TCR (Bulek et al., 2012a) allowed intelligent design of 
modifications to help the phage display process that would not have been possible 
without knowing how, and which, CDR loops engage the peptide component of the 
bipartite HLA A2-insulin peptide ligand.  
 
7.1.2 Enhanced MHC contacts mediate TCR high affinity without loss of 
specificity 
I used TOPS to crystallize and solve 9 T-cell-associated melanoma-related protein 
structures (7 TCR/pMHCI complexes, 1 free TCR and 1 free pMHCI) as described 
in Chapter 4 and Chapter 5. I also performed an in-depth thermodynamic analysis 
of melanoma antigen recognition by a wild-type and an enhanced affinity melanoma-
specific TCR. Altogether, my data revealed that TCR affinity could be enhanced, 
without losing peptide specificity. Surprisingly, specificity was maintained even 
when the vast majority of new bonds were made with the restricting MHC molecule 
rather than with the peptide. These results do not support the suggestion that 
improved CDR3 loop/peptide contacts is a general structural feature of high-affinity 
TCRs that retain peptide specificity (Colf et al., 2007; Sami et al., 2007). This 
unanticipated and interesting observation begged further exploration in order to 
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understand the mechanism that allowed the unexpected maintenance of peptide 
specificity. 
 
7.1.3 A novel thermodynamic mechanism mediates high-affinity TCR 
specificity 
The exquisite peptide specificity we observed for α24β17 TCR (Chapter 4) could 
not be explained by the final structure of the complexes or by movements in pMHC 
required to accommodate TCR binding. We therefore examined the thermodynamics 
of binding and discovered a surprising result, that specificity can be mediated by 
changes in solvent interactions between the TCR and the pMHC occurring through a 
knock-on effect in modifications to the peptide sequence. Unfortunately, it was not 
possible to witness these altered interactions in real-time as no technique exists for 
visualising such rearrangements. 
 
My results are consistent with a model for T-cell antigen recognition in which 
TCR/peptide scanning permits TCR/MHC engagement (Borg et al., 2005; Rudolph 
et al., 2006; Tynan et al., 2005; Tynan et al., 2007). As such my results fail to 
support the current “two-step model” postulating that the germline-encoded elements 
of the TCR and pMHC engage prior to peptide scanning by the hypervariable CDR3-
loops (Wu et al., 2002).  
 
7.1.4 A new molecular mechanism of TCR/pMHC recognition 
The first clinical studies of genetically modified autologous PBLs expressing 
MART-1 specific TCRs (DMF4 or DMF5) adoptively transferred into melanoma 
patients (Johnson et al., 2009; Morgan et al., 2006) have established that TCR gene 
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therapy is achievable and safe in a clinical setting. However, the low response rates 
for objective cancer regression of 13% (Morgan et al., 2006) and 30% (Johnson et 
al., 2009) suggest that there is room for significant improvement of the technique. 
 
Structures of the DMF4 and the DMF5 TCRs complexed with the heteroclitic 
MART-1 decamer (ELAGIGILTV) and the natural MART-1 nonamer 
(AAGIGILTV) presented by HLA-A2 have been recently solved (Borbulevych et al., 
2011). Borbulevych et al. observed that, upon A2-AAG recognition, both TCRs 
induced a peptide conformational change so that the nonamer mimicked the 
heteroclitic decamer, a mechanism first described as “peptide induced-fit molecular 
mimicry” by Macdonald et al. (Macdonald et al., 2009). However, the molecular 
mimicry was imperfect due to the additional glutamic acid in the decamer and the 
difference in the peptide anchor positions (P2Leu for ELA and P2Ala for AAG) 
(Borbulevych et al., 2011). Here, I reported a novel peptide anchor residue switch 
from P2Ala to P1Ala upon MEL5 TCR ligation of A2-AAG. This “molecular switch” 
led to a nearly identical bulged ELA, EAA and AAG peptide conformation. The 
anchor position switch explains the ability of MEL5 to bind to A2-AAG with a 
higher affinity compared to all other published melanoma specific TCRs including 
Mel187.c5, DMF4 and DMF5 (Borbulevych et al., 2011; Ekeruche-Makinde et al., 
2012; Insaidoo et al., 2011). The AAG nonamer peptide is believed to be the 
dominant species at the melanoma surface (Skipper et al., 1999). Thus, the low 
response rates observed in the clinical trials might be due to poor recognition of the 
AAG nonamer. MEL5 T-cells are effective at recognising the AAG peptide and in 
lysing melanoma cells. I therefore conclude that use of a MEL5-like TCR would be 
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likely to result in a higher clinical response rate than observed with either DMF4 or 
DMF5 TCRs. 
 
7.1.5 Heteroclitic peptides can alter T-cell antigen specificity due to changes at 
the atomic level 
The identification of the tumour-associated antigens (TAAs) (van der Bruggen et al., 
1991) suggested that therapeutic vaccination to target these antigens might be an 
effective treatment for cancer. Unfortunately, the early optimism about this approach 
has not been realised. The majority of tumour antigens are derived from self-proteins 
and T-cells with high affinity TCRs against such antigens are likely to be culled 
during thymic selection.  
 
In order to break tolerance, development of melanoma vaccines in the HLA-A2-
restricted MART-1 system has focused on heteroclitic antigens that have been 
optimized for HLA-A2 binding (Sliz et al., 2001; Valmori et al., 1998). Such 
peptides are likely to be presented at a substantially higher surface density compared 
to the natural antigens with a poor N-terminal anchor for HLA-A2. This increased 
density is likely to have greater potential for T-cell stimulation and the breaking of 
peripheral tolerance mechanisms. Indeed, the heteroclitic ELA version of the 
MART-1 antigen primes the biggest population of T-cells seen to date in HLA-A2+ 
humans and this system has become the model of choice for the study of human T-
cell priming (Challier et al., 2012; Dutoit et al., 2002; Valmori et al., 1998). 
However, my laboratory recently described how TCRs can distinguish between the 
heteroclitic decamer peptide ELA and the natural progenitor EAA (Cole et al., 
2010). These results suggest that the HLA-A2-ELA must be viewed as a non-self 
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structure - in part explaining why T-cell responses against this supposedly ‘self’ 
antigen can be so strong. To date, the structural difference between HLA-A2-EAA 
and HLA-A2-ELA has only been inferred from differences in TCR binding to these 
to molecules. I aimed to see this difference by solving the structure of the 
MEL5/HLA-A2-EAA structure. Comparison of this structure to the previously 
solved MEL5/HLA-A2-ELA structure showed the improved anchoring provided by 
position LeuP2 reduced peptide flexibility and altered the bonding with MEL5 TCR 
compared to the AlaP2 natural peptide. Collectively, the results reported here suggest 
that the failure of the vaccination trials using the heteroclitic ELA was due to the 
primed T-cells being unable to recognize the flexible EAA and AAG natural MART-
1 antigens. The use of anchor–modified heteroclitic peptides for vaccination thus 
requires further re-evaluation (Cole et al., 2010; Ekeruche-Makinde et al., 2012; 
Speiser et al., 2008). Nevertheless, a recent study from my laboratory demonstrated 
that it is possible to design altered peptide antigens for the selection of T-cell 
clonotypes with enhanced specific antigen recognition by using an approach termed 
TOPSORT (“TCR-optimized peptide skewing of the repertoire of T-cells”) 
(Ekeruche-Makinde et al., 2012). This approach uses a TCR-optimized peptide 
(TOP) for a “good” T-cell clonotype like MEL5 in order to skew the repertoire of T-
cells towards more effective T-cell clonotypes. In short, TOPSORT is an approach 
aimed to sort the top T-cell clonotypes in a given situation (Sewell, 2012). 
 
Interestingly, vaccination with EAA peptide induced T-cells with superior lytic 
activity against tumour cells compared to those induced by vaccination with ELA 
peptide (Speiser et al., 2008). To date, there have been no trials with the dominant 
natural nonamer AAG peptide. I hypothesise that vaccination with this antigen will 
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produce a better outcome and I hope that such trials are initiated soon. Our 
collaborators at the Danish Cancer Immunotherapy Centre are currently trying to 
raise funding for such a trial.  
 
7.1.6 MEL5 TCR gene transfer generates melanoma-specific T-cells 
The superior affinity of MEL5 for HLA-A2-AAG compared to other TCRs that have 
been used in therapeutic approaches against melanoma to date combines with data 
showing that this peptide is the dominant species at the melanoma surface (Derre et 
al., 2007; Held et al., 2007; Michaeli et al., 2009; Skipper et al., 1999) to suggest that 
therapeutic approaches that used MEL5-like TCRs would have better response rates 
than the trials undertaken to date. I therefore completed my studies by examining 
how the MEL5 TCR performed in TCR gene transfer experiments. My unique access 
to MEL5 TCR variants with a range of affinities for cognate antigen also allowed me 
to establish what the optimal TCR affinity was for recognition of antigen in this 
system. 
 
MEL5 TCR gene transfer into CD8+ T-cells resulted in the generation of cells with 
the required antigen specificity. Crucially, these cells were also able to kill real 
melanoma targets suggesting that they recognise natural levels of the natural 
peptide(s) presented at the melanoma surface. 
 
7.1.7 Detrimental motifs can be introduced during TCR affinity maturation 
Phage display has been used extensively to identify and affinity mature antibodies 
(Richman and Kranz, 2007). TCR affinity maturation was enabled thanks to the 
“Boulter-disulphide” method of pairing TCR α and β chains using a non-natural, 
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TCR constant domain-internal disulphide bond. Excitingly, my laboratory has just 
demonstrated how such affinity-enhanced TCRs can be used to induce tumour 
regression as soluble molecules (Liddy et al., 2012). My laboratory has also shown 
how such TCRs could be useful in gene therapy approaches to HIV infection 
(Varela-Rohena et al., 2008).  
 
In order to examine high-affinity TCRs in the MART-1 system, I obtained a panel of 
MART-1-specific TCRs that exhibited a range of affinity for cognate antigen. These 
TCRs were generated by a phage display and directed evolution process originally 
described by Boulter and colleagues (Li et al., 2005b). One of these TCRs failed to 
confer specificity for the cognate antigen despite being expressed at the cell surface 
(as determined by CD3 expression in TCR-negative Jurkat cells). Subsequent close 
examination of the altered sequence of this TCR revealed that the process of TCR 
affinity maturation had introduced an N-linked glycosylation site into the TCR β 
chain CDR3 loop. As protein glycosylation rarely occurs in E. coli (Benz and 
Schmidt, 2001; Lindenthal and Elsinghorst, 1999; Sherlock et al., 2006), addition of 
this motif did not cause a problem prior to expression in eukaryotic cells and I had 
not considered such problems prior to building the lentiviral construct to express this 
TCR in T-cells. TCRs expressed in T-cells undergo post-translational modifications 
such as glycosylation prior to expression on the T-cell surface (Moremen et al., 
2012). The presence of oligosaccharides on the CDR loops is likely to abolish the 
TCR/pMHC interaction by blocking the TCR access to the pMHC surface as 
observed with the MEL5 β13 TCR. Therefore, my results demonstrated that, when 
enhancing TCR affinity by phage display for a use in TCR gene transfer, particular 
attention should be paid to the presence of motifs that might add post-translational 
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modifications to the protein of interest or that introduce other potentially problematic 
sequences such as protease sites.  
 
7.1.8 An optimal TCR affinity for TCR gene therapy against melanoma 
I used a panel of enhanced affinity TCRs derived from MEL5 to determine the 
optimal TCR affinity for TCR gene transfer directed against melanoma. Because 
TCR gene transfer of high-affinity TCRs could lead to a loss of specificity (Holler et 
al., 2003; Robbins et al., 2008; Udyavar et al., 2009; Zhao et al., 2007) and/or a loss 
of effector functions (Irving et al., 2012; Schmid et al., 2010; Stone et al., 2009), I 
used a panel of TCRs with a range of affinities (KD = 0.54-29 µM) within the natural 
range (KD = 0.1-270 µM). Preliminary results were promising, showing that a 6-fold 
enhancement over the wild-type affinity produced T-cells that were substantially 
more responsive to cognate antigen than T-cells transduced with wild-type TCR. As 
described before (Irving et al., 2012; Schmid et al., 2010), self-specific TCR affinity 
may not need to be optimized beyond a given affinity threshold as above the optimal 
affinity transduced T-cells displayed a gradual attenuation in activity. The 
attenuation in T-cell activity with higher affinity TCRs could be related to the longer 
off-rates of the high affinity TCRs inhibiting serial triggering during T-cell 
activation (Palmer and Naeher, 2009). Lower responsiveness might also be the result 
of T-cell/T-cell recognition; such a situation has recently been shown by my 
colleague Dr. Mai Ping Tan in several different systems (unpublished). In summary, 
my results suggest that enhancing the TCR affinity for cognate tumour antigen into 
the range normally reserved for interactions with non-self, pathogen-derived antigens 
could considerably improve the effectiveness of TCR gene transfer therapy. 
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7.2 PERSPECTIVES 
The new mechanism for conferring TCR peptide specificity during antigen 
recognition by a high-affinity TCR was revealed by my in-depth structural and 
thermodynamic analyses. My results suggest that future TCR/pMHC studies should 
include these sorts of analyses in order to reveal new important molecular 
information of the nature of T-cell antigen recognition. It would be  especially useful 
to obtain detailed thermodynamic parameters for all of the TCR/pMHC interactions 
for which both ligated and unligated TCR and/or pMHC structures are already 
available (Armstrong et al., 2008a; Rudolph et al., 2006). I think it is likely that the 
MEL5 example that I discovered will not be the only example of where a TCR 
maintains specificity through altered thermodynamics of binding and it remains 
possible that this mechanism of upholding TCR specificity is commonplace. It is 
well established that binding kinetics provides a wealth of information for rational 
drug design (De Mol and Fischer, 2008) and that an increase of water molecules at 
the interaction interface can extend the complementarity of the surfaces and increase 
the hydrogen bond networks (Ladbury, 1996; Perozzo et al., 2004). Moreover, it is 
increasingly acknowledged that there is a need for thermodynamic and kinetic 
studies to fully appreciate the properties of potential drug candidates (De Mol and 
Fischer, 2008; Henriques and Ladbury, 2001; Holdgate et al., 1997; Murphy and 
Freire, 1995). My results show that this need clearly extends to examination of 
TCR/pMHC interactions. 
 
The next step in the development of the optimal TCR for TCR gene transfer will be 
to use a CD8+ T-cell model. One major concern is the effect that TCR affinity 
enhancements could have on self-tolerance of T-cells that have not undergone 
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thymic auditioning. Artificial engineering of TCR sequences might lead to altered 
peptide specificity and the possibility of autoimmunity. The preferred peptide 
landscape recognised by CD8+ T-cells transduced with MEL5 TCR was tested by 
PS-CPL screening and compared with the MEL13 (equivalent to MEL5) T-cell 
clone. No macro level differences in TCR specificity were observed. My group has 
recently established that the CD8 glycoprotein controls TCR cross-reactivity 
(Wooldridge et al., 2010). Jurkat cells do not express CD8 so it will be interesting to 
see how introduction of this T-cell co-receptor alters the TCR affinity optima in the 
MEL5 system. 
 
7.3 SUMMARY 
Overall, the work reported in this thesis has improved our knowledge of TCR/pMHC 
interaction. The design of a specific TCR/pMHC crystallization screen led to the 
discovery of a new mechanism of TCR binding and TCR specificity. Important 
implications for melanoma therapy have been uncovered, such as the optimal TCR 
affinity for anti-melanoma TCR gene therapy and the unexpected maintenance of the 
exquisite specificity of a high-affinity anti-melanoma TCR via an unanticipated 
thermodynamic molecular mechanism. In conclusion, both soluble TCR therapy and 
TCR gene transfer therapy are showing great promise for the future treatment of 
cancer and careful evaluation in patients at several centres is now needed. 
Monoclonal antibodies accounted for >45% of all new drugs that came on the market 
in 2012. It is possible that drugs based around the other type of antigen receptor, the 
TCR, may come to eclipse even this phenomenal success so that TCR-based 
therapeutic approaches could become commonplace in a near future.  
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APPE	DICES 
Appendix 1: MEL5, α24β17, HLA-A2 and β2m sequences 
MEL5 soluble α chain 22.5 kDa: 
MQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYS
NGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVNVAGKSTFGDGT
TLTVKPNIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITD
KCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESS 
 
MEL5 soluble β chain 27.4 kDa: 
MSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYWYRQAAGRGLQLLFYS
VGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGFYLCAWSETGLGTGELF
FGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVEL
SWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNH
FRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
 
Mel α24β17 soluble α chain (mutations from MEL5 in bold and underlined) 22.6 
kDa: 
MQKEVEQNSGPLSVPEGAIASLNCTYSFLGSQSFFWYRQYSGKSPELIMFTY
REGDKEDGRFTAQLNKASQHVSLLIRDSQPSDSATYLCAVNDGGRLTFGDG
TTLTVKPNIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYIT
DKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESS 
 
Mel α24β17 soluble β chain (mutations from MEL5 in bold and underlined) 27.5 
kDa: 
MSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYWYRQAAGRGPQLLFY
WGPFGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGFYLCAWSETGLGMG
GWQFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPD
HVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQD
PRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD 
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HLA-A2 heavy chain 32.0 kDa: 
MGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAP
WIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMY
GCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKW
EAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDH
EATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAV
VVPSGQEQRYTCHVQHEGLPKPLTLRWEP 
 
Biotin tagged HLA-A2 heavy chain 33.8 kDa: 
MGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAP
WIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMY
GCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKW
EAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDH
EATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAV
VVPSGQEQRYTCHVQHEGLPKPLTLRWEPGLNDIFEAQKIEWHE 
 
β2m 11.9 kDa: 
MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHS
DLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 
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Appendix 2: TCR/pMHC datasets obtained for 25 complexes in my laboratory 
TCR/pMHC complex Screen 
Resolution 
(Å) 
pH 
PEG 
(%) 
PEG 
Glycerol 
(%) 
Salta 
α24β17/A2-ELA TOPS 3.02 7 15 4000 0 1 
α24β17/A2-ELA TOPS 3.21 7 20 4000 0 1 
α24β17/A2-ELA TOPS 2.99 7.5 15 4000 0 1 
α24β17/A2-ELA TOPS4 2.43 7 20 4000 0 1 
α24β17/A2-AAG TOPS 2.81 7 20 4000 15 0 
α24β17/A2-ELA-4A TOPS 2.46 7.5 20 4000 0 1 
α24β17/A2-ELA-4A TOPS3 2.71 7 15 4000 17.4 0 
α24β17/A2-ELA-4A TOPS4 2.44 7 20 4000 8.7 1 
α24β17/A2-ELA-4A TOPS4 3.08 7 20 4000 4.4 1 
α24β17/A2-ELA-7A PACT 2.7 6.5 20 3350 0 1 
α24β17/A2-ELA-7A TOPS4 2.97 7 20 4000 8.7 1 
α24β17/A2-ELA-7A TOPS4 2.63 7 20 4000 17.4 1 
α24β17/A2-EAA TOPS4 2.1 7.5 15 4000 8.7 1 
MEL5/A2-EAA TOPS 3 6.5 15 4000 15 0 
MEL5/A2-EAA TOPS 3.12 8.5 25 4000 15 0 
MEL5/A2-AAG TOPS 3.16 7.5 25 4000 15 0 
P1/A2-CLG TOPS 2.6 6 15 4000 15 0 
SB7/A2-FLY TOPS 2.56 6.5 15 4000 0 1 
868/A2-SLY TOPS 2.94 6 15 4000 0 1 
868/A2-6I TOPS 2.91 6 15 4000 0 1 
868/A2-3F6I8V TOPS1 2.75 5.5 15 4000 0 1 
1E6/A2-ALW TOPS 2.7 7.5 15 4000 0 1 
1E6/A2-ALW TOPS 2.7 8 15 4000 15 0 
1E6/A2-ALW TOPS 2.56 6 15 4000 15 0 
1E6/A2-ALW TOPS 2.76 7.5 15 4000 20 0 
1E6/A2-ALW TOPS 3.12 7 15 4000 0 1 
1E6/A2-ALW TOPS 3.16 8.5 25 4000 0 1 
1E6/A2-ALW PACT 3.01 7.5 20 3350 0 1 
1E6/A2-ALW PACT 2.78 7.5 20 3350 0 1 
1E6/A2-ALW PACT 2.58 6.5 20 3350 0 1 
1E6/A2-ALW PACT 3.2 7 25 1500 0 0 
1E6/A2-ALW PACT 3.04  20 3350 0 1 
1E6/A2-ALW PACT 2.97 6.5 20 3350 0 1 
1E6/A2-RQW PACT 2.33 6 20 6000 0 1 
1E6/A2-YQF PACT 2.11 7 20 6000 0 1 
1E6/A2-YQF PACT 3.21 5 20 6000 0 1 
1E6/A2-WQY TOPS 2.51 7.5 15 8000 15 0 
1E6/A2-WQY TOPS 1.87 7 25 8000 0 1 
1E6/A2-KLP TOPS 3.09 6 15 8000 0 1 
1E6/A2-KLP TOPS 2.92 6.5 15 4000 0 1 
1E6/A2-KLP TOPS 2.85 6.5 15 8000 0 1 
1E6/A2-KLP TOPS 2.96 7 15 8000 0 1 
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1E6/A2-YLG TOPS 2.5 6.5 15 4000 0 1 
1E6/A2-YLG TOPS 2.6 7.5 15 4000 0 1 
1E6/A2-MVW TOPS 2 7.5 15 4000 0 1 
1E6/A2-MVW TOPS 2.46 6 15 4000 0 1 
1E6/A2-RQF(I) TOPS 1.9 7.5 15 4000 0 1 
1E6/A2-RQF(I) TOPS 2 7 15 4000 0 1 
1E6/A2/RQF(A) TOPS 1.9 7 15 4000 0 1 
GP100/A2-YLE JBScreen 2  20 3350 0 1 
ILA/A2-ILA TOPS 3.06 7 20 8000 0 1 
ILA/A2-ILA TOPS 2.57 7 20 8000 0 1 
AS01/A2-GLC TOPS 2.56 6 20 4000 0 1 
TCR/pMHC complexes I obtained are in bold and underlined. One dataset represents a full 
diffraction dataset obtained from one particular crystal growing condition for a given 
complex and usable to solve, analyze and publish the structure. We often collected several 
datasets from the same condition for a particular complex but only one is included in the 
table in order to avoid any redundancy in the analysis. 
a Presence of salt was described as “1” and absence of salt was described as “0” 
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Appendix 3: Frequency of appearance of the 29 different conditions where we 
obtained TCR/pMHC complexes 
Condition n° pH PEG (%) PEG Salta 
Frequency 
(%) 
1 7.0 25 1500 0 2.0 
2 6.0 15 4000 0 3.9 
3 6.5 15 4000 0 2.0 
4 7.0 15 4000 0 2.0 
5 7.5 15 4000 0 2.0 
6 8.0 15 4000 0 2.0 
7 7.0 20 4000 0 2.0 
8 7.5 25 4000 0 2.0 
9 8.5 25 4000 0 2.0 
10 7.5 15 8000 0 2.0 
11 6.5 20 3350 1 5.9 
12 7.5 20 3350 1 3.9 
13 5.5 15 4000 1 2.0 
14 6.0 15 4000 1 5.9 
15 6.5 15 4000 1 5.9 
16 7.0 15 4000 1 7.8 
17 7.5 15 4000 1 11.8 
18 6.0 20 4000 1 2.0 
19 7.0 20 4000 1 11.8 
20 7.5 20 4000 1 2.0 
21 8.5 25 4000 1 2.0 
22 5.0 20 6000 1 2.0 
23 6.0 20 6000 1 2.0 
24 7.0 20 6000 1 2.0 
25 6.0 15 8000 1 2.0 
26 6.5 15 8000 1 2.0 
27 7.0 15 8000 1 2.0 
28 7.0 20 8000 1 3.9 
29 7.0 25 8000 1 2.0 
The conditions producing more than 5% of the datasets (conditions n°11, 14, 15, 16, 17 and 
19) are in bold and underlined. 
a Presence of salt was described as “1” and absence of salt was described as “0” 
  
299 
 
Appendix 4: α24β17 TCR/A2-ELA contacts 
Peptide TCR 
H-bonds 
(≤3.2Å) 
H-bonds 
(3.2Å -3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å -
4Å) 
Glu1Oε2/H2O αGly29O/H2O 1 1  2 
Glu1H2O αGln31H2O  1  2 
Leu2O αGln31Nε2 1   1 
Ala3 αGln31    2 
Ala3 βLeu98   1  
Gly4N αGln31Oε1 1  2 3 
Gly4H2O αSer32H2O 1 1   
Gly4H2O αAsn92H2O 1    
Gly4 βLeu98    2 
Ile5 αTyr51    1 
Ile5 βLeu98   2  
Ile5 βMet100    1 
Gly6N βLeu98O 1    
Ile7 βGly97   2  
Ile7N/O βLeu98O/N 2   6 
Leu8 βGly99    1 
Thr9 βThr96    2 
MHC TCR 
H-bonds 
(≤3.2Å) 
H-bonds 
(3.2Å -3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å -
4Å) 
Glu58 αPhe27    4 
Gly62 αAsp93    1 
Arg65 βIle56    2 
Arg65NH2 αAsp93O 1   3 
Arg65Nε αGly94O 1  2 3 
Arg65 αArg96    7 
Lys66H2O αGly29H2O 1    
Lys66H2O αGly31H2O  1  1 
Lys66H2O αAsp93H2O 1    
Lys66 αGly94    1 
Ala69 βTyr49    1 
Ala69 βIle56    2 
Ala69 βLeu98    1 
His70 βLeu98    2 
Gln72 βGly51   2 1 
Gln72Oε1 βPro52N 1  1 3 
Gln72Oε1 βPhe53N 1   4 
Gln72Nε2 βGly54O  1   
Gln72 βIle56    2 
Thr73 βGly97   2  
Arg75 βPhe53   2 11 
Val76 βAsn30   1  
Val76 βPhe53    3 
Glu154 αTyr51   1 2 
Gln155 αTyr51    3 
Gln155 βGly99    1 
Gln155H2O βMet100H2O 1   2 
Arg157 αArg52   1 2 
Ala158 αTyr51    2 
Tyr159 αGln31   1  
Thr163H2O αGln31H2O 1   2 
Thr163 αLys66Nζ  1   
Trp167 αLeu28    3 
Trp167 αGly29    2 
Arg170 αLeu28   1 1 
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Appendix 5: α24β17 TCR/A2-ELA4A contacts 
Peptide TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Glu1Oε2/H2O αGly29O/H2O 1 1  2 
Glu1Oε2 αGln31Nε2  1  2 
Leu2O αGln31Nε2 1   1 
Ala3 αGln31    2 
Ala4N αGln31Oε1 1   6 
Ala4H2O αSer32H2O 1    
Ala4H2O αAsn92H2O  1   
Ala4 βLeu98    2 
Ile5 αTyr51    1 
Ile5 βLeu98   2  
Ile5 βMet100    1 
Gly6N βLeu98O  1   
Ile7 βGly97   2  
Ile7N/O βLeu98O/N 2   7 
Thr9 βThr96   1  
MHC TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Glu58 αPhe27    4 
Gly62 αAsp93    1 
Arg65 βIle56    2 
Arg65NH2 αAsp93O/Oδ2 1 1SB  3 
Arg65 αArg96    8 
Lys66H2O αGly29H2O 1    
Lys66 αGln31    1 
Lys66 αGly94    3 
Lys68H2O βIle56H2O 1    
Ala69 βTyr49    1 
Ala69 βLeu98    2 
His70 βLeu98    1 
Gln72 βGly51   2 1 
Gln72Oε1 βPro52N 1  1 3 
Gln72Oε1 βPhe53N 1   5 
Gln72Nε2 βGly54O  1  1 
Gln72 βIle56    2 
Thr73 βGly97   1 1 
Arg75 βPhe53   2 15 
Val76 βAsn30    1 
Val76 βPhe53    2 
Glu154Oε1/Oε2 αTyr51OH 2   7 
Gln155 αTyr51    4 
Gln155 βGly99    1 
Gln155H2O βMet100H2O 1   2 
Ala158 αTyr51    2 
Tyr159 αGln31    1 
Thr163H2O αGln31H2O 1   2 
Trp167 αLeu28    4 
Trp167 αGly29    2 
Arg170 αLeu28    3 
SB: salt bridge 
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Appendix 6: α24β17 TCR /A2-ELA7A contacts 
Peptide TCR H-bonds (≤3.2Å) H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Glu1Oε2 αGly29O  1 1 1 
Glu1Oε2 αGln31Nε2 1   1 
Leu2O αGln31Nε2 1   2 
Ala3 αGln31    4 
Ala3 βLeu98   1  
Gly4N αGln31Oε1 1  2 3 
Gly4 βLeu98    2 
Ile5 βLeu98   1 1 
Ala6N βLeu98O 1   2 
Ala7 βGly97    2 
Ala7N/O βLeu98O/N 2   6 
Leu8 βThr96    1 
Leu8 βLeu98    1 
Leu8 βGly99    1 
Thr9 βThr96   1 1 
MHC TCR H-bonds (≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Arg44H2O βSer58H2O 1    
Glu58 αPhe27    4 
Gly62 αAsp93    1 
Arg65 βIle56    2 
Arg65H2O βSer58H2O/H2O 2    
Arg65NH2 αAsp93O 1   3 
Arg65Nε αGly94O 1  1 3 
Arg65 αArg96   1 6 
Lys66 αGly94    2 
Lys66 αLeu98    1 
Lys68 βIle56    1 
Ala69 βTyr49    1 
Ala69 βLeu98   1  
His70 βLeu98    1 
Gln72 βGly51   2 1 
Gln72Oε1 βPro52N 1  1 3 
Gln72Oε1 βPhe53N 1   8 
Gln72Nε1 βGly54O 1   4 
Gln72 βIle56    2 
Arg75 βPhe53   1 13 
Val76 βAsn30    1 
Val76 βPhe53   1 1 
Glu154 αTyr51    3 
Gln155 αTyr51    3 
Gln155 βGly99    1 
Gln155H2O βMet100H2O 1   3 
Ala158 αTyr51    2 
Tyr159 αGln31    1 
Thr163H2O αGln31H2O 1   3 
Trp167 αGly29    2 
Arg170 αLeu28   1 1 
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Appendix 7: α24β17 TCR /A2-EAA contacts 
Peptide TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Glu1Oε2 αGly29O 1  1 2 
Glu1Oε2 αGln31Nε2  1SB  2 
Ala2O αGln31Nε2 1    
Ala3 αGln31    2 
Ala3 βLeu98   1  
Gly4N αGln31Oε1 1  1 3 
Gly4 βLeu98    2 
Ile5 αGln31    1 
Ile5 αSer32    1 
Ile5 αTyr51    2 
Ile5 βLeu98   2  
Gly6N βLeu98O 1   2 
Ile7 βGly97   1 1 
Ile7N/O βLeu98O/N 2  1 5 
Thr9 βThr96    1 
MHC TCR H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW 
(3.5Å-4Å) 
Glu58 αPhe27   1 3 
Gly62 αAsp93    1 
Arg65NH2 αAsp93O 1  1 3 
Arg65Nε αGly94O 1  2 3 
Arg65 αArg96   2 14 
Arg65 βIle56    1 
Arg65 βSer57    3 
Lys66 αGln31    1 
Lys66 αGly94    1 
Lys66 βLeu98    1 
Lys68 βIle56    1 
Ala69 βTyr49   1  
Ala69 βLeu98    2 
His70 βLeu98    2 
Gln72 βGly51   2 2 
Gln72Oε1 βPro52N 1  1 3 
Gln72Oε1 βPhe53N 1   6 
Gln72Nε2 βGly54O  1  3 
Gln72 βIle56   1 2 
Arg73 βGly97   1 1 
Arg75 βPhe53   1 17 
Val76 βAsn30    1 
Val76 βPhe53    2 
Val76 βThr96    1 
Glu154 αTyr51   1 2 
Gln155 αTyr51    6 
Gln155 βGly99    1 
Gln155 βMet100    3 
Arg157 αArg52    2 
Ala158 αTyr51    1 
Tyr159 αGln31   1  
Thr163 αGln31    3 
Trp167 αLeu28    2 
Trp167 αGly29    2 
Arg170 αLeu28    1 
SB: salt bridge 
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Appendix 8: α24β17 TCR /A2-AAG contacts 
Peptide 
AAG bulged 
TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Ala1O αGln31Nε2  1   
Ala2 αGln31   3 4 
Ala2 βLeu98    2 
Gly3N αGln31Oε1/Nε2 1 1 2 2 
Gly3 βLeu98   3 2 
Gly3 βGly99    1 
Ile4 αGln31    3 
Ile4 αSer32    1 
Ile4 αTyr51    1 
Ile4 βLeu98   1 1 
Gly5N βLeu98O 1   2 
Ile6 βThr96    1 
Ile6 βGly97   2  
Ile6N/O βLeu98O/N 2  2 7 
Thr8 βThr96   2  
Peptide 
AAG 
stretched 
TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Ala2O αGln31Nε2 1   3 
Gly3 αGln31    2 
Gly3 βLeu98    1 
Ile4N αGln31Oε1 1  2 2 
Ile4 αAsn92   1 1 
Ile4 αGly94    1 
Ile4 αGly95    1 
Ile4 βLeu98    5 
Gly5N βLeu98O  1 2  
Ile6 βGly97    2 
Ile6N/O βLeu98O/N 2  1 6 
Thr8 βThr96   2  
MHC TCR H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW 
(3.5Å-4Å) 
Glu58 αPhe27    3 
Gly62 αAsp93    1 
Arg65NH2 αAsp93O/Oδ1 1 1SB 1 3 
Arg65Nε αGly94O 1  1 6 
Arg65 αArg96   3 10 
Arg65 βIle56    1 
Arg65 βSer57    3 
Lys66 αGln31    1 
Lys66 αGly94    2 
Lys66 βLeu98    1 
Lys68 βIle56   1 1 
Ala69 βTyr49    1 
Ala69 βIle56    1 
Ala69 βLeu98   1 1 
His70 βLeu98   1  
Gln72 βGly51   2 2 
Gln72Oε1 βPro52N  1 1 3 
Gln72Oε1 βPhe53N 1  1 6 
Gln72Nε2 βGly54O 1   5 
Gln72 βIle56   1 1 
Arg75 βPhe53   5 16 
Val76 βAsn30   1 1 
Val76 βPhe53   1 1 
Glu154 αTyr51    4 
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Gln155 αTyr51    5 
Gln155 βGly99    1 
Gln155 βMet100    3 
Ala158 αTyr51    2 
Tyr159 αGln31   1 3 
Thr163 αLys67    1 
Glu166Nε1/Nε2 αLys67Nζ 1 1SB 1  
Trp167 αGly29    2 
Arg170 αLeu28    1 
SB: salt bridge 
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Appendix 9: MEL5 TCR /A2-EAA contacts 
Peptide TCR 
H-bonds 
(≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å 
-4Å) 
Glu1Oε2 αGly29O  1  3 
Glu1Oε2 αGln31Nε2  1SB  1 
Ala2O αGln31Nε2  1   
Ala3 αGln31    1 
Gly4N αGln31Oε1 1  2 4 
Gly4 αAsn92    1 
Gly4 βLeu98   1 3 
Ile5 αGln31   1 2 
Ile5 αSer32    1 
Ile5 αAsn92    1 
Ile5 βLeu98    2 
Ile5 βGly99   1 2 
Gly6N βLeu98O 1   2 
Ile7 βGly97    2 
Ile7N/O βLeu98O/N 2  1 8 
Ile7 βGly99    1 
Leu8 βGly99   1 1 
Thr9 βThr96    1 
MHC TCR H-bonds (≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å-
4Å) 
Gly62 αAla94   1 4 
Arg65Nε/NH2 αAla94O 1 1 3 3 
Arg65 αLys96    3 
Arg65 βTyr49   1 5 
Arg65NH1 βGlu59Oε2  1SB  2 
Lys66 αGln31   1  
Lys66 βLeu98    1 
Lys68 βTyr49    2 
Lys68 βSer57    1 
Ala69 βLeu98    3 
His70 βLeu98    1 
Gln72 βVal51    2 
Gln72 βGln55   1  
Thr73 βGly97    1 
Arg75 βGln55    1 
Val76 βAsn30   1 3 
His151 αTyr51    1 
Glu154 αTyr51    3 
Gln155 αTyr51    6 
Gln155 βGly99   1 2 
Gln155Oε1 βThr100N  1 1 4 
Ala158 αTyr51   1 1 
Tyr159 αGln31   1 2 
Thr163 αGln31    3 
Glu166Oε2 αArg28NH2  1SB  4 
Trp167 αArg28    1 
Trp167 αGly29    2 
SB: salt bridge 
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Appendix 10: MEL5 TCR /A2-AAG contacts 
Peptide AAG 
bulged 
TCR H-bonds (≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å -
4Å) 
Ala2 αGln31    1 
Ala2 βLeu98    1 
Gly3N αGln31Oε1 1  1 3 
Gly3 βLeu98   1 4 
Ile4 βLeu98   1  
Ile4 βGly99   2 2 
Gly5N βLeu98O 1   2 
Ile6 βGly97    2 
Ile6N/O βLeu98O/N 2   5 
Leu7 βGly99    2 
Thr8 βThr96    2 
Peptide AAG 
stretched 
TCR H-bonds (≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å -
4Å) 
Ala2O αGln31Oε1 1    
Gly3 βLeu98    1 
Ile4 αGln31   2 6 
Ile4 βLeu98   1 3 
Gly5N βLeu98O 1  2 1 
Gly5 βGly99    1 
Ile6 βGly97    2 
Ile6N/O βLeu98O/N 2   6 
Leu7 βGly99    2 
Thr8 βThr96    2 
MHC TCR 
H-bonds (≤3.2Å) 
H-bonds (3.2Å -
3.4Å) 
vdW (3.2Å –
3.5Å) 
vdW (3.5Å-
4Å) 
Gly62 αAla94   1 3 
Arg65Nε αAla94O 1  2 5 
Arg65 αGly95    1 
Arg65 αLys96    4 
Arg65 βTyr49   2 3 
Arg65NH1 βGlu59Oε1 1    
Lys66 βLeu98    1 
Ala69 βLeu98   1 1 
His70 βLeu98    1 
Gln72 βVal51   1 1 
Gln72 βGln55    1 
Thr73 βGly97   1 1 
Arg75NH1 βGln55Oε1   1  
Val76 βAsn30   1 2 
Glu154 αTyr51    3 
Gln155 αTyr51   1 5 
Gln155 βGly99   1 2 
Gln155Oε1 βThr100N 1  1 3 
Ala158 αTyr51    1 
Tyr159 αGln31    1 
Thr163 αGly29    1 
Thr163Oɣ1 αGln31Nε2 1   2 
Glu166Oε2 αArg28NH2  1SB   
SB: salt bridge 
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Appendix 11: Detailed analysis of Mel5/A2-AAG, Mel5/A2-EAA, α24β17/A2-
AAG and α24β17/A2-EAA buried surface area and contacts 
TCR-MHC  
MEL5/A2-
AAG 
bulged 
MEL5/A2-
AAG 
stretched 
MEL5/A2-
EAA 
α24β17/A2
-AAG 
bulged 
α24β17/A2
-AAG 
stretched 
α24β17/A2
-EAA 
Total No. 
contactsa 
4/1/55 4/1/55 3/2/73 6/2/114 6/2/114 5/0/112 
No. MHC α1 
helix 
contactsa 
2/0/34 2/0/34 2/1/40 5/1/90 5/1/90 5/0/87 
No. MHC α2 
helix 
contactsa 
2/1/21 2/1/21 1/1/33 1/1/24 1/1/24 0/0/25 
No. Vα 
contactsa 
2/1/30 2/1/30 2/1/40 3/2/51 3/2/51 2/0/53 
CDR1α27-32
a 1/1/4 1/1/4 0/1/14 0/0/11 0/0/11 0/0/14 
CDR2α50-54
a 0/0/10 0/0/10 0/0/12 0/0/11 0/0/11 0/0/12 
FWα67-71
a 0/0/0 0/0/0 0/0/0 1/1/2 1/1/2 0/0/0 
CDR3α89-100
a 1/0/16 1/0/16 2/0/14 2/1/27 2/1/27 2/0/27 
No. Vβ 
contactsa 
2/0/25 2/0/25 1/1/33 3/0/63 3/0/63 3/0/59 
CDR1β27-32
a 0/0/3 0/0/3 0/0/4 0/0/2 0/0/2 0/0/1 
CDR2β49-59
a 1/0/9 1/0/9 0/1/15 3/0/53 3/0/53 3/0/46 
CDR3β91-106
a 1/0/13 1/0/13 1/0/14 0/0/8 0/0/8 0/0/12 
BSAb (Å2) 789/831 788/837 804/880 980/964 980/971 913/920 
TCR-peptide 
MEL5/A2-
AAG 
bulged 
MEL5/A2-
AAG 
stretched 
MEL5/A2-
EAA 
α24β17/A2
-AAG 
bulged 
α24β17/A2
-AAG 
stretched 
α24β17/A2
-EAA 
Total No. 
contactsa 
4/0/29 4/0/29 6/1/43 6/0/42 5/0/32 6/1/31 
No. Vα 
contactsa 
1/0/5 1/0/8 3/1/17 3/0/16 2/0/13 3/1/15 
CDR1α27-32
a 1/0/5 1/0/8 3/1/15 3/0/15 2/0/9 3/1/13 
CDR2α50-54
a 0/0/0 0/0/0 0/0/0 0/0/1 0/0/0 0/0/2 
CDR3α89-100
a 0/0/0 0/0/0 0/0/2 0/0/0 0/0/4 0/0/0 
No. Vβ 
contactsa 
3/0/24 3/0/21 3/0/26 3/0/26 3/0/19 3/0/16 
CDR3β91-106
a 3/0/24 3/0/21 3/0/26 3/0/26 3/0/19 3/0/16 
BSAc (Å2) 240/415 162/383 308/374 251/431 255/407 313/382 
a Number of hydrogen bonds (H-bond) (≤4Å) / salt bridges (≤4Å) / van der Waals (vdW) 
(3.2-4Å) contacts calculated with CONTACT program from the CCP4 package  
b Buried surface area (BSA) (Å2) of Vα-MHC / Vβ-MHC calculated with PISA program from 
the CCP4 package 
c Buried surface area (BSA) (Å2) of Vα-peptide / Vβ-peptide calculated with PISA program 
from the CCP4 package 
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Appendix 12: MEL5 βwt, MEL5 β5, MEL5 β9, MEL5 β12, MEL5 β13, MEL5 
β15 and MEL5 β17 sequences for lentiviral expression 
 
Mutations from MEL5 βwt are in bold and underlined. 
 
MEL5 βwt: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGLQLLFYSVGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGLGTGELFFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQK
ATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYCL
SSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
 
MEL5 β5: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGLQLLFYSVGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGLGMGGWQFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQ
KATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYC
LSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
 
MEL5 β9: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGLQLLFYSVGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGLGVGGWEFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQ
KATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYC
LSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
 
MEL5 β12: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGLQLLFYSVGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGL	LGGWFFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQ
KATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYC
LSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
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MEL5 β13: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGLQLLFYSVGIGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGL	VSGWFFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQK
ATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYCL
SSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
 
MEL5 β15: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGPQLLFYYGPFGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSGF
YLCAWSETGLGMGGWQFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHTQ
KATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYC
LSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAW
GRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDA
GVLESGSG 
 
MEL5 β17: 
 
MLCSLLALLLGTFFGVRSQTIHQWPATLVQPVGSPLSLECTVEGTSNPNLYW
YRQAAGRGPQLLFYWGPFGQISSEVPQNLSASRPQDRQFILSSKKLLLSDSG
FYLCAWSETGLGMGGWQFGEGSRLTVLEDLKNVFPPEVAVFEPSEAEISHT
QKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRY
CLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEA
WGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRK
DAGVLESGSG 
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Appendix 13: Anti-CD3 sorting of transduced Jurkat TCR negative GLuc 
 
 
Jurkat TCR negative GLuc transduced with rCD2 and (A) MEL5, (B) MEL5 β5, (C) 
MEL5 β9, (D) MEL5 β12, (E) MEL5 β13, (F) MEL5 β15 and (G) MEL5 β17 were 
sorted as described in Chapter 2 with anti-CD3 antibodies. Staining with anti-CD3-
FITC and anti-rCD2-PE followed by FACS analysis revealed that the populations 
were 100% double positive. 
 
 
 
 
